var title_f22_48_23296="Complete airway obstruction in children";
var content_f22_48_23296=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    Management of complete airway obstruction in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 700px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ORL: otorhinolaryngologist (ear-nose-throat specialist); OR: operating room; BLS: basic life support; LMA: laryngeal mask airway; ICU: intensive care unit; ETT: endotracheal tube.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_48_23296=[""].join("\n");
var outline_f22_48_23296=null;
var title_f22_48_23297="Zephyr Endobronchial Valve side view";
var content_f22_48_23297=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Zephyr&reg; Endobronchial Valve, side view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Strange, C, Herth, FJ, Kovitz, KL, et al. Design of the Endobronchial Valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reduction. BMC Pulm Med 2007; 7:10. Copyright &copy; 2010 BioMed Central Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_48_23297=[""].join("\n");
var outline_f22_48_23297=null;
var title_f22_48_23298="Two-dimensional method for calculating abdominal circumference";
var content_f22_48_23298=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Two-dimensional method for calculating abdominal circumference",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The abdominal circumference measurement is&nbsp;calculated by the ultrasound machine&nbsp;by placing four calipers (+)&nbsp;around the abdomen on the skin edge, not the rib cage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jennifer T Ahn, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_48_23298=[""].join("\n");
var outline_f22_48_23298=null;
var title_f22_48_23299="Pentastarch: Patient drug information";
var content_f22_48_23299=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pentastarch: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/27/14772?source=see_link\">",
"     see \"Pentastarch: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F207901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pentaspan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F12806512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691514",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat low blood volume.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F12806511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3434939",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pentastarch, corn, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2737529",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding in the brain, bleeding problems, high chloride levels, high sodium levels, very bad kidney disease, or a very weak heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F12806515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697137",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a low platelet count, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F12806516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F12806518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F12806514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F12806519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F12806520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16456 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-7BCA055868-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_48_23299=[""].join("\n");
var outline_f22_48_23299=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207901\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12806512\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12806511\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12806515\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12806516\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12806518\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12806514\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12806519\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12806520\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/27/14772?source=related_link\">",
"      Pentastarch: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_48_23300="MCFONTZL classification system";
var content_f22_48_23300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MCFONTZL classification system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 560px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     R: right; C: center; L: left; F: forehead; T: temple; O: orbit; Z: zygoma (cheek); N: nose; M: maxilla; L: lip (Up: upper; Lo: lower); Ch: chin.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lee R, Gamble WB, Robertson B, Manson PN. The MCFONTZL classification system for soft-tissue injuries to the face. Plast Reconstr Surg 1999; 103:1150. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_48_23300=[""].join("\n");
var outline_f22_48_23300=null;
var title_f22_48_23301="The cell cycle";
var content_f22_48_23301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    The cell cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 532px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIUAhADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiudvfGOj2XjfT/ClzOyatf2r3UCkfIyqcbc/3jhyBjojdOM9FQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFMmljhjMksiRxjqzNgD8a47Wfin4H0aZ4b7xNpv2hM7oYJfPkBGQV2x5O7IxjrQB2lFebH4tWF3n/hH/DfivWQQCktvpbxRNntvl2AY/wD1Ug8ZeO7lpPsfw5MMZJEUl7rMKH2LIgYj6ZrGWIpQ+KSXzHZnpVFeaG/+KtzGohsPBuntnJaa4ubnj02qqfnup01v8T7m2aM694UspCRiW30uZ2H/AH3MR+lZPH4dbzHys9JorzAaF8ST97x/py/TQFOf/ItTf2D8Qf8AooNr/wCCGP8A+OVH9pYb+b8H/kHIz0mivMpdC+I4z5Pj/Tz6b9BT+klOl/4WvCqLb3/gm624Baazuomb3O2QgH6Cmsxwz+1+YcjPS6K81bxH8SLLebjwZo2pDHy/YNZ8s/8AkWMUp+Jt7Yxg674D8V2j7QWNrBHeoD3G6JycD1IGfato4mjLaS+8Vmek0VwNl8X/AALc3P2eTX4bGfdt2ajFJaHp/wBNVXj3rtbO/s722+0Wd3b3EGA3mRSK64IznIOMY5rdO4jxXXfDP/CfePvHU8M4t77R1sbPSL9W3m2uo1M7MvYfNIqsvse9eh/DDxa3ivQHN/CLTXdPkNnqdoTzDOvUgf3W+8p6YPfFc/8ABBnvvCN5rsqbJdd1O71EgkHCtIUTkAAjYi89xzVfx3DN4L8Sx+P9Kjd7TYtt4gtowT51sPu3AUdXi+mSpI4ryKWOtipU5bN6eu34mjj7tz1jvRUVncw3lpDdWsqy286LLHIhyHUjII9iDUteuZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRTZHWNGeRgqKMszHAA9TXn2sfFPSxfvpnhKzuvFWrocPDpmDDCf8AprOf3afmTntSlJRV29APQ6wfFXjDw94TthP4i1e0sFbO1ZHy74GTtQZZvoAeo9a4o6R8QfE7Btf8QQeGrBs5sdCXfOyns1y4+Vh0yi1s+GPh74Y8Nzm60/S45NQY5e+uibi4c+pkfLflgV5tbNKNPSPvMtQbMyT4mahq7bPA/g/V9WjJGL6+H2C1I/vBpBvYdOi96Q6V8RdbBbVvFOn6DA55ttFsxLIFOePOmzzg9Qg5AIrv6K82rmtafw6FqCPPk+Enhy5lSbxFLq3iO4TkPq9/JMATjOIwQg6Djb2Fddo+gaPosQj0fSrGxjA6W1ukf8hWnRXDOtUqfHJspJIKKKKyGFFFFABRRRQAUUUUAFFFFAFe+srW/gaG+toLmFuDHNGHU/geK4u/+Evgy5mae10j+y7oggT6VM9mwBBB4jIB4JHIPU13lFaQqzhrFtBa5n+HdHtfD+hWGkacrLaWUKwRBjltqjHJ7mrs0Uc8LxTIskUilXRhkMDwQR3FPoqG23dgeb/D6dvAfiuXwLqEjHSLwvd+Hp5OgXOZbTPqhO5euVJ9AK9RvbqCxs57u7kWK2gjaWWRuiIoySfYAVyPxB8Lr4q8PPaxTG01OB1udPvF+9bXCco49ux9QTUnwz8VP4s8Ov8A2nbi21uxkay1SzI/1U69ceqMMMCMjBxk4NfT5fi/b07S+Jf1cxnGzOl0zUbLVbRLvS7y3vLV87ZreRZEOOuCDirdfM83gNPBPxNutN0TVdT8OxayxvNGu7SbMJkUZktZYT8jhc7lBGdvGSRXdQ+P/FXhQqvjfRk1XSxgHWNEQsYx/eltz8w9SVJHtXpcjtdB7OTXMtj16isnwz4k0bxRpy3/AIf1K21C1b+OF87T6MOqn2IBrWqSAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiuP8cfEDSPCjxWb+dqOu3HFtpNivm3MxPfaPur33NgYB69KG7asDsDxkk8V5vq/xRt7jUZtI8C6bN4n1eJikpt28u0tj0Pmzn5fwXJOKzv+EW8ReOmFx8Qro2GlEkx+HtNnZVKntczKcynHZcLXf6VptlpFhFY6XaQWdnEMJDBGERfoBXk4nNYQ92lq/wAP+CaRhfc4M+ANT8UbJviTrkupR7i40fTybexTJyFbGHmx0BYj6V3ml6bY6TZR2el2lvZ2kYwkNvGI0X6AcVborw62IqVnebuaJJbBRRRWIwooooAKKbI6xRs8jKiKCzMxwAB1JNYA8aeHGbVAmr2sg0y2W8vGjbesUTLuViw4OVGcAk4I9RVKLlsgOhqpquo2ek6dcX+pXEdtZ26b5ZpDhUX1Jrh7H4ll7jTJtV8M6xpWi6pKkNlqVyYirM/3PMRWLRBuMFh3HStz4oWZv/hx4othndJplwFwM8+WxH6ir9k4ySn1Fc6ZGDqGU5UjII7ilrxBNW8XaV4J8LeMrjxEj2d09j9o0oWsfkLbTlEAEmPM3gOCWzjOeMVtRWN/498Z+Ko7vxBrOl6bo1ylha22l3P2cl/LV2mkYDLHLAKDwAOhrR4e2reiC56rRXh48V67J4J0eO51GVtTsPGEOh3V3F8hu40n2kkD+8pXI7nNdz4j1K8g+K/g2whuZUsrq01B5oVOEkZBFtLDvjJx9aTw7Ttfv+AXO3orxP4fDxNd/Dq78Yx6vqmra15F6unac82bfiVwm5esj5Xgk9MKKs/DbXtR1TW9NFn43GssUb+2NJ1S1S1ubdtnDQoEVhhuCDkYPXNOWGa5rPYLnsdFFFcwwooooAKKKKACvN/H0U3g7xFF4/0tHe1RFt9ftoxkzWoPyzgd3izn/dJ9K9IpssaTRPHKiyRuCrKwyGB6gjuK2w9eVCopxE1dWMLx34dtfH3gryLK7RJXEd9pl/Gc+TMBuimUjtz26qx9a5bwF4il8QaO5v4fsmtWMps9StcjMNwnDYx1U/eBHGD3p3gK4bwJ4pbwNfM39jXe+58PzucgLndJaEnuhJZcnlT7Yqv8U7CTwl4lg8e6ermwlVLPX4UGcwg4juQP70ZOD1yp7YNfaYXERklOOzFRqezlZ7EWs+BbKfUn1jw9cz+HfEJH/H/p4CiTpxLF92Rc4yCO3WrGn/EzUfDMiWfxMsEtrcALHr1iGktJj0HmKBuhY9efl966aF0ljSSJleJwGV1OQwOCCD6Y/nSSxxzxPHOiyRyLtZXUMrA9QQeorsnRjLU66lCM9VudhbXEN1BHPayxzQSDckkbBlYeoI4IqWvFIPD+teCbhr34eSo1gzbp/Dt3Ji2k5yxgc/6lzk8fdJPIrvfAXjzTPF63FvHHPp+tWfF5pd4Nk8HOM4/iU8YYccjp0rknBw3OGdOUHqddRRRUGYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUdxPFbwPNcSpFDGpZ3dgqqB1JJ6CsnxZ4m0nwnpD6lrt2ttbBgiDBZ5XPREUcsx9BXnUGg618SpY7/x9A+neHUcSWnh1WwZcHKyXZHU9D5Y4GBnnNYV8RChHmmxpN7Fm88Ya148uJtO+HR+xaOj+Xc+JZkDKcdVtEP+sPbecKOcZ4NdF4M8E6N4RhlOmQvLfXHN1qF05lublupMkh5PPbp7V0NvBFbQRwW8SRQxqFSONQqqB0AA6CpK+bxWOqYh22XY2jFIKKKK4igoooyM4zz1xQAVT1TU7HSbR7rU7uC1t0VmLyuFGACx69cAE/hXJ2PjK81b4jXXhzTdPENvpQLanNeZVmDqPJMABIYMckk9APXFQfHDQzq/gK4ube3S4vtHlTVbaNhkO0J3MvvuTeMe9bRpWnGM9LivoVv+Fnx65ff2V4G06bUta2GZ49QSSxiigGMSsXTJDFgFAGTz0ArH1/xvqGv+DdBW0abQb7UdeTQtTaJw0lkwZhIqPjALFVCtj+MHrWtrUj3XifwL438PwTXVrfINPvBBHvY2twoeN2x0VJACT23Gp774cxajrHiyK9df7B10W90EhcpPb3sfBlQ4wCQsbZ9QcjHXoXsoWbVvxe9mv1FqzNlsJPAvjTQLKDUdS1Dw/wCIXlsLm11G5e5MU2wukiM5JAbDKwzjnNZPw/8ADSaj8EvE/guzCQ31rc3+lu5GN0ocmNmPUgq0fPoOK7PQvAtzDrdjqviXxHf6/dacGFis8UcMcBZdpcqgG98ZG4nueK6+0sLSzlupbS1hgkupPOnaNAplfAG5iOpwAMn0qJ17Kyd3pr5q/wCjCx8/wWw1bS9P0+40TxbrHjDzIUmttdkufsNo6sN8rFCkRQAErjJPy19BX1ut3ZXFtIAUmjaNvoRg/wA6norKrW9o0NKx59/wgNzd/By08F32oRR3UNtDAbuKMuqtE6srBSQT90elT6z4I1H/AISW+1vwn4jk0K61FES+jNol1FMyDasgViNrheM8g4GRXdUUlXmn/XULHCP8MdIk8DJ4akutQ+W4+3HUEl23Jut+8z7sY3bie3Sn6D8ObPTPENprt3rOuavq1tFJAk9/chxscDK7QoAHGePXnPFdxRR7epZq+4WRxcHgX7F8NB4S0rWb+zeOMiHUY22zRuZDIG+XHGTggYyMisux8HeJNT8YaLrni+/0VzovmG3OmWrxyTs6FCZGdjhcEnavGa9IooVeav53/HcLBRRRWQwooooAKKKKACiiigDmviD4XTxZ4eezSdrTUYHW5sL1OHtbhOUkB/Q+oJpfAevx+NvC1zaa7ZxR6pb79P1jT3XKrLjDjBzmNx8y9cq3U810lec+PYbjwh4hg8faTE8luiLba9bRjJntM8TAd3izn3XIyAK9XLMX7OXspbP8yJxvqZHg4T+DvEVz4D1KWSSKCM3WiXEhJM1mTgxE93jPB9VwcY69zn/9dV/iV4d/4THwvaan4cnibW9PxqGjXcbqVd8ZCbuhSQfKeccg9qzPBfiK38UeH7bU4EaGR8xz27/ft5lOHjYHuD+mDX19CpzLlZ04erzLle6Nvt+tc34u8I2XiI2915s+n6xac2mp2j7J4D6ZH3lz1U8V0o4xx+tIDyCT1rZpPRnQ0mrM53wx8Q77RtTt/D/xJWC1u5iUstZiGyzvsDoxJ/dynk7Twe3YH1WvP9Z0mw1vTJtP1e0iu7KcbXikGQ3uD2I9RyK5TTfEWr/C94rbX5rjV/A+Vig1Ajdc6YM4CzY5ki5GHHIxg54rkqUXHVbHDVoOOsdj2uio7aeK5t4p7aVJoJVDxyRsGV1IyCCOCCO9SVgcwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyPxE8b2vg+wgVLeTUdbvmMWnaZAf3t1J/7Kg6sx4A98Aw/ETxuvhpbXTdJtv7T8U6llNP05T19ZZD/AAxL1J74wO5FLwT4Ol0y9m17xJdLqviy8QJcXpXCQp2hgX+CMfmxyTXHi8ZDDR7vsVGNyp4X8GXdxrS+KfHEyX/iM829upJttMU/wQqeresh5Pb372iivmKtadaXPN3ZslYKKKKyGFcBffFfw7aX7xtHqcmmx3AtJdXis2axilLbdrS9OpwSAQD3rvyMjFeAp4V1555PhGus6emgJZnUTdi1LXRt2uDthILbCd2csB0Hqa6MPCE78/T8uomz3yUv5TmIAybSVB6E9q8L8D+CtO8Z/D8eIbq5uovHTPMZdVNw4ns7tHYbMZwqLgDZjG365ru/h1rWsza94n8OeILiC/udFkgMd/DCIhNHMhZVZBwrrjBx2I/F+ufDHQtW1a8vvO1Ww+3/APH/AG+n3r28N6cYzKi9SRwSME985qoS9i3Fu2zuv663Fucz4Vl1XX5fAvxA0608y51C0/s7WoYyFDREkiYAnGEkUnuSr4FeusqupVgGUjBB5BFQafZW2nWNvZWMEdva26LFFFGMKigYAA9AKsVlVqc70Wg0ivp9lbadZQ2lhbxW1rCoSOGFAiIPQAcAVYoorIYUUVBeXdtZQma8uIreEdZJXCKPxNAE9FcLqXxb8C2DMr+I7O4Zeq2Ye6P/AJDDVAfiWbjd/ZHg3xjqAGPnXTfITnpzKyk/gDXRDC1p7QYuZI9Borgv+Ei+IFxO0dr8O1tkAyJb7WoFU+2Iw5z+nvQf+FrXEW+Cy8GWLH/lncXNzMw+pVVFbrLcQ/s/ihc6O9orhBofxNuIUabxT4btJiMslvpMkiqfQM8uSPfAp0Xh/wCJSct4v0GXno+isP5TCtP7Kr+QvaI7miuAU/Fay+aey8Haom7AW2nuLZyPU7wwH096R/G3ibTGP/CQfDzWo4wT++0ueK/UgdWwpVwPTK5Ppmsp5biI/ZuPnR6BRXCWfxY8HTXQtL3VG0m94Bt9Wgks3UkA4PmADoR0Peu1tLmC8t0ntJ4p4XGVkicMrD2I4rknSnT0mrDTT2JqKKKgYUUUUAFFFFABTZI0lieOVFeNwVZWGQwPUEdxTqKAPOfA90fAfixvBGoOw0a+L3Ph+eQkhRnMloSe6Zyvqpx1wKo+NrU+AvHS+JIVEfhnXnS31QDgW13nEdwf9l8hGOOuCetdf8QfC0Xi7w1Np5lNteoy3Fldr962uE5SQH2PX1BNUPBmrQ/EXwPqeieKLYRavAr6ZrVnnlZMY8xePuuMOpHAzwTjNfU5bjPaxs37yMtacuZGjyD6EUdO/HrXGeArq+0q7vPBviGUy6tpCqYLhjze2ZOIpR7jGxvcV2YOTknk19BGSkro9KElNXQme+cHrxTZY0lheKVFeJ1KurgMrKeCCO4p44xx+tAPIJPJ6VRR59bzan8Kbw3eni4v/ALEtdaePnl0rJyZYe7RZOSnbkivatMv7TVNPt77TriK5s7hBJFNE25XU9CDXK44wV4PH1rg43u/hZqMupaVFLdeCbmQyX+nRgs2nMT81xAO8fdkHTqK5atK3vROKvQt70T2+iq2mX9pqmn299p1xFc2dwgkimibcrqehBqzXMcgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcn4/8AGdt4UtLeGKBtQ12/bydO0yJsSXMn/sqDqzngD3wDb8deKrLwd4em1S+DSvkRW1rGf3l1M3CRIO7E+nbJ7Vy/w+8LXcF9d+K/Fe2XxVqY+dQ25LCHqttFnoB/ER1bP48mLxUcNC73exUY3ZN8PvB0mhvd6zrtwNQ8V6nhr68PIUdRDF/djXgAd8AnsB2lFFfK1KkqsnOT1ZulYKKralqFnpdlLealdQWlpEN0k08gRFHuTwK8p8WfFHVr3wzrOp/D7Rzcadp1u88us6irQ27AAkiBCN0rcHnhRxk8jOlHD1K7tBCbS3PX6Kr6bP8AatOtbgkEyxJJkd8gGrFYtW0GFcx4u8E6Z4nurS9nmv7DU7QMkN/p1w1vOiN95Nw6qfQg+3U56einGTg7xAxvCvhnTPC+nvaaRC6iWQzTzSyNJLPIeryOxJZj6mtmiilKTk7sAoqvqF7a6bZTXmoXENraQrvkmmcIiD1JPArz1fFXibxtJJD8PLBLLScYPiDVYmEbg97eHAMnszYXitqGGqV3aCE5Jbnc67remaBYPe63qFtYWq9ZZ5Ag+gz1PsOa4tfiDqmvgDwF4T1HVIW+7qN//oNmQc/Mpcb3HH8K+nNa/hr4X6Np19FqutyT+I/ECjnUdTbzCpzn93GfkjHptHbrXe17dDKacdaju/wM3UfQ8yh8H+ONbXPinxmumxMPms/DtuIscj/lvIGfpkcBexq1p/wc8FW8y3F9pkms3gIJudWuJLt2IOckOSv1wBnHOa9Dor0qdGFP4FYhtsqadptjpkCwabZ21nAoCiO3iWNQB0AAAGBVuiitBBRRRQAUUUUAFFFFAFXUdOstTt2t9Ss7a8gYENHcRLIpB6gggivJPij4B8KeFvBmv+JtDt5fD+pWls80U2mXklorSfwKUU7CCxAxt7gV7LXnHx4ZbjwZZ6OxXOtatZaeFIJLBpldgPfajHnsDUztyvm2A6jw7Hcw+H9Mjv5nnvEtYlmlf7zuEG5j7k5NaFFFfFN3dzpCimTzRW8ZknkSKNerOwUD8TXJax8TvBOkbhf+KNJV1OCkdwJXB91TJ/SnGEp6RVwudhRXny/FGyvZBH4f8OeKdZJIXfb6Y8UYP+08uwD8aUa98RNSONM8D2enRsCVm1bVVGMHGDHErEE/WuqGAxE9o/oTzo9Aorgj4e+JWpE/bfF2iaOmR8umaUZ2I7jdM/B9Dg/SszWPCPh+xJfxv8SNbl2D97Dc6wllEd33cpHsI6jHNdUMoqv4mkL2iPQ9S1XT9Lj8zU7+0s4/71xMsY/NiK8X8YeO/DmlfEDSvEng3VoNW1OXbZappunBrg3ttyQ67AVMkfJGT046dZLG++Bun3DJpml22u3ZO12j0+bUnLL33Mrcn1B5rprX4h6gLZl8J/DPWEjYhh9t8jTkLHqWBJPTvtOa9DC5X7GampNv0E25aJGn8WfD1xqGn2Xivw5HnxDoim4hXaVN3bkZkt2GM/MucA9G+pp/hzWrPxDolnq2mSb7S6jEiE9V7FW9wcgj1FZcmufE2/kDQ23hXRYCeFlkmvZAPQ7di/j/AJNb4f8AhS+8L/2mb7Wl1E6hcG6aOOzW3iilb77IoJwG4yOmRnvXuUVOOjWh0YeM4uzWh12e+cHrxQD+VKOMcfrQDyCTyeldJ1hnvnB68UnBGCOCOfp/WlHGOP1oB5BJ5PSgDgLG7Pwj1aa5WOSTwHqMwe4jTLHSJmP+sVf+eLE/MB908j0PttvPFdW8U9tKk0Eqh45I2DK6kZBBHBBHOa4y4giuLeSC4iSWGVSjo4yrqeCD7dvxrk/AupyfD7X7fwnqs8snhzUJCNEvJnyLZ8Z+xux7d0Pf7vpjkrUre8jhr0eX3o7HsdFFFc5yhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFVdU1C10rTrm/1CdLezto2lllc4CKBkk1aryPxC5+JvjJtChJfwdoU+dVbHy314jArbcjlYyAzY4JIHas61WNGDnLZDSuP8GWNz428Qx+O/ENu0VtGGTw/YSrg28Df8vDjJ/euMfRcV6VSKAqgAAKBgAdBXBat8SLaXVW0XwXYy+JtcU4dLVgttbdeZpz8q9DwMntjJr5abq4yrdK7/I30iju55Y4IXlndI4kBZ3c4CjuST0Feez/ABDuPEF5Lp3w100a7cIdsupTMYtOtz7y9ZT/ALMec+vWn2nw51LxLcJe/E7VI9TjUh4tEsQ0VhEexb+KYj1bjrwa6XxV4u8P+A9PtbaZcTyARWOk6fCHnnPOFiiXtwRnhR6ivUw+VRj71Z38jN1Oxg6T8Mku71NX+ImpnxLqUZ3xQSp5dhaH/pnB0JHTc+Scdq6T4k2sNx8N/E1vJGDCdLuRsHA4ibHT6CvI/ijp/jHxD4B13xB4nuv7Fs7K3N1ZaFZyBvmUqwN1J0c8Z2DgfUV7ZqFuNZ8J3Ntcsyre2TRyNGMEb48Ejr616lJwtansjNmR4BuGu/Avhy5c7nm022kJ9SYlNb1cb8GZ/tHwo8JP1xpsEf8A3ygX+ldlXyFVWm15nSgooorMArl/G3jTT/CkdtDLHNfavekpY6ZaDfPct7Dso7seB+lZ3jnxrNp+p2/hrwpbR6n4uvV3RW7E+Vax9552H3UHp1boOtangPwHB4cln1TVbo6z4nuzm51W4QB8do4h/wAs4x/dH49sengsvdf356R/MiU7aIwtH8A6h4nvbfW/ic8dzLGwltNCgcmzs+hBkH/LaQdCTleuARXp6KqIqRqFRRhVAwAPSnUV9FCEaceWKsjFu5yPxb1y68NfDbxDq+nkLeW1oxiY/wALHChvwzn8K8fb4Q+APDfgm0vfiXql2ur6gFE+oz3rqyzspYqmCVOOeTuztz3xXuPjnw7D4t8IatoNxM0Ed/btD5qjJQno2O+CAcd68z0vVfijomhxaHdfD+x1qSxjjt4L+LVIkhmCjaHZH+YfLj8c+tWB0vwMlth4L+w2fiuLxTBZXDxJeqjB1U4YRuWJ3Ebuvpgdq9BhljmjWSF0kjblWQ5B+hrx34Z+Adffw74psvHcs9leanq5vvO0m8MO5TGnCMhyqggrg44H411HwLgS1+FeiW8IIih8+JAeuFnkAz74FAHe0UUUAFFFFABRRRQAUUUUAFec/FrTPEeo6r4Pn8OaXHqcWnag15cRS3SW8YYRskbMxy3Bdj8qnp9K9GopSipJxezA80Sx+KWpE+fe+FdChIOPJgmvZVPb7zIv6Uq/DjW78g+IfiH4iuF+U+Xpyw2Cn+8CUUtg/UEetelUVhDCUYfDBDcmzzyD4N+CRcpcX+lzarcoSRLqd5NdE54wQ7FSPqK6/R/D2jaMm3SNJ0+xXaE/0a3SPKjoDgcitSit0rbCGyhzG4iZVkIO0sMgHtkZGR+NeAeMtW+KehaxM/iTU2tfDTEFdR8OaWlwIh38xJC0iDuThueh7V9A0U0CPCNE8KaN4m01LyXxf4h8TWbgje+sP5fP3lKx7cehU1uaX8PvCGlFDZeG9KR16SPAJXHb7z5Na3ir4WaZf3kuseF55PDfiNjuF7YjEcxz0mi+7IDznIzznNc3Y+Lr7RNTh0T4iWUek6lIRHb6hES1hfHp8kh+45wfkfB/OuqnOD0tY7aVSm9GrM7SJFijCRKI1A4VBtAH0FO75/WlHGOP1oB5BJ5NdJ1iZ75wetAP5Uo4xx+tAPIJPJ6UAJnv0PXigHHrQSEG5sKo5JJwOO+fSvE/EPinXvEYOrmDWdO+HUJO+802REu7lAcGY5O9YRz90ZxzUylykynyntvIPoR2pAcVwvgdL3TvFOq6TDeahqPh5bS3vLO5vZDKVeQtmNJTy64AbnOP593nkEnr0pp3HF3Qme+cHrxWX4m0Kw8S6HdaVq0Pm2dwuGx95T2ZT2YHkH/J1Rxjj9aAc4JPXpTauNq5kfCfxNfNPd+DvFEvmeIdJjDx3JwBqFqThJ1HqOFf0bHrXpNeQ+PtAvNQgs9X8PSC38TaQ/n2EpJ2y9N8D4IzG4GCM9fxrvvAfim08Y+GbXWLKOSDzC0c1vKMSQSoSrxsPUEH8MHvXBVhyPyPMrU/Zy8joKKKKzMgooooAKKKKACiiigAooooAKKKKACiiigAooprtsRm2lsDOF6n2FAHC/FfxFf6dYWWheGmH/CTa5IbazPX7OgGZLkj0Rf1K9awLfxF4d+H+n2Hg3wzb3Gt61BHsTTrAB5WYn5pJn+7HljkliOvSsLSPh34z8XeLdS8TeLdTfw/a36rAmn2bhrpLRTkQGYcRg9W2ZJPUjpXr/hbwvonhSwNn4e023sYCQX8tfmkI7ux5Y+5JNceIwv1iS537q6dylK2xwkfgrxP4ylWX4g6mllpDDJ8P6TIyq4PaecYZ/cLhc16Fpem6V4b0hbXTbW003TbdS2yJVijQdSx7e5J/Gsfxv460jwikEN40t1qt3xZ6ZaL5lzctzjag5A4PzHAHrXHJ4R17x7cR3vxIkFppCsJIPDVpLmPsQbmQf605Gdo+UH8RWjdLDRslYWrLd3491Pxdcy6d8MYY5oEbZceIrpCbOA8ZEK9Z369MKOMkitnwb4F03w1PLqDST6nr1wP9J1W+bzJ5M9VB6Inoq4HTrXT2ttBZ20VvaQxwW8QCxxRKFVAOwA4AqWvPrYmVTTZDSOW+K1ubr4Y+LIRnLaVdYA9RExH8q1/Bl2+reBtCvJlRHvNOgldU5VS8SkgZ7c0eJrb7b4a1a1/572k0X5oR/Wsv4N3n2/4U+Ep9mz/AIlkEeM5+4gXP47c104F+6xMw/gQPL+FWhwb9/2bz7bdjr5c8iZ9vu131effA+N7Xwbd6fMVMthq+oWz7TkbhcyE4Pp81eg187ilatNebN47BXE+MvFN7/aieFvByRXXie4Tc7vzDp0R/wCW03/sqdWOO3WPx74wubPU7Twv4UjW88V6iPkGN0djCThrmb0Vew/iPH16bwN4RsfCGlvb2ryXN7cuZ72/nOZruY9Xc/yHQCu/AYD2v7yp8P5/8Aic7aIZ4G8G6d4RsZFtt1zqVyfMvtSnAM93IeSzt1xknC9B2rpqKK+iSsZBRRRQAUUUUAFVNJ02z0mwjstNt0trSMsUiToCzFj+ZJP41booAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqjrWk6frmmzafq9nBeWUy7XhmUMpH+Pv1FXqKAPE9T07VfhVL5tuL3WPAYG6QsxmutJ9T/ekh79yoB7DnsrC8tr+zhu7GeO4tJ0DxzRMGV1PcHvXcsAylWAKkYIPQ1434j8KXnw6uJNc8GW8tx4bdzLqehx5YxAklp7YdiO8Y4IHFb0q3LpLY6aNfl92Wx2We+cHrxQD+VVdJ1C01XTra/02dLizuEDxSxnhh/T0PvmrYPOSeTXYd5HcRJcW8sMwzHKhRwOMqRg/zry8+DfGI8OL4OTVNHj8NCP7KdQCP9tNr/zz2Y2bsfLuz+tep+mRwf1pQeQSeTScUyZRUjnPCWsWc7XeiwW01jdaOVt2tJiC3kgYilUj7yMo6jvkHnrftvEGj3OrS6XbatYS6lF/rLWOdWlX1yoOeP0rktSvdf1vx7qOkeHtQtNFh0q2t5Li6ks1uJblpQzKoDEYjGDk+pOOted6Rp9xNotr4Z0rw3cHxRpGsCOXX4o1EKSRyh5JmmzuJaNsFCP4u/So52jN1Gj6EB75wetAP5UpxnIGATxQDyCTyelaGwh5HP1riWu1+HnxAGtMSnhnxA62+pAfdtrw8R3B9FcAqx9cE1244xx+vWqOt6XZ65o95pmpx+dZ3kRikX1B7j3B5B9aipDnVjOpDnjY9Aorzn4M+ILq50698Ma9O0viDw+4t5pX63MByYZh67kwD7g5616NXn2seY1bRhRRRQIKKKKACiiigAooooAKKKKACiiigAoorlPGvjzRvCbw2t08t5rFzxa6VZJ5t1cE/wB1B0HB+ZsDg89qAOnuJoraCSe4kSKGNS8kkjBVRQMkkngACvMbzxvrHjO5l0/4ZRotijGO48SXcZNtGQcEW6H/AF7defujjk5qOPwlrfjmWK9+JLpBpqkSQeG7OUmFT63EgwZm/wBkYUe9ej20EVrBHBbRRwwxqFSONQqqB0AA4A9q4a2MS0pjSOX8FeBNK8KtNdxma/1u65u9VvW8y5nPf5j91f8AZGBXWUUV50pOTuygoooqQGyIJI2Q/wAQI/OuJ/Z9nSf4PeGwisvkxPbHOOWjleMnjsSpNdwO1cL8BZI18BSWSbvMsNU1C2lBGMMLqRuPXh1r0MC9ZIllX4RLNDJ44trgbZIvFF8wXOflkKSKevcODV/4g+LpNCW00rQ7cah4p1MlLCzHIHrNJj7sa9Se+MDuRxtr4tTwpr/xCiW1lvdYu9cRNO06MYkupXtotuPRBtyX6Ac+me7+GvhC50SG51jxJLFe+LdT+e+ukB2xr/DBHnpGg446nk9q5VgXWxM5z+FP7y+aysWvh74KtvCNncSyzvqGu37edqWpzD95cyf+yoOiqOAPfJrraKK9pK2iMwooopgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFeP/ALQXizUPDzeF7C31t/D2marcyxXurR23nPbhVBUDsNxJyeuBkdDVPwtY+JY/F+kah4S+IK+L/Dkh2ajb3k8TtDGQvzqU6tncRwMYwc5NADvFGj3fwx1m88Q6Qklz4NvpjPqlig3Pp8jH5riIf888n507dRx07S2niuIIp7eVJYJUDpIhyrqQCCD3B7V2c0UdxDJDPGksMilHRwGVlIwQQeoPpXienQP8NfFsXhe7dj4Z1WR20K4c5+zy9XtGPYc5TPXOMk5x0UalvdZ1YerZ8rO8z3zg9eKAfypR24xnvQDyCTyeldZ3HMeJ/CFvreoQ6lbahqOj6tHF5P23TpRG7xZzscEEMMnI4yKueGNB07wnohs7JnWBWaee4uZdzyu3LySOepPrW0OMcfrXJeL/AAxY63dreeJtVmOgW0YdtNdxFbM4OTJKwwXHT5ScDHfNS1bVIlq2qWpRsviAPEev/wBneCbaHVILaVPt+oyS+XbxITyI8fNI+OmBt967zPPGcf0ryqyaDxT4v8PX3gvSktNG0aZvtGsCEQR3ERUqbeJcAyITg7sbQRke/qo7ZPJHB/rSg7ig29xM984PXigHH0pRxjj9aAeQSeT0qyzhvHEreFNe0zx7axs0div2PVo4ly01i5HzY7mN8MPbNe0QypPDHLCweORQ6sOhB5Brib21gvrOa0vIhJbXEbRSoeQ6sMEfkazvgfqV0mjah4U1WXzdR8Nzi0EjHLTWrDdbyH6p8v8AwCuTEQs+ZHDiYWfMj0qiiiuc5QooooAKKKKACiiigAooooAKiurmCztpbm7mjgt4kLySyMFVFHJJJ4AHrXL+NvHmleFHgtJBNqGt3X/HppVkvmXE+e+3+FeDlmwOD9K5WHwXrHjW5g1D4mzR/ZEIkg8N2jk2sTDoZm6zP7fdHOM5rKrWjSV5ALd+M9e8czyWPw1RbTSlYxz+JbyImMEHBFtGf9aeD8x+X9DXReCfA+k+EkmmtRNeardYN5ql4/m3Ny3+055x7DiumhijghjihjWOJAFVEAAUDoAB0AqSvLrYiVXTZFJCUUUVzjCiiigAooooAK4P4LbI4fGVqrfPD4lviy/3d7Bx+jA13lcL8LfKh8VfEa2V085dcWZkBG4B7aEgkehIb8jXdgX77Qma+neAtJtPiFq3jKVTcaxepHFEzji2jWNUIQerYyW9OBjnPXUUV6ZIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHmvxd1/UvD13o88+gf274QmMkOqW8Fl9pnQlcRsFJ27STg5Ht3FeV6jp/hnUfHfhO++Ffh3WtL14alG13JDZS2Vulp1l3h1Ccg4wOvI54B+nqMUAFYXjXwzYeL/Dd3o2qKxgnAKyIcPFIDlZFPZlIB/ToTW7RQB5F4B1e9ube90bX2x4i0WX7LenaV85f+Wdwo/uyLz9c11Q4+lc78YdOk0K+sviBpcZd9OT7Pq8KZzc2JbJOP70bHeOnG7ngCt61uIbq3hubeVZYJkV45FOQysAQw9sGu6jPmjruelQqc8dd0SZ75wevFVtSsbTU7GWz1G2hurSUASQzIHRwCCMg9eRVkcY4/WgHPU9a1Njy2y0S38d+IfEf/AAlE8zabo161jbaNHMYIY0VQRNIFILFs8dgM1e+FE0Kar4p0/Q55bnwvZ3ESWErSGVUcofOijc5LIrYx2Ge9P+LGheFY9Iu/E3iDQf7RntVRNsUrRtcEsqIjlSARlhyc4o0Lw54gYWcut6jbaBpVkVkh0XRAI4k2nOJpiMsPUABTzzWVrMxs1I9Bz74PWgH8qg06+tdRtIrvT7mG5tZPuTQyB0bBwcMDjggirAPIJPJ6VqbCZ79D14rjNfmPhj4i+GvE8e8Wl640PUtpGNkhzBI2f7snGfRsex7QcY4/WsTxpoa+JfCup6S7bJLqEiF/7ko5Rx9GANRUjzRaIqQ54tHptFcn8KvEcnirwFpOp3Ssl8YzBdo3VZ4yUkzj/aUn8a6yvPPKCiiigAooooAKKKKACvMvjF4h8X6SLW08L6PeGwuFxd6zawrdy2gJPEduDuZgBnJG0ZHU5x6bRQB5R8I5vAaC4/4RfVY7/XLn5r64vXP9oTt3MgfDgZ7ABa9MrF8VeBfDHizDa/otpdzgALcbdky46YlXDjGexrh/A1veaR8Vdb8PadrurX/h/TNPhea31GUTmG5mOUVJGG/aI1Jxk/e9q83EYblTncpM9SooorgGFFFFABRRRQAUUUUAFcD4CiEPxf8AiUeAZhpkuPX9wy5/8drvq4LQIvK+OviVsf63RLFyf+2sy/0rswTtU+QmekUUUV6pIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAMkjWWN45FDI4KspGQQe1eMeAA3h3Wtd8ET7lXSZftGnFzkyWMpLJg99jFk/Kvaq8t+NVi+lNpPjuxjJn0Jyl+qD5prCQgSj3KHDj0w1aU5csrmtGfJK5v575wevFAP5UkTpJGkkTB43AZXU8MDggg+mP504HoSevSu89Mq6pp9pq2nXNhqUC3FncoY5om6Op6jjp+FeN6tpukaXeLpfjLX9c8XXyHfb+H7PzJAqZym9ActxjmRsfXv7d6ZHX9a5nxbrr6Dc6Olhp8VzqGsX0dkGZhGANpZmZsZOFDYHr+sTSepE0nqZPgPxRNcarcaDqXh8eGZY4xLp1gVOZIBwzZUbBgkfKpyOc+/edO/HrXj2qeLNfsdZ17XDqMA0nSNZi0r+yTbrmeF9nzrJ97zDv3ADj5TXsR4YgnJ6UQfQUHfQbnvnB68UD/JpRxjj9aAeQSeT0qzQ5v4WSro3xC8aeHclI7qSPXbVOxEo2TY47SIO/fgdSfVq8e8UWGt2fi3QfE3hiytr68tI5rK5tp5xAJoJACD5hDY2uoPAyc0pb4matta/wDEei6Amf8AV6VY/aXI9C83Hfsvb8+KdKXM7I8+dCTm+VHrzsEUsxCqBkknAAqCw1Cz1FJX0+7t7pIpDDI0EiuEcdVODwRkZHWvAfHvhfS9I8LX+seJtQ13xNcwpttoNRvnaOWdsJGgij2rySAeDnk+9esfCbwjD4J8B6Xo8aKtwsfm3TAAb535c8eh4HsoqJwcNzKdNw0Z19FFFQQFFFFABRRRQA1mCKWboBk15j8FA2o6RrXimXcz+IdUnvIiwAYW6t5cKn6KmfxzW38Z9Wl0X4X+Ibq1d1unt/s0BjGW82VhEmOR3cc9uvatjwxpMWg+HNL0m3AEVjbR26++1QM/U4zXFjZ2go9xo0qKKK8soKKKKACiiigAoorkPFPxH8MeFdeg0nX9QNncywC5DtEzRqhYqCzKCFyQeuB71UYuTskB19efRxsn7RMUoJCS+FXUgHglbtMH/wAfP5+9drpWqWGsWaXek3tte2rdJbaVZFP4gkVxmu74fjj4LkjZlFxpmoQyYPDqphYA+2efwrowmlVJiZ6VRRRXrkhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVV1Wwt9V0u70+9TzLW6heCVc43IwII/I1arI8Q+JtD8OWxn17VrHT4uxuZlQt14AJyTweB6UAeY/Cu4uI/Dk2iXzs1/4fupNKmZgQXWM/un9w0ZQ5712QP5V53omvafrPxh1TUPCUN1c6HqWnp9tvRbPHAbqJyEKswAYlDgleuAeea9FB5BJ69K76TvFXPToy5oJsTtWP4p8P2viTSxaXck8DRypcQXNuwWW3lU/K6HnkZP4HFbI4xx+tAPIJPJ6Vo9TVq5zPhvwfZaPa3C3c0ur3dzeDUJ7q+RWdpgAFcADC7QMDHSumB//AF0DjHH60A8gk8npSSS2EkktBM984PXigH8qUcY4/WgHkEnk9KYxM984PXigH/8AXSjjHH61n69q1toWiX+rX7YtrOBp39SAOg9ycAfWgH3OdEJ8W/FvTtL8sSaX4ZQanenPym7cEW6fVRuf/PPslcF8GNAutH8Im+1fnW9bmbU77nIR5MFYx7KgVfqDXe1505c0rnlVJ88mwoooqSAooooAKKKKAPNPjERqGq+BNAAy1/rkdy4KZBitkaVuexyE+ozXoFef6h/xM/j5YR/u2g0XQpJ9ynLLNcShACO3yRkjvya9ArysbK87dikFFFFcYwooooAKKKKACvPfhai674o8ceJpog8FzfDS7Rn5DQWw2krx91pDIffHtXU+NNXHh/whrWr5ANlZyzrnuyoSo/PAqr8JNI/sL4aeHLBiWlWyjkmYtu3SON7nOBn5mNehgY6uRLKGrfCfwrd3bX2mWs+gaoRgXmizNaOOMcqvyN+Kn9TnKsvAniy38e+HNVvPFMGr6ZpZuVP2m0WK6Mcse3YXQbX+ZUOcKeD1zivUqK73FN36iCiiiqAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKRslDsIDY4JGQD9KWigD58x4s1Xxle+HfHfi7U9OuUBlsrfR0WzhvrfjLpKMuWH8SZyvbIzXUaN4B8L6RcG6ttHt5bxm3td3ZNzMxJ5JeQsck+ldf8Q/BNj400uOOWR7PVLR/OsNRg4ltZR0ZT3U916Ee+COQ8Ja/fS39x4e8VQpaeKLFA0ip/qruLoLiE91ODkdVOQcV00JR2a1OvDyg/da1Oo545xjoB2FAP5Uo4xx+vWgHoSevSuo7RM984PXigH8qUcY4/WgHkEnk9KAEz3zg9eKAfypRxjj9aAeQSeT0oATPfOD14oB/KlHGOP1oB5BJ5PSgBOeo478VxPiuBfFfjfw94MA82yyNW1YDkfZ4j+6jb1Dy449BXZXNxFaW0tzcuIoIkMkkjHhVUZJz6AA1k/BDT7m40/VfGGpq8d54jnE8MTjBhtEBWBPxXLf8CHfNY158sbdznxM+WNl1PTRRRRXEeeFFFFABRRRQAUUUUAebeFN9x8YfiHcvGFW3TTrJGGfmAhMpP5ygfgK76vPfhCqTXHjjUEB23fiS62kjBKxhI/8A0JWr0L0rxcS71WUgooorAYUUdhRQAUUUelAHnfx1xd+DbTQt5jbX9Us9L3K20hXlDPzz/CjV6fXmvjdmuPid8OLFGAAuby9YHuI7cpx75lr0qvXwatTv3JYUUUV1CCiiigAooooAKKKKACiiigAoqtqd/a6Xp11f6hOlvZ20bTTSueERRkk/gK+fYfj94l8T390Ph54Bu9V062Yq1zKzZb0yFGFJH8O4mgD6LorhPhF48n8eaNfXF/olxomoWFybS4tJ2JKvtVs8qpHDDgj866iPxBo0mo/2fHq2nvf5x9mW5QyZ9Nuc0AadFeN/tBfFDWvhze+FYtDttOnXVZJ0nN5G7FQhiA27XXH+sPXPal+IfxQ1rw38bfCvg6xtdOk0zVY7d55Zo3MymSaRDtIcKOEGMqec0Aex0UVS1TVdO0mJZdUv7SyiY4V7mZYwT9WIoAu0VnnW9KW1ium1OxFtN/q5jcJsf/dOcH8Ks3N5bWtt9ourmGG34/eyOFXnpyeKAJ6KrtfWi2X2xrqAWe3f55kHl7fXdnGKpQa9pt/YXdxo+o2N95EbMTbzrKAQMjO00AatFeRfs6fErWPiVour3mu22n28tncJFGLON0BBXPO525/KvSrnxBo1rfrZXOrafDescC3kuUWQn/dJzQBp0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAVxXxJ8Cw+Lba2vLK4OneJNPJk0/Uox80Tf3HH8UbdCtdrRQB5P4Q8Rz6m11pmt2w07xJp5C3tnngg9JYj/FG3Y9uh9+lB/KqvxL8CN4ie11vQLhNO8W6cp+x3hHySryTBMB96Nsn6ZyO4OT4O8SDXre4hvbWTTtbsXEOoafLy9vJjqD/ABIeqsOCDXbSq8+j3PQo1ufR7nQZ75wevFAP5Uo4xx+tAPIJPJ6VsdAme+cHrxQD+VKOMcfrQDyCTyelACZ75wevFAP5Uo4xx+tA55J6jr/WgDh/iSZNal0bwXaO6z+IJ9ly0fWKyT5p29sjCf8AAjWf+0Nr97pVvpHh/wALxwRwaTHFrd9HztjtreVBFGQOxcZx/wBM63PhW8Gpan4o+IepFItOw1jp08jcJZQEmSUf7LuGbP8As/ny9pYv4i8A+OfE1+kiXfie2uJoVk+9FapEy26fkN3/AAKuNr2s32R51R+0mz6Ct5UngjmiOY5FDqfUEZFSVz/w8vJdQ8AeGb25Kme50y2mkKjALNEpOB25NdBWBgFFFFABRRRQAUGiigDzT4HXKX/gaTUYVkSK+1TULlA/XDXcmM4NegV53+z7H5fwk0MYxl7l/wA7mU/1r0SvDra1JepSCsrxXd3lh4W1i80qHztQt7OaW3j27t8ioSox3yQOK1ayfFutx+G/DGqa1PE80djbPcGNDgvtGcA9s+tZx3QzxHwbYaTda3Z3UfivUZhqHhae71HVjqTB0maWEblydsRT94MADHQ16r8I9Wv9d+HOiajq7mW8miYNMV2mdVdlWXHbeoDf8CrzO78Eazq14us3Xwv8EG7nImZJL99xJ5+cBNhPPPXPvXuGj/aP7Jsvt1vBa3fkJ5sEDbo432jKqcDKg8Diuis00JFuiiiuYZwMsZvPj7p4khDxad4dmmV2/wCWck1wqgj3KxuPz9q9JrzjSX3fHrWRn7vh60HXP/LxMa9Hr28OrUokMKKKK2AKKKKACiiigAooooAKKKKAPNv2j4Lq4+CfilLEMZRBHI23r5ayo0n4bA1c9+yNqGl3Hwgs7Oxki+32s8322MH5w7SMVYjrgpsAPT5SOxr2eWOOaJ4pkWSJ1KsjDIYEYII7ivDtb/Zl8G3upS3em3msaQJSd0FrMpjAPULuUkD2yRQBN+0f4yS1+FWuN4Uv4nuTexadfT2j5aHcNzKWHcgBT6BscGvCbX4YeI/EPw/0Sbwx8OkgumSO5TXI9diL3Axkkxs4C5POOCpGPXP1P4Y+E3hPw/4Kv/C0FnLd6VftvuhdyF2lbAAbIwFI2ggqBgjI5ri0/Zw0GGN7S28TeK4NIckvYR3qiM56jGzGPqCfegDzL9pJ9Rk8OfB59cZX1Q28n2l1kWQPJi1y25SVbPXIJBzW/wDGr/k6/wCHf/XGz/8ASqavVvGfwd8OeLdN8L2N7canbW3h2LyLJbWZBlNsYAcujZwIl6Y71d8UfC/RfEnxC0bxjfXWox6npSxJBFDIghYRyM43AoWPLnOGHGKAO8r5F8HaDY/Fj9oPxlF4+ea5j05pktrAzNGNiTbFUbSCFUckDGS2T3z9dV5V4/8Agb4Y8X6+ddE2o6RrDcyXGnShPMOMbmBB5xxkYz3zQBx/xO+DWgaf8IvFGn+ExI01ncjV44Hl8xoHWMB4wfvYMWSASSSR7V5Pf+Mrz4o+CPhx8PbKVzqTXHk3z8nCx/JE59QIyzH3WvqbwD4H0j4a+GtRgsZ9QvopWe8upbphLLK2wA4CgZ4XpjP1rxH9lLwDcReMNe8V6no11pcMJa3062uomRk8wksRuAJ2phc995oAq/Hezjvvi54C+HtzcSWHhCOC2RIkbYrZdkznpnCKgPOCT6mvXdG+E3g3wTrM2reG4pLC9fT54PsxumkWVSFLNhyWyMDocc9OlbfxN+GPhz4j2cEWvwzJcW+fJu7Zwk0YPUZIII9iDWJ8P/gvo/g7V7jVE1fWtSvpbV7MPezqwjibGQoC9ePXHtQB4R8CNZv/AA/8A/iVqeksyX0DJ5Tr96MsoXePdQS34Vzfg/wDrXi/4bNNo/w/TVb67kkI1863GkgcOcgws4xwMEMMnO7PIr6v+HHwq8P+A9D1XSdOe8v7HUzm5j1BkkDDbtK4VFGCDyDmuQb9nTw9b3E/9ieIfFGj2Vw26W0s70LGR6DKk9OPm3UAdh8DLbXrH4ZaRZeK/wDkK2nm27/v0mO1JGVQXRmBIAC9eNuDzmu9rD8E+GdP8HeGLHQdH877DaBhGZn3udzs7EnjqzE1uUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeefEfwPc6jfw+KPCUkdr4rs02AOcRX8PUwTfXs3Y/p6HXK/Ebxvp3gHRrXVdZjmaxmvI7SR4hkxBwfnI6kDbyBz6ZoTtqhp21RznhTxFb+IdOaeKOS1vIH8m8sphiW1mH3kcfyPQjmtoH8q5zxv4Vnub6Hx/8O5IZ9WkhRrm2SQeRrFvgbRu6BwuNj/QHjpe8La/ZeJNJj1CwZwpJjkilXbLBKOHjkXqrKeCK7qVTnWu56FGt7RWe5q575wevFAP5Uo4xx+tAPIJPJ6VqbiZ79D14rkPiZfXa6HDoujMBrWvTrptof8AnnvH7yQ47IgY/lXYDjHH/wBeuT8BQr4s+J+seIJl8zTvDqnStPY8q1w3zXMg9x8qZ9Cazqy5YmNefJAZ8TrOKx8MeF/hlogdY9UC20zjkxWMAUysT2ZvlX3LGumu7WL+ybi1jjVYPszQqg6BNhAA/CuR8ETN4p8V+IPG0pWS1nkOmaSwOR9khY5dT/00kyfwrtZ/9RLz/A3b/ZNGHhywv3OWnGyuQfAqeW4+D/hJ55DI/wBgjTcfReAPwAA/Cu7rz/4A/wDJGvCf/XkP/QjXoFcBzhRRRQAUUUUAFBoooA84+BW3/hVHh/ZjHly5x6+c+f1zXeV57+z+/mfCTQzkHDXK8e1xKP6V6FXhVfjfqUgrnPiRJdxfD/xE+nW8NxdCwm8uKZQyOdh4IPDcZ4PXp3ro653X9RaRtU0yXw3fanarYmZiUjMF0ScGAbm5cjJwRjHelDcDzbw3odqPD+niz+MWqNbiBNhW7tcYwOm5Swx0wTkdK9f0ZPL0iyj+2vfhYUX7W5UtP8o+cleCW68cc14y+j20+Tb/AAFt29DLJYxZ+vzV7JoMIt9E0+FbBNNEdvGoskIZbfCj92COCF6ZHHFaVdf6X6Ai9RRRWAzz7Qd3/C/vEm4jH9hWeAPTzZev45r0yvN9ITb8etbOMB/D1ofr+/mH9K9Ir3KH8NEBRRRWoBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXl3x/ijuNF8KQzIrxSeJbBWVgCGG5sgg9R7V6jXmfxnDz6l4CsuPKl1+OV8jP+rikcfqKqPxIa3Od0/VpvhLqS290ZJvh/dS4Rzlm0aRj909zASeP7pP563jXwleaJrE3jXwFB58twA+raRCRs1FOvmxdhOM5H976n5ujuraC9tJba7hjmtp0Mckcg3K6nqCPSuM8P+ILj4Y6nbaJ4guJZ/Bl04i03U5mLNp7npbzMesf9xz0HB46dFak4Pniayi4PmidL4f1qx8QaRb6npM4mtJxuVgMEHoVYdmB4I7fz0OnfiuS8X+FrzwRrd14s8IW0lxpN0/m6zo0I5J73MA/vjqyj7w966PSdStNX0221DT7hLizuUEkUqHIYHv8A0x1BrWnU50dtKqqi8zG+IGuTaB4XubmxjMuqTlbWwhUZMlzIdsYH4nJ9lNZ/iq1fwJ8INH8E6TMJdf1kDTI5QcEyS5a4uOMHChnbPXlc5qTTbYeLvi/FC+W0rwlGtw687ZL+UYQHt8iZP1am2twfF3xU1fWZMNpnh0PpGnY5DTsAbmX6j5Y+PQ1jL95U5UctaXPPlWyOn0XTbXRtJstNsECWtpEsMYA/hUYz9T1P1qa/cRWF1J0VYXYn6KanH04zWH45vBYeCfEF4xx5On3Dg+/ltj9a7Xoiy98BUZPg54TDKVP2FTgjHUk131c78ObWax+Hvhe0uk2TwaXaxSLkHayxKCMjg8iuiryTjCiiigAooooAKKKKAPMvgTCtl4CbTFk8z+zdT1C0L4xu23UhzjPHXpXoVeffCbEN947sVj8tbfxJcMqHIwsiRyZ57EsT+Neg14ldWqSKQV5N438R3Phf4xabcxaXrOsQ3uhSwiz01PNYOk6tvKlgMANgnryK9ZrB1Lw5He+MNF8QG4eObTYLiARBQRKsuzqeoxsyPrUU2k9QOU/4T3xZcDOnfDLW39PtV5b2/wDNjXdaBc395o9rcavp402/kXM1oJlmERyeN44PGDx61fFH86JST2VgCiiioGef3QjtP2gdHnlcob7w7c20YOfneO4ikx+Cljz/APr9LrzH4gMmn/EX4catIyohvrjTGZgT/r4CVAx3LRgD616dXs4V3pIlhRRRXQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiisXXvFXh/w9JFHr2t6ZpskoLRrd3SRFgO4DEZFAG1RVHR9X07W7IXmjX9pf2hYqJrWZZUJHUblJGavUAFeV/EEm/8Ai94LsgXEdhZ32ouN3ysSEhXI7kb2wfc16pXkNtnUvjV4u1BgNmm2NppMTBCOTuncHPXG9eR6/npRV5oqCvJHXdD71U1XTrPVtOubDUbdLizuYzHLE4yGU/5yD2PNWx9OM0D36n2r0zqOQ8JeKbzwPrdr4U8X3MtxpN04i0XWZeSfS2nb++OArH7w96oeK9BvvhbdX2veE7GbUPC9zumvtHgGWs5evnQD/nmTgMnbqOOnW+INFsPEGkXOm6rbiaznXawzgg9mU/wsDyCO9ZfgfxhfaDrlv4N8cXJluJeNI1iThdQQdI5D0E44H+19SN3DVpum+aOxjJOm+aJRtnuvhn8E5bu5Rj4t1ZjIyjBebUrk/KvPHyZAx6Rnr32PBWgR+GPCunaRGxkNvEBLLnPmysS0jn1yxJrL8QT/APCW/GCK2C50vwjGJXY9JL6ZQVHodkfPsWrrx0Gev51phoaOTHTX2mHf3rivjNLIvw31e2t0eSe/8mwjjQZZ2mlVMAdzgmu1H04zXG+N1OpeK/AWirtc3GsC9kRs4MdtG0hJx/tFcds4raq7QbLm7RZ67aQC2tYYEJKxIEBPUgDFS0UV5hyhRRRQAUUUUAFFFFAHmnhSRrb4xfEKzldT9pTT7+IA8hfJMTZ98xD8xXoFef62Dp/x70G5Lt5eraHcWO0rhd8Mqygg9zhn49BXoFeRi42qspBRRRXKM8O1vWtcu9d1XxBJrd3aWHh/xHbaYdIt2CRtbs8aPLNgbmLeblecADvXW/DW4uLLxZ4s8Nf2tdaxpulG2e3uLuTzZYGlVy8DSfxbdoIzyA2DXDeNdc+GXivxle2V3oupa5qEdum6bRVndrkhypjcRlQdmF5YkfNwRiuw+HP9pwapaWeieDJfC/hCKCVpVvTGJ55yV2NtVmbIAbJYnOR6V1yXubWJPTqSiiuQo89+Ohe08Dx63EjSS6HqFrqgVQCSI5QGxnj7rNXpiMHUMpDKRkEHIIrB8U6Umu+GdW0mQDZfWktsc/7aFf61lfBvVzrXwx8PXMpc3MdqtrchwAwmi/duCBwPmU16eBleLiSztKK8O8QWNz8Uvi5rnhbUdSvLPwt4cht3ntLRzE95PKu8FmHVAB7c9PWs+HS/C/gr4paS/gfxrp+nRyTfZdU0O61J51mBO0BASxEgbPDHg46AkHuEfQNFZ82t6VBqkemzanYx6jJjZavcIJWz6ITk9D27VoUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAI3AJr5/+CekaHrnhXVPiV4ztl1PVLua5mlku4vtItoYyV2RJgkgKvGBnsPf6B6ivDtL8P+PvhbeanZeCtHsvEvhe8uWubS0e8FtLYluWXL8FewwT0zwScgFH4P614Ht/ihrieEG1bTYNQtDPJp89n9ntF8ojMyljlf4uMAcn0Ar1jw34/wDCfibUHsdB1/T768VS5hil+YgdSAeoHtXlr+EfE2oeML/xl8SF0+z0V9Au7G5tLKYu9nblcldwHzsQZCSM4PTsKj+Gr6Z4q8S+Er+2k0bRdK0KCSPR9OF5FLqN4Gh275gp+QbMts5bcCTQB7xczxWtvLcXDiOGJDI7noqgZJ/KvHPg9HLP4Tl1u6hEV1r95Pq0i+glf5B7/Iq/nXRfHe/mj8CnRbByuoeIbiPSIMckCU/vG+gjD5NaFjaw2Nlb2lsuyC3iWGNcdFUAD9K6sLG7cjWktbk3f3o/CgfTjNA9+p9q7TcO/vWT4o0Cx8SaPJp+oK4RiskU0TbZYJFOVkjb+FgeQR/WtYfTjNHXqeT7Umk1ZhoznPAfh1/DOhtbXV4b/Uri4ku728K7TcTOxJYjtxtGPauj/Dg0v4cUg9+p9qEklZAlYOhrlvDcbav8cb2cHNroGjpAAM/6+5feeeh+RF4PqDXUkqo3OQqDksewFYXwFt/tfhzVPFMqkXHiPUJrxS64YQKxjhU8dNqZHX72e9c+JlaNjOq9D02iiiuE5wooooAKKKKACiiigDzb4xj+zrvwX4jVf+QZrUUU0mT8kFwrQufTqycn0/A99XO/FrRv7f8Ahr4j05UaSWSzeSFVUsxlT548Ac53KuPf1qz4K1ceIPCGi6uDze2cU7D0ZkBYfgcivOx0dpDRs0CiivPKOA16y8QnTW1GXU/D/hS5t3mSXUFthclLPIK4aTaFJIywORnHpXFeHdX0WfxJZXVjrfjnxzfRTAebbKy2ELfdLEKEiwMnu3416T8UvD//AAk/gXU9OVwj4S4TfG0is0TrIFZV5ZTswQMnnjJrm9N8ZeNtZsIRonw/bTMoMzazeC3hi+kar5hH/AVrpg7x/pCPT+9FZ3h68kvdHtpbm5sLq6ChLiSwfdD5o4YISScA9jzWjXO9NBhXn3wzY6N478ceGHbbALlNZslZusdyD5gUf3VlRunGW969Brzn4hlvD/jrwd4sjZkgNx/YuokYw0Nwf3bOT0VJQD/wL8+nBz5alu4mYnieLW/h18WNS8Y2Gi3ut+G9dtok1KOxQSXFtLENquqdWXGO/ds4wM8b4sB8d6x4evvBnw1vdLtbXWre81HU7jTo7WeU+Z8wAXLOvzF2Y55Az7/T1FeuSfLHiLTNNk8A/ErxHJbW7eJrDxdcGyvSga4VkuIxEgY5O3BICdD6V9TLkqM9cVx1/wDDTwrf+Kl8RXOml9RE0dycTyCJpkGFkaMNsLgY5IrsqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCG8tYL21ltryGK4tplKSRSqGV1PUEHgj2rF0zwV4W0q+ivdL8NaJZXkWfLuLewijkXIIOGVQRkEj8TXQVznxD8TxeD/B+o6zKnmywptt4R1mmY7Y0A6nLEdO2aAOBvrgeK/jJPcI3maZ4TtzaxEDg3swHmYOediBV9ix/Hsf5Gub+Hugz+H/DMFvft5uqXLveahN3kuZW3SHPsTjPtXSD36n2r06UOSNjqhGyDv70fhQPpxmgY/iOPcj9a0KDv70fhXnfgT4hXHiDWFttR01LWx1FrmTRrtHyLqKGQqwYfwsB82ehB/PstP13TNQ1W/02zvoZdQsGC3MAPzxkgEEg9Rz1GRUqSewk0zS7+9H4UD6cZoHqf5VQzkPitqE9n4OurWwbGp6tJHpVmAcHzZ22Aj6Asfwr1DQNKt9D0PT9Ksl221lbpbxj/ZVQB+PFeXxRHxL8ZdMsky1h4YtjqNzhhg3MwKQqe/CB2/GvX68/ES5p27HPUd2FFFFYGYUUUUAFFFFABRRRQAjKGUqwyDwQa8w+DWNKt/EXhJjg+H9TligU5z9lmPnQk5A7Oy8DHy8cV6hXmWrhPD3xx0q7BCW3ibT5LKXC4H2m3IeNie5KM6j6Vz4qHPTfkNHoVFFFeMUYvii+vdNt7W8t7rS7WxinVtQm1BmUJb/xbCDgPnAG7jmvJPEz+Cx4h1Kz+IHi7W9buopV8vSNzpC6uNyLHBAAZcDAJOeRz7+26hZWupWFxZX8EdxaXCGKWKRdyupGCCPSvMvFOhaR8ONNtrzwNo1hp2tanc2+iw3JVjHF50mBJIM/Nj1PJ4GccVvSa26iZ0Hw4vzPbyWum+DLvw1oEKBrVrhI4GlYn5v3CksvrluTmu1rwTW9S1vQ9E1rUr/xNfnxR4TuUgaMuEttWgkcPFvgxje6uyAryCnfFe9KSyqSCpIBwe1TVjbUELWL400CHxT4V1PRbhiiXkJRZB1jfqjj3VgrD6VtUVmnZ3QzmPhL4jufEvgq1n1Taus2jvYalGDkpcxHa+fTOA2PRhXZV5dER4M+L5cqqaN4wVVLYwItQiU4Geg8yMfiy+9eo17tOaqRUkQFFFFWAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeO+IrpfHPxOisI1Z9B8JSiacn7lxqDL8ij1ESkk/7RxXW/FbxZL4W8OrHpcf2jxBqkn2LS7f+/Mw++fRUGWJPHGMjNZHgvw/F4Z8PW+nJK1xPlprm5flrid+ZJWJ5JLE/hit8PT5pXeyNKcbu7Nzv70fhQPpxmge/U+1egdAd/eqWuWcuoaLf2Vrcm0mubd4UuAm8xFlI3Ad8ZzV0fTjNclP4o1G78WTaPoGjrewWMkcepX09wIY4C4DbUGCZHCncQOOQM80m0txOxha/op0rSvDMXhZI9Q1LwhJDLJYRMFmlgeNo3AGeGYZYZ6kH8ZfDbXfib4hw+JP7Cv8ARrCy06Sy36hEIp7t5HU42jJ2IFOCe7cVq+EL7w83irxTa6dqYudblvt95DLhZU2IqKijA3RqBwRnqc12Hv3qFFPUSQd/eob67t7CxuLy7kEdtbxNLK56Kigkn8hUw+nGa4b4krJr11ofgu1fEuu3Gbs5IKWUWHmOR/e4QeuTVTlyxbHJ2VzofgVp0/8Awi1z4k1BCuo+JbltTkBbOyJuIU47CML+Zr0imQxpDEkcKKkaKFVVGAoHQAelPrym76nIFFFFABRRRQAUUUUAFFFFABXCfGjR59S8DXF7pwH9raLIurWLY58yH5tv/Al3L/wKu7ooauBieHtWtte0LT9WsWzbXsCXEZ9AwBwfcZx+FaFecfCjd4e1TxF4HuQEGl3LXmnDoHsZ2LJt/wBxt6HHA4r0f0rwqsOSbiWFYnjS10K98M31v4ra1XRnT9+1zKI0UA5DbsjaQQCCDkEDFbdZmuaBpWvJarrWn2t+ltMJ4UuIw6rJgjdg8HgnrUxdmB4Fo1vo2seJ5rz4daTqfjLV7HYq6x4ivpDZWmMlAm75pCMnAAyM5B5yfXfhv4i1HUor3RvFEQh8T6Vs+2hAvlSrJlo5IiOqEAjnkFeeaxrzSPF/hXW9cuvCMWhXmkarOL101Kd4Gs5vLVHOVBDRkIpxwRWH8M9ZY+Kb+azNx4t1nVLiNdW1izTyNOso4wQkUTN/rAuTwuSckk5rpl78W0I9oooorkGc74/8ODxV4Wu9Ojl+z3nyz2dyOtvcRkNFICPRgM47Zo+GHil/FXhWG4vkEGtWjtZ6nbdDDcx8OMdgfvD2YV0VeYeLnPw+8dQ+M4lYaBqoSx15VHywvkCG7I9vuN7EdTXdg6vLLkfUlnrVFIpDKGU5B5BB60temIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAopksscMZkldUjHVmOAPxp9ABVfULy306wub2+mSC0to2mmlc4VEUZZj7AA1YrxvxvqDfETxRJ4VsHz4X0uQNrc6kEXcwIZLRCOwIy+Ppx3qMXJ2Q0ruyIfCL3HjPxHJ471WCSC3eL7NodpL96C2P3piOgeQ/iFwMkYruv5UiIqIqooVFwFCjAAHQD0FL/X2r0oQUFZHVFJKwd/ej8KB9OM0D3/lVjA9feuBv9F8U6D4i1XUvB66XfWWrSLcXNjfu0TRzhQhkR1HIIUZB9OK6bxQuvfYIpPDD2Au0lDNFfK3lzoAcoGXlD0+bnpWDoXxD0+41RdF8RQyeH/EOB/oV6w2S56NFKPlkB5x0NRKz0YnY4nxJ4QnW10XTr8RT+L9e1pr2fU7RGjNigAaUxOOVARFQAnnk4r2zAAwM4xgZOaXBHBBAzSD36n2pxilsCVhGIGSSB3J9K5r4OQL4h1zXvHUqsY7tzpmlFugs4m5df8ArpIC3/ARVL4m3V5cWFj4Z0Z/L1bxFN9hiccmGHGZ5voqZH1YV6toml2miaPZaXp0Qis7OFIIU9FUYH1PHWuXEz+yjKrLoXaKKK5DEKKKKACiiigAooooAKKKKACiiigDy/4uRDw3q+hfECD5BpkgstUCj/WWMzBST6+W5Vx/wKvREZXQMhDKQCGByCKXV9OtdX0q807UIhNZ3cTQTRnoyMMEfka89+EGo3NrZ6h4O1mYyax4akFrvbg3FqRmCb8Uwp91561wY2ldKaGmehUUUV5pRzPxL8OT+LPA2r6JaTrBcXcQEbOSFLKysFbHO1tu047E1xmj+LfE+uWQ0jwT4Qj0cWjG1lv78hbK3KnawgRMGYAg4ICjjmvWGJCEqu4gcDPWvK28PeL/AIgszeMJ5PDXhwkgaLYTZubhf+m846A/3E7HmtqbVrPYTOq8DeINPvRNocfiNPEGs6Yi/brqOMKCzE/3PkBGMbQSRgZ5rq6ztA0TTPD2mRadodjb2NlF92KFNoz6n1PqTkmtGs5NN6DCq2pWNrqenXNjfwpPZ3MbRSxOMq6MMEH8DVmikgPO/hlqN14Y1h/h7r0rySWsRm0W8fpd2QIAQnp5kWQpH90A+9en1xnxC8KL4q0WOO2n+xaxZSrd6bfAZa2uF5U+6now7g/Sl+HHjE+JrW7sdTtmsPEulMsGp2TD7jkcOh6NG+CVI7fr6+Gr+1jZ7olo7KiiiukQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWN4u8S6Z4R0G41nXJnhsIMb3SNpCCTgDCgnkkD05oA2a4vxf8UPBnhDUI7DxDrtva3jgN5Ko8rKPVginb+OK7C3mjuII57eRZIZVDo6HIZSMgg+mK+XfAN3e+EbbXNA1D4aat4h8W3t9Oby6eAG3u0YnaxmYEbTu6Yxhic5OKAPpzS9QtNV0+C+025hurKdA8U0TBlceoIq1Xi/gbxf4n0Dxd4f8H+KPB+naHpupwSDTBp029YTGpcxvzgkL1I7nPOTj2igAooooAKKKKAPOf2hZ/I+D/iAFN/nrDbYzjHmTImfw3ZrnotJ8W+CsnwTqf8AaulRn/kCaxKX2r/dguPvL7Bsiuh/aAQS/DC8jOCHvbBcHoc3cNa7/fbPUk9RXTQpxmnc1pxUk7nDa78UL/xDZR+GfDGnalpHjG7+S6W8gIGmQjHmT78bZB1VMHkkHjgHpPDGh2fhzRLbS9ORhBCOXc5eVzyzue7MckmtPaMg7eemfb0pR79T7V006SpmsYKIdD70fhQPpxmge/U+1alB396yfFGv2XhvSmv78TSIXSGKGBN8s8jHCxovdien51rEgDLcL6k15X4j8Q6L47azsvCutW6eItMvEv8AThdRvHDdyR5BVWIxIpBYZXOOvvUydkJuxn3OoXE3i4TWcuueCvEmokeXBqyCfT9RYDAUgMVV8AD5Sp9ievSWHhbU/Eer3N/8QdO0ZoPsYsYbG3JnjYF97SszAEHIG0Dkc+vOV4hn8QeN9NtfD9z4Pv8ASJzdwS3F9cSxtb2wjcOXhcHLsdpUYA+9zXqxO5iT1PPSojG7Elco6Nptto2mW2n2KyLbWybI1eRpGA56sxJPXvV0kAEnhccknjHvQPpxmuJ+I91c6i+meDtJlaPU/EMhhklTrb2i8zy+3y5UeparlJQjcbaSuXfhHb/8JP4k1jx5MN1o+dM0YMOltG37yUdvnkB98L716zVLRdMtNF0iz0zTYRDZWkSwwxjnaqjA579OverteW25O7OVu7uFFFFIQUUUUAFFFFABRRRQAUUUUAFFFFABXmHxbifw1qWlfECwjz/Zp+y6ssa5aawkYBicckxthx/wKvT6juYIrq3lguI0lhlUo6OMhlIwQR3FKUVJWYFW3miuII57eRZIZVDo6HIZSMgg+hFPrzX4dzv4R8SXnw+1B8wQob3QpXYkyWZY5hyeS0R47krg9q9K9K8OpTdOTiywooorMAooooAKKKKACuH8feFr25v7PxP4UdYPFGnYCqW2R38GctbSn0PO1j908jHWu4oq4TcHzRAyfA/izT/F+kG8sPMhnicw3dnMNs1rMPvRyL2I/I9RXQ15n428Kanb62ni/wACmOHxDEoS7s3bbDqkI/5ZyHs4/hft0PHTq/BHiyw8X6R9ssRJBcRP5N3ZTjbNaTD70ci9iP1HIr2KNaNVXW5FjoaKKK2AKKKKACiiigArznXvihb6V8XdF8CrpzTy6hD5r3azgCEkOVXZjnhPUdR1r0avkq/t4df+Jx8cvlseOrDR7OQH5TDGCHOeMg7UPTj1OaAPqPX9d0vw9Yi91zULbT7QyLEJriQIu49Bk8djV21uIbu1hubWWOa3mQSRyxsGV1IyGBHBBBzmvkv436nP8U9esIdNmceHYNYi0XT2Qjbe3L/66TOT8iKFAbBHzZ7mvqm8e30bQZ5N629rZWzNvI4jRE64A6AD0oA0KK8o/Z8gu9U+CVi2sXF613qYuXmuHmYykO7qHUknb8oXGOOM4rzrx18N00Dx74F0Sy8W+MHtddnuIrlpdTJdRGikFCFAByx6g0AfTlRzzR28LzTyJHEg3M7sAqj1JPSuf8B+ErfwbpE1ha6nq2pJLOZzLqdz58ikqq7Q2Bhflzj1Jry7XNH/AOFmfHLWvD/iS6nbwz4ctreVNMikKJdSSoG3SkEE4J6ew6ZOQD2uxv7PUEZ7C7t7lFOGaGQOAfTg1j/EHxZZ+CPB+o+INRjllgtFB8uMfM7MwVVz2yzDntXjPxS8F6Z8I4tL8deAon0wWF3HFqFkk7tFdwOdpBDMctz645z1Fez+O/DemeMPCGo6NrfmCwuY8u8bYeMqQyuPcEA9xxyDQB523iD4v2dvaa3e+H9ButNeSLzdIsGle9WN8A4YnZuUnJ7AA84BNep65pVp4i8P3ml6nCxtL6BoZY2xuAYY9xkevqK8P8NeFbS/8KDWbT40eJG0VYvLjn+1iBYWXjDh+RgA/KcHvmu0/Z313VvEPw5jutcuZr2SO7mggvJk2tcQqQEcn+LuM+3OTk0AUP2fdWu7Ky1XwFrsm7WPC8v2dGPHn2h/1TrnsBx7DbXS/EfS/G13Npl94C1uytJ7VmE1jfxZt7oNgZZlBYFeeB+nexJ4C08/E2LxvDcXMGoCzNnLDEQI5x2aTucDHHH3VPauwoA8x8IeAtcm8V23i74h6tb6jrlpE0VjaWKNHa2IcEOVycuxBxkjp68EenVT1nUItK0e+1GfcYbSCS4faMnailjj8BXL/C34gad4/wBBW7tUe01GJU+2WEvEluzDIPOMow5VsYI9DkAA7SiiigArG8UeJdJ8L2MN3rd2ltFNMlvEMFmkkc4VVUck/ToAT2rE+IXj608KCGwtLeTVPEl4hNjpcH35ecb3PRIwerH0OM4rxf4l+HLxvBXiHxf4tukuvFKwxy2xj5g04LKjLFAD79WPLHPqc6QpyndoD1D4+zyJ4U0e1jCFL7XtPt5NwzhfPV+PxQfhmt1vvNjoawfjgvnaT4QDc58SaefX+JjW7157n2rpwuzN6Wwd/ej8KB9OM0D36n2rqNQ7+9H8qB9OM1z3jHxE+hWtnHZWn2/V9RnFrY2u/YJJMFizN/CiqCSf8aTdldgVPiBqMTWMnh2DVLXTdZ1eCSKze7jYxP8Awsm4YAYhsDnPcA4weZ0mXRtd0mx8EeOtJXS9Zs4UighkO1ZdihRNaSjvxnA5HPBrXe+0zX7UeFfiC3h8a1dOQNNt7svkfwMpOGR+pHfuKrfC+y1G7sLqPX5o9U0/TdQli0ma+tj9qjETsodmbrxjDYz1z2rJ+9Il6s7Hw5ptxpOkw2V7qdzqksRYC6uVAlZc/KGK9SBgZ6mtP8DQPpxmge/U+1apWKIb67gsLO4vLyVYbaCNpZZG6IgBJJ/CsX4M6ZPqb3/jvV4dl5rYVbCJx81rYL/q19i+d5x1ytY3ie3k8b+LbTwVa5/suDy7/XpVGQIQ2YrbPYyFcn/ZBPNezxRpFGkcSKkaAKqqMBQOgA9K4sTUu+VGFWV3YdRRRXMZBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBxXxU8MXWv6HDeaGyxeJdIl+26ZM3/PQfejP+y65UjpyPSrXgTxRbeLvD0WowRPbzq7W93aSDElrcIcSROOxB/TB711deUeNrV/h94sPjbTIpW0PUGWHxDbRAsIxjCXiqO69H9Qc4zk1y4mj7SN1uhpnplFMgljnhjmgkSWGRQ6OjBlZSMggjqMd6fXkFBRRRQAUUUUAFFFFABXC+NvBdxd6tD4n8IXMemeK7YBfMYfuL6P/njcAfeXsG6rxjoMd1R/OrhNwfNERy/gXx5a+JLifS9QtX0fxNaZN1pNw4MigY/eI3SSM5GGHrXZ1xPjvwbpnieCG5uZptN1WyBaz1a1k8qe1JHZu6+qng/rXJ+Evi3b2HiNPCXjnVNJl1ViBa6pp8ytb3eWwquqkmGT1B+U9j0z61DEKqrdRNHsVFFFdAgornvEfjXwz4bRzruu6dZMo3GOWdfMIxnhM7jx6DmuV/4W7p+oL/xSmgeIvEDNkJLb2RhgPoTLLtAB9RnpQJtLc9KYBgQeh4NeYeK/g1oesfDqDwfplzc6Vp8F6b6Jk/fFWJclTuOSPnOOc8Dk95/AHjjxD4k8dazo+qaDaaXaaZaxyS7Lv7RKJZDmNGZQEHyBiQM445Oa9JoBO+qPKz8NHtPGPgD+zFgj8L+GLa4xGznzWncYDcAZyfmJzgkHjnnrfie9ynw58S/YbSS8uX0+eOOCJSzOWQrgAAknnoK6eigZx/wf0uTRfhd4XsZxIs0enxNIkqFGRmXcVIPIILEc88VzPxT0+9u/iv8ACu5tLO5nt7W6vGnljiZkiBjjALsBhc89a9WFFAAK8b8c6N4n8I/EtvHfg3S21uz1G2S11jTEk2ytswEljz1IAUYGeh4+YkeyUUAeG+LV8VfFu4tvDjeFr7w74VW4iudQvNU2rNMqHPlJGpOMkdQe3bofcgAAAOg6UUUAeeXXwW+Hl1qsmoTeGLQ3EknmuFkkWIt6+WG2ev8AD3rvrS3htLWG2tIo4beFBHHHGoVUUDAAA6ACpa53wd4x0fxguqPoU7Tx6dePZSuRhWdQCSp7rzwfY0AdFRRRQB558fruS2+FGtw25T7TfiKwhVs/M00ixkDHfazH8K5nxL4VuoZrHWvB80dj4m0uFYYZCP3V3CowbeYd0OOD1U8jFbHxokN5rPgLRAH2XWsfbJSCNpS3jaTafqxQ/hWwPfqa7cNTUou4Fv4deOLPxnp0xWJ7HWLJvJ1HTZj+9tZfQ+qnBw3Qj3yK5vxn4/vtQ1Kfw38OxBdamgAvNWch7XTc/mJJcZwg6HGe4rL8V+BrbXdVj1S01HUNF1TymtprzTnCPPCwwY39fY9R+Ard8PaLp3h7SLfTNItktrOFcIi85PdmPUk9yetEcJ72uwGf4T8K2XhwXM6yS3uq3jeZe6jcndPcN7nsvoo4FZXxniFx8ONUtS5jF09tbFwM4ElxGucfjXbfyrivjAf+KKwSfn1GwUcf9PMZ/pXTNKNNpdgN/wCMjSf2h8P7VXIjk8QRFwBydkUjD9RW8On1FY/xZUv4h+HoAPGtM3HtazH+lbA6DPXHpXNhfhZvS2Dv70fhQPpxmge/U+1dRqHf3rB8XeF7bxLBZiW6vrG6s5fOtryxl8uaFiCrYJBBBGQQRW8Ppxmjr160mk9wPKB4CnOrWmkWuiWlhoVnqEWpS6xLci4vb90+YA8blYt94k8Dp1r1g8knqT3pB9OM0Dnr1PtSjFR2EkkHf39qpa3dXFjpF7d2NlJfXUMLPFbRkbpmAOFGfU/5z1uj6cZo+p5+lUM5P9n7UtDk0W5gGpJP4wu5mu9ZinRobjzifu+W/wA2xBhRjjA969crxj4lWvg0ww3fi67t9NvITutb6OfybyJhyDEy/OSMdAD9Kr/CvxX47vtbjtP7OvNe8JNt8rW9RgGnzqh77T/rgB3CqT1J9fNq0+R7nNOPKe30UUVkQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUdxBFdW8sFzEk0EqlJI5FDK6kYIIPBBHGKkooA8j8PyTfDPxPD4W1KSaTwpqUh/sS9cfLaSsSTZu2endCeucc9vUaqeKvD+neKdAu9H1iIy2VyoDBW2spBBVlPZgQCD6iuE8CeItV0jWB4K8cODrESFtO1I/c1WBe4P8Az1UY3L1789a87F4f7cfmNM9GooorzygpHZUQs5CooySTgAUtMnhjuIJIZ0WSGVSjo4yGUjBBHoRmgDktZ+JvgrRmKX3ibTBLnBihmE0mfTamTn8Ky/8AhaC3xx4b8I+KtYBBKzLYG2gbHX55ivOe2M1U+C9jZeGtW17wdNY2kN/pUgmtLlYVWS6sZGLRsWxlijZQn1Ara8VfEaTSvE03hzRfDWq61rUUC3BjjMcEIRjhWMjt0zkZAOCCK9SGEptXvchytqykt/8AFDVC32Tw74e0FNxXdqN+92+McMFhAXrxjd/9dy+CfGepYOvfEK6ijbaWt9GsIrUL/eAkbe59AePpzVZ734oay/yf8I34ZtTz0fULgcnj+GPpgd/rTH+Hs+qDPizxb4i1ncMNAtwLO3PBH+rhC+p6k1tGjSjsjCWKpx63M3XvB/ws8PYfxzrTajdJznXNXeeVyCDnyt3J5HRelWNJ8aeGrAiP4c+AtQ1AEHbcWGlLZW5yTkebIEz0B4B4IrovD3gfwv4d2toug6fayLjEqwhpP++2yx/Ouj64zWnMlsc8sb/KjiG1H4n60D5dv4d8L27jH7x31C4TIHIxsjznPXP6cwP8PbvVG3+K/GPiPVgfvW8NwLK3POf9XFg/TLGu+opczOeWJqS6nM+H/AXhXw9tOj+H9NtpB0lEIeT/AL7bLfrW3q+oW2k6VeajfPstLSF55WPZVGT/ACq3XnPxtuof7H0TSNRnWy0jV9UhttQvJWKxxW4O9lZv4d+0KCeOTkihamcE6k0mdD8ENNuLfwUusanGyarr876tdBs/KZT+7UA9AsYQY9q9BqK1aF7aJrVkaAqPLaMgqVxxgjtUtaHtJW0CiiigYVmeI9f0vw1pE2qa7exWVhDjfLIeMnoABySfQc1y/jb4h22h6kmh6JZSa74omXcmnWzgCIcfPO/SJcHOTyfTvXOaZ4Mur7UR4i8e3Uesa6qloLdAfsWn5HSGNs5PA+dsk4q4QcjOpVjDc9L8M6zbeIvD+n6xYCVbS+hWeISrhgrDIyATg1p1xHwR/wCSReEf+wbD/wCgiu3qDQKKKxPGviSy8I+Gb/WtS3GG2TKxpy0znhI1/wBpmIA+tAHG/GDX7qf7N4L8PTtFrOroTc3CcmxsukkvszfcX3JIOQK5nwvBZ/D74naPb2EUdroWv2a6YVzgLdQAmEn1Z0LLz1PfsbngfSr+GO71zxHtbxFrDie8wTiBR/q4Ez0VAcfUnrTviNpdzqnhS4bTeNVsmTULFgMkTwnev54K/wDAq744a1J33MnP3j2WivOYvjF4PXw3pepT6rE93f26Sx6dagz3JcgZjEa5bOTjnA461vfDjxcvjfwymtRafc2EMk8sUcdwQXZUcruOOOSDwCcEHk1wGpxXiaQ6l8dbaMBTBouhs5IU7lluJQOvcbI+3qa6XtXI+F5v7V8f+P8AWdxaI6hFpkPz7gFt4gG2npje7HHYk11w9T1Nepho2poA7/4UUfyo+tbgHf8AwrjvidBHd6doNlMXEV5r2nQOUODtM4J/lXY/yrjPiVJsn8Eg5PmeKNOUY/32PP5VlW/hsZqfFRWf4qfDJQX8tX1KRgCcZFuADj8f1NdP+FYPxGUP8U/h90JSLUnxnp+7iGf1reH+eKww3wG9LYO/vR+FL+HGaQc9Tz9K6DQO/vR+FGcKWIwo5JJ4H49q47UviLoNvePY6bJc67qg4+xaPAbqQH/aZfkXv1NJyUdxNpHY9/eoL+9tNOtHutQuYLS1QZaaeQIgH1PFcxbWHxF8S7GSHT/B+nOcl5yL2+29sKMRofrnGfYitnR/hF4dt7xb/X2vfE2pLgi41mbz1Q9fkjwEXnHbt165554mK+HUzdVdDnf+Fgx6pKYfBOiar4mmyVE1rF5VoD0+a4fC4z6Z6H0q7D4N8deIXB8ReIrbw/YN96y0JC87L6NcyD5T0+6v/wBf1eCKOCFIoI0jiRQqIgwqgdAAOgp9c0q85dTN1Gzj/Cvw28K+GZvtOn6XHNqJO5r+8JuLlm458x8kdB0wK7CiisiAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArnPHvhO08Y6A+nXUsltOjrPaXsOPNtZlOVkQ9iOhxjIJHeujooA868CeKr9tRk8K+M0jtvFdom8OgxFqMI4E8Pr/ALS9Qc8DoO6rE8e+DrHxjpUcFzJLaX9s/nWOoW5xNaSjo6H09V6EfgRzPgfxlfLrTeEPHEcVn4pt03RSpxDqcQ/5bQn14+ZOoOfcDzMThuX3obFJnoNFHb2orhGeb/FuKbQbrR/HunRs82huY9QjQZaewkIEowOpQ4cemCab8WiunSeHPiJpbrLbaYfLvmiGfP0+fbubI5YIdrgfU16Ld28V3azW1zGssEyGORGGQykYIPtg1558J4Ra6Z4g+Heust0NIdoYFl5+0abMpMROeuAXjOOBtAr08FUuuRkTimrM7WJ0liSSN1dHAZWU5BB6EU6uD+FFzNZWup+ENRd2v/Ddx9lRpPvS2jZa3kz3+TC/8BrvK6WeHODhJxYUVjeL9K03WNAubfW5JIbFB57zxztC0JT5hIHU5BXGfwrzb4b+I/G40az1C806bX/Dd5Oy2k7MqajHBv2xyyrwsikc8YbHJzRYIw5ldHsVFFH86CAqG8tbe+tJbW9giuLaVdkkUqB0cHqCDwRU1cDrPja71TV5fD3w9tYtW1lDtuL2Qn7Dp5weZXAO5uDhF59fShK5cISm7ROb8WW8nwmtVvvB3iI2VvM58jw1eRtdQ3MhOdkCqfMjJJ/h455xXs/hLUNT1Tw/Z3mu6SdH1GVcy2RmWYx88fMvHI5x1GcHmuf8EfD6z0C8bWNWuG1zxTKMTarcp8yjn5IUyREmCRhevfNXPHHjzR/CCwQ3jTXeq3XFpplmnmXNyf8AZTsP9o4HB+laJHsU4yhG0nc6O+vLbT7SW7vriG2tYhukmmcIiD1JPAFeT3/i3X/iFK9n4GaTSPDWdsviGVCJbgZGRaRtj3HmMMenIGYYvC+seNby31T4lPCbaNhJa+HbZt1rCeOZm/5bP0/2RzjrivQkRUVVRQqqAoAGAAOg/wDrV0Qo31kYVcR0gYnhHwtpPhPTmtdGt9nmEPPO7b5rhv78jnlj+noBWzNzC/GRsP48U/0oIBBDDIPWuhKxxt31ZmfBL/kkfhD/ALBsP/oIrtq8hsvAV/pNtBa+G/G3iLTbKA/6PaHybiKIZyEG9MlR0AJPHFHwm1PxZrfjDWnvPErav4X00m0WZrCGD7Vdfx7Cg+4nTOeSe4FccoOO56cKsZ6I9erxC6vx8R/HH9oKwk8KeHp2jsQOUvbwcNOD0ZE5VT0JJNdF8X/EN1K9t4L8PTNFrOsITcXKdbGz6SS57MeVXvk57CnaPptpo+lWmnadEsNpbRiKJAOij19T3J7k10YWjzvmeyCcraFzvyeaO3tR274zQOcHuRXpmRzt9Z6P4S0XWtW07TbKykit5rqWS3gVGYqhOSQM9e3+T1XwgsU0H4R+GonXaI9OS4l2sXyzjzHI9clifxrhPi6Xk8DXOnxbzLqlxb6cioMsxllVSFHrt3V3fxiv00T4S+JpUAXGnyW0QDbMNIvlpj3ywwB9K83GP3lFGtPY4r4QCSTwNbajcAC51a4uNTkKrtBM0rMCB2+XbxXaVn+HdPXSPD+macg+S0tooB2+6gH9K0PrXbCPLFI1Dv8A4UUfyo68/wD16oA7/wCFcj41t47zxL4At5t2w6/HN8rY5jhldf8Ax5R+vrXXfyrk/FLf8Vz8Ol9dXlP5W0n+NZV3+7Yi94xjDfHLw4xAymh3jZ/7aRj+tdN16AnIrl/iPY+Jl+Jejar4Y0EaqE0ue0Z5bhYIoWeVGBZjknhDwoJ57VDJ4H1/ULY3nxD8ZLp+nrgy2OjH7JABno9wx3sDkD+H9a46VaMIWe5rCaii74k8aeH/AA5KsWranDHdsQEtIsyzuT0AjQFv0rNg1Txv4kQHwt4YTSrOQfLf+IZPLJHqtumX+m7HUe9VND8U/DfwpNJbfDnQZdc1P7jyaRamZicf8tLp+Mep3HrnHWrt7qnxE8SABZtO8H2THlYcX14VxjBYgRoe/AJHr6v2lWp8CE6jexLc/DTT/I/tD4m+LLvVoIyGeGaZbHT19AY1IyMkfeY579TnPn+K/hDwxodwnw/0E31ja5Es9rALOxjI4y07ABj0+6GLds1zviHRvC3h+9tpNcj1Pxl4ouSRZ2t5K15cTN1+SP7kaDHXbgAd8V3HhX4cXeqXlrrXxF+z3Fxbt5ljoluc2Vh02kjjzJR0LH5Rk4HQ1lOHL8b1Ieu4z4Pa18RPFt42veKoLDSPDzxultpyQMJpTldspLfMBwcZxnJ+XGDXrNAorEQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVgeNvCmm+MdEfTtVWRcMJYLmFtk1tKPuyRt1Vh/8AWOQa36KAPKtE8U6r4R1W38N/ESTzBKVj0/xCsZS3vCekcvOI5uDwThsce/pVQ6/o2n+IdHutK1m1ju7C6TZLFIMgj1HoQeQRyCARXmMsviH4Un/TDd+IvAynC3AHmXulrwAHHWaIZ6gblA56c+fiMJf3qf3DTPVK86+KAfw3q2jePLQHbpjfZNVVRzLYSsAxPcmN9rgf71dzo+qWOtabBqGk3cN5ZTrujmhfcrD6+3QjqKlv7SDULG4s7yJZba4jaKWNhkOjDBB+oJripzdOal2Ged/FAxeHPEvh7x7bN/oRK6VqsicobSU5jlJzjCSlee4eu6/lXA/Dq2j1Dw34i+GXiYtPJpKmzVn+9cWEgJgkB9Qvy8dCg71Z+FWpXUuiXOh6vL5mteH7g6bdPnmUL/qpfo6bT9Qa9ltSXMjzsZT2min8UbbUPEl3pHg+yhuo9P1JjPqt6ikIlrGQWiD9NzkgY9M9jXe28MVtbxQW8axwxKERFGAqgYAHtjipKP50jhcrpIKzfEOuaZ4d0qXUtbvYbKyiHzSSnHPoB1YnsBkmsX4l+Lz4K8NNqa6dNfsZFhUKQkUbNwGlc/cTPBbnqPWm+Efh8bnUrTxR421CPXtdCiS2SPixsgRn9wnRjz/rGyTgEYppXN6GHdXV7GNb2Hib4nBzdC/8K+D26IMJf6ihyOf+eEZ44xuYH0Nep6Do2m+H9Kg03RbKCxsIBiOGFdqj1PuT1JPJ71T8XeKtH8I6S2oa7eJbxdI0+9JO3ZI06uxyOB+PHNea3Fp4i+Jm2TxMlx4e8JtymjRyFbq8Bxg3Lj7i9/LXnnk8CtYwctEeh7lGPY0tZ+Id/wCJLy50b4ZRR3MkT+Vda9OubK0ORkJ/z2frwOBwSSKteEPBth4dknvHln1PW7sD7Xqt62+ebpxn+FOwUcYA61vadY2mm2VvZ6dbQ21pCoSOGFAqIPQCrPf611wpqJx1Kzn6AP8AOKPSoLW8trvzPstxBP5T+XJ5UivsYdVODwfarHf61oZAPX88Unp9KPT0rL8U69ZeGdAvdY1RylrapvbH3mPRVHqxOAPrQ9ASuc78Q9Vvrm5sfCHhuQpr2tghrhAT9htBxLcH0OMqoyMseOa6u+uND+F3w8BjiMWl6XAI4YE5eZzwqrn7zux/EnNZnwo8M3ljDe+JvEyAeJtb2yToeRZwgfu7ZT2Cjr6tn0rkbu9PxE8etqAbf4V8OzNFYr1S8vRw8/usf3V6gnJBrls607I9GnBUok/gfSL63W+13xEVbxJrMguLzb0gX/lnbr6Ki4Huc9e/U9vagcAdcZoHPOeSK9aEVCPKiG7u4dDyefajqPbFHp9aBzz3qgOT8SpHqPxE+H2jybTu1CXUmVicH7PEWXp3DOCPpW/8dt93o/hzRkLbNU1y0imUAbXijJmYH0H7sHjuKzvCMbaj8b7+4XLQaPokcJIIwJLiUv06/diHT8eop/j8rqPxm8J2e5T/AGVpt5qLKM5UyFYVJ7Y+/j6GvLq+/XsbwWh0RbcxY9Sc0Ufyo+teiUc/4/1TUtE8H6rqeiW0N1f2kJmWKXO0qOWOBycLk474rzrxNYXMPgSTxheeP9T/ALQ+yi7sZIZFtrUsRuWNYBnfu+7ySa9kdVZCrqGVuCrdCO4rx/4c+E9F0fx1rmianZrdX9gVvNJkunMoSzkPAjRiQpR8gkDOTWNRNtAeoeHbu5v/AA/pl5qEH2e9uLWKWeLGPLdkBYfgTXLePNQbSvGngrUf7H1HVo7SW7l8ixi8x95h2oewAy3UnAruvr3NGeOvWrnDnjysDmp9f+Iuvki1ttK8JWbH785+33mOOijEan2O7r7c50Pw20i5uVu/E9zqHia9BLCXVrgyoueu2IYRR7YNdsOO3FH1qIYeEegyKGGC0t1igjigt4xwkahEUfQcCuNk1/WvGF3Npnw4hjeFCY7nxBcrmzgPdYv+ez/TKjIzUnxT8Nah4m0CO3024b9zKJZrBpTFFqCAjMLuuGUEdCDjJ59R3/w08QaLrvhuNdBtF00WR+z3GmeWI3spB1jZB05yQRwetZYirKGkRCeBPAek+DluJ7Uz3ur3eDeandv5lxcHOeT0VfRRgcDr1rraKK88AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzbWPAN9omqT638Nbq30u7mbfd6TOp+wXp452r/qnwPvqOT1HJNXPCHj6y1vUH0bVbWbQ/E0K7pdKvSA5H96JvuypwfmWu9rnfGfg3RfGOni11u13tGd8FzE2ye3fs8bjlSOvp6g1z1sPGrr1GmcV8Uw/hbXdD+IFqjFNPb7Dq6oMmSxlYZY46+W+GH1NHjaJPDHxD0XxfbEf2VrQj0jVCv3dx5tpz+OUJPZhVXVk8W+E9NutP8AElpJ428HzRNBLcwIP7RhiYYPmxDiUAH7y/N1JrN+GF3pfxN+FeteCb3UBfPpubFLvYQ7Q9bafa2CGAABB53RnPWjDxlBckiJxU00+p6xSfyrkvhjrl1rPhhYtXG3XNMlfTtSTOcTxcFs9ww2sD/tV1v86s8SUXF2ZHcwRXVtLb3MaSwSoUkjcbldSMEEdCDXnmnXVz8JboW9y8t18P5pNsUrEvJozMfuserQEng/wd/f0emTwx3EEkM8aSwyKUdHXcrKeCCDwQfSmnY0o1ZUndHCfEjwrdReJrH4ieG7Ya1d2cHlz6c58zzYCM+Zak52Sgdhww9/vdJ4Z13TvEuj2+qaPcCeznHBHDKf4lYdQwPBBrlbG7uPhRdrDO0tx8P55AI5GJd9GdjwpPU25J4PVO/FWvF/hq+8PanP4z8Awi6S5Al1bR4T8l+nXz4ccCYDnjhx7/e6KVTl9DvnGNePPA7Qev54riPiv4rbwzoMNvYTwRa3qsosrAzSBER2wGlYngKgOcnvtHeuh8L+IdN8UaLbapo1wJ7SYY5GGRh1Rh/Cw7isKTwPb6n401HXPEv2XVYHt1tLCymgDR2sXV8hshnZuc46cV1NtrQ5IpJ+8cp8HtHtfCfjvxXoFjcm5t3sbC9WYvvMzlWWSQnPdjn8a9d9K810XwVF4Z+LseoeHtIistCvdIeC4NuAsa3CyhlyM8EjA4GOK9L7/WlBWVh1Hd3EHP446e9cDpNt/wALF8frdvl/Cfhm4/cj+C/1Ber/AO0kXQerevNTfEbWrqS407wf4eukh8Q66TGs24f6JbgfvZ8EjJC5Cgck5I6V6LoejWvhjw1baVoVqBb2UGyCEsF3kD+JsdWPJb1JNZVp/ZR0Yan9tnDfGHxDdyy2ngnw9M8Ws6xGXubiPrY2QOHlz2ZuVX3z6CpNI0200fSrXT9OhWG0toxFEg7KP5nqSfU1534b1weHNe1S5+JVtdaN4l1i5LyXd4g+yOi8RwwzKSm1FHQkE9TXp0TpNGksTq6OMq6kEMPUHvXXhIRUbp6s2m7scPvD3I6V5z8NPHN/r+v65o+uxQRXNtPL9jeFSqyxRyGNweTllO0/RhXo3b2zXib2U9jfeL9T09C+o+HPEDamka/ekt54kM8f/AkBI91rao3FpoUbGxqvijV0+OGm6bBdOugIVsp4V+69xJBJKCfXA2f56+qdQMZORxXiELPqGjaX4stUdxfeM1vUOw5+z7jAmfYKufxr22V/JR3Cs7ICwVRknA6D1NKk73uKRmfBKJbzV/Hmuhf+PrWDZIxBy0dtGqDB6Fdxfp3zXG69460HRPjX4uk8SXz2kkNrZ2NrugkkBQKZXwUU4BaQcH3qz8KfHUvhTwRZ6Zqvg7xnLqIkmnuXh08PGZJJWc7SXBx83pXWP8Y7dMbvBPjo59NKB/lJXmpzjPnSN1axzX/C4PAn/QeH/gHcf/G6kT4t+BnBI1+MDp81vMP0KVvf8LnteMeCPHnP/UI/+zpIvjXprXKQzeEvG8AZgpeTR2ITPc7WJx9Aa2+s1ewXMP8A4Wx4H5/4qCHPtBN/8RQPid4EM3nf27ZeaVCeYYpN23rjOzOM54rr/wDhbXh/g/YfEuD/ANQO6/8AiKYPjB4a4/0bxDz/ANQW6/8AiKPrNTsF0cwvxS8FFsDxDaA/7kg/XbUh+JngsA58SaeB67m/wrY1D45eDNNSN9Rk1izSRtqNcaVcRhj6AlOa9A0TU7fXdHgv7eG4S2uVJVLqBonK9MlGAIB68jkGl9bmt0M8pT4leCnJx4o0kH3nxTz8RvBnP/FU6N/4FCvUP+Ef0Y/8wnTv/AZP8KP+Ef0b/oEaf/4DJ/hR9bl2A8xHxD8GkZHirRP/AALQVzOv+JvDlvrCeJfCfi7QLbxBAoSWOS9QQ6hEP+WUuD1/uv1X6V7p/wAI/op/5hGnH/t2T/Cj/hHtFPXSNO/8Bk/wpSxPOrNAc78LviLo3xE0aS70pxFd27bLuydwzwNzjkcMpwcMOD9QQO1qpY6dY2JY2NnbWxcAN5MSpux0zge5q3XKAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYtr4X0a08T3HiG0sIoNXuYTBPcRZXzlyp+cDhiNowxGccZxW1RQB5R4jjbwh8W7PVRldG8VKlhckniK9jB8lvbemU+q13dVfiR4a/4S7wVqekRyCK6lj32s3/ADynQho2B7YYDkc4zWJ8OfETeJ/Cdnf3EZh1FM219AeDDcxnbIpHbkZ+hFRJdTzsZTs1NHS0VyXjTxjJ4e1PSdOsNFvtbvr4Sym2sivmRwxgFpADweSoAyM5454pfDnxB8N69d/Yre/+yaqMBtPv0a2uVOM42Pgn/gOam3U5PZy5ea2h1M8MdxBJDPGskMqlHRxuVlIwQQeCK88hvp/hExEoub3wA7cFQZJdHYnpjq1uSfcp716NTZokmieKZEkjkUq6OMqwPBBB6imnYqlVdJ3RwHirw9daRfN48+G6pexXiifVNJgbMepRkZ8+HHAmAOePv/X73S+FvEGm+KNFt9U0e4E9pMMejIwxuV16hgeoP9a4eJ7v4N6i00Cz3fw5upMzQLl5NGkY8ug6mAk8jtnP+9p+LPD13o98/jz4bJHfR3iifU9JgYGLUo8ZE0JHAmAOcj7/ANeG6aVXl0ex6E4Rrx54bnde/wDKj0rI8KeI9N8VaJb6ro84mtZuCDw8bjqjj+Fh3H41sd/rXXe+pxNW3MLxP4T0PxRCqa5p0Fy6YMc4BSWI9ikikMuD6GsCLTvHXhPJ8M63H4j04HP9na8x89R3EdyOT2A3g13fpS9/rUShGW5cKkobM5Ww+JfhvWp10Dxlp0uhajPhTYa3CvkzN6JIcxyc4xyCewqpe/CWCxMt98OtbuNAllw4s8/aNPl7/wCqP3c56oRjsK6jVdMsNXsms9Vs7a9tH4MVxGHQ/gen1rjIvBGreGAH+HXiGfTIFO7+ydQBurFj6Ln54hk/wn/6+LpSi7xZ1QxMZaSKN34i1/wrK0fjvw/NDapydY0lWubQj+8643xfiCPf13dEuNG1OKbUtEksblLvBmubYq3mkDA3kckgcc9KdafFOXR5ktfiJodxoBYhV1KFvtNhIen+tUZjz6MPqal1D4c+E/FEa6/4RvBpF/ON8eq6HKqrKf8AbQfJIM9QRnryK1hi5R0mrmvLGSvEtoiRKqxqsaDoqDAA9gKdxj2rlr2Px14TZ/7W0tPFOkxjd/aGkqI7pV/27YnDH/rmT9Ku+GfFeieJkY6PqEU86cSW7ZSaM9w8bfMOc9q7adaFTZkOLRud+aOMdOvej88Zo988kVqIOO/6Udu+MetA7ZzjNcfL4h13XtY1DR/A2jC5urKT7Pd6hqLeTa2z4zjH35DyDgDBznJqJ1IwV5DSvsdTf3tvp9pLd31zFbW0Q3PNNIERR7k8Vylr4h17xk0sHw7sA9mDsfXdSDR2g9fKTG6Y8Hp8vTJ5ro9F+EljLdw6l44v5vFGpxnciXKhLOA/9M7cfL7ZbcT1r01FVEVUUKoGAAMAD0rgq4ty0hoaKmupwPg74Y6bomoR6zrNzceIPEgXB1G/O7yz38mP7sQz0xz7139FFcbd9zQKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAryW6X/AIQ/4xtCqCPRvF0XmoR91NRiHzjGMDzI9p56spr1quR+KfhR/GPg660+zmFtqsLLdadckkeRcxnMbZHQZypODwx4oZFSCqRcWc38MIz4h8c+KfGL82qMNE01sdYYWzK6nuGlz/3xXb+J/Ceg+KrQ2/iHSbPUIyNoM0YLoP8AZf7yn3BFN8DeHoPCnhDSdEtQuyzgWNmUYDv1d/8AgTFm/Gt2gcYqKUUeXv8ADTV9EO7wP4w1GyhU5Gn6qPt9tjP3VLEOg+jHpUP9r/EDRUP9veD7bVokGWuNAvQxIwScQzbWJ46A9+K9WopWInQpz3R5G/xU8KA/Y/ERvtEmmBRrfWbCSAMOjAkgoRzzzjmua0TxHp/w1vWufD+q2usfDq5k3T29pcLcSaM7HmRApLGAk8r/AAnke/v08UVxC8U8aSxONrI6hlYHsQeork9Z+GfgnWvMOo+FtIkkkILSLbLHIcdPnXDdvWhKxEMOqbvFnHeLfDl1pF+3j74aKl6l2gm1PSoHzFqcR586LHAmA54+99chum8J+ItN8VaJb6po0/nWsowQeHjYfeR17MD1H+Nb3g7wtpXg/SDpmgxTQWHmtMkLzvKIy3UJuJ2rxnA4ySepNcl428J3+l6nN4r8DQx/2owB1HTOEi1NB39FmHO1+/Q8VtTqcuj2HWo8+q3OnHr+eKTuKyPCviLT/E+kRahpcjGMsY5YpF2yQSDho5FPKsD1H41sAEsByMkc+ldd76nntW3Aev54pB/SuB0HxD418Sx31zoOgaD9it72eyDXepyq7GJyhbCxEAHHrV4wfFOSRAumeDYFJGXa9uZNvqcBBn6frWbqxNlh5vode6rIjpIqujjDKRkMD2I6Vw958ObO1u31DwdqF74V1JmDs2nN/o8zDoZbc/I45PYVb/sT4ozSqsmseELWEkBnisZ5HUdyAzgE+xp6+BfGs8rNe/EV0jxwtho0EJznuzF8iolVg9y40KkdnYgg8b+LPDTlPGmgDVNPBAGq+H0aTaPWW3J3r6krke1XrjR/h/8AFqwXULRrW8uI/uX1k5gu7Zvdhh1Psw/CmJ8Jre4ZX1rxb4u1Q7fnjfUjBEx9dsQXH0z+dbPhf4Z+D/C+orqGi6Jbw6goI+1OzSy8jBO5iTk5OT3zXO7dDsjzW944688LeO/Czs+jXkHi3SVGfs1+4t79R6LKBsk4yfn2+lQ6L460fUL1dOvftOjawRzp+qxG3lPb5d3DjIP3Sa9orI8S+GtF8UWH2LxDplrqFtnISdA20+qnqp9xit6eJnDfUTgmcv0PPB+lcnb3C+Efi1p2qBMab4nRNKuyucLdLk27kd9w3J7cc+t+5+GmveHWMngLxCXsl5XR9a3Twgf3Y5v9ZGMdAd3WuN8aa8l7oNzoXjnTrzwlqVwv+iXVyd9r9oQ7keO4T5chlzzg4PvXTOtCvBx2ZKi4u59HUVyPwo8V/wDCZ+BNM1eXYLxkMN2iMCEnQ7XHHqRkexFddXnGoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHm3jjwlqGn6xL4u8DxKdWKgajppbbHqkY/RZgPuv36Hir/hPxFp/ifSYtQ0yRjHu8uWKRdssEgPzRyL1VgeCD+HWu6rzPx54R1HT9Wk8X+BEUazgf2hppbbFqsa9j2WYD7r/ga1p1OXR7GFajz6rcm+ByGPw9ryMMEeINR49P37V6NXkn7OWq/wBs6N4uu0S5it38R3TxQ3K7ZIgyROUK9iGZsj1Jr1us3ubR2QUUUUhhRRRQAUUUUAFRXVvBd28kF1DHPBIpV45FDK4PUEHgipaKAOe8JeDtE8I/b18O2YsYL2UTywRu3lK+MZRCcLkAcD0FdDRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBBa2draPcPa20MD3EnnTNFGFMsmAN7Y6thVGTzgD0qeiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cell cycle is comprised of the following stages: G0, nondividing cell; G1, cell growth; S, DNA replication; G2, protein synthesis; mitosis, which lasts for 1 to 3 hours and is followed by cytokinesis or cell division. The stages of mitosis are P, prophase; M, metaphase; A, anaphase; T, telophase.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Wolters Kluwer",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_48_23301=[""].join("\n");
var outline_f22_48_23301=null;
var title_f22_48_23302="Normal adrenarche";
var content_f22_48_23302=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Normal adrenarche",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/48/23302/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/48/23302/contributors\">",
"     Robert L Rosenfield, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/48/23302/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/48/23302/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/48/23302/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/48/23302/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/48/23302/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/48/23302/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenarche is the term for the maturational increase in adrenal androgen production, which becomes biochemically apparent at about six years of age in both girls and boys (",
"    <a class=\"graphic graphic_figure graphicRef79533 \" href=\"UTD.htm?18/5/18527\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Adrenarche seems to be unrelated to the pubertal maturation of the hypothalamic-pituitary-gonadal axis; although the clinical manifestations of adrenarche ordinarily closely follow true puberty, the two phenomena may be dissociated, as occurs in the presence of hypogonadism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Adrenarche is a unique phenomenon confined to a few higher primates [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical manifestations of adrenarche'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24070873\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenarche is the result of a developmental change in the pattern of adrenal secretory response to adrenocorticotropic hormone (ACTH) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/8\">",
"     8",
"    </a>",
"    ]. During adrenarche the baseline pattern of adrenal steroid levels changes in a unique way (",
"    <a class=\"graphic graphic_table graphicRef75217 \" href=\"UTD.htm?42/59/43965\">",
"     table 1",
"    </a>",
"    ). In the preadrenarchal child, ACTH stimulates cortisol secretion but has very little effect on 17-ketosteroid secretion. During adrenarche, 17-ketosteroid responsiveness to ACTH gradually increases in a selective manner, while cortisol responsiveness to ACTH remains unchanged (",
"    <a class=\"graphic graphic_figure graphicRef53342 \" href=\"UTD.htm?37/34/38447\">",
"     figure 2",
"    </a>",
"    ). The adrenarchal secretory pattern is characterized by disproportionate responsiveness of",
"    <span class=\"nowrap\">",
"     &Delta;",
"     <sup>",
"      5",
"     </sup>",
"     -steroid",
"    </span>",
"    intermediates (17-hydroxypregnenolone and dehydroepiandrosterone, DHEA) relative to",
"    <span class=\"nowrap\">",
"     &Delta;",
"     <sup>",
"      4",
"     </sup>",
"     -steroid",
"    </span>",
"    intermediates (eg, 17-hydroxyprogesterone and androstenedione) in the presence of stable responses of cortisol (",
"    <a class=\"graphic graphic_figure graphicRef58179 \" href=\"UTD.htm?8/10/8355\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/8\">",
"     8",
"    </a>",
"    ]. As a result, dehydroepiandrosterone sulfate (DHEA-S) becomes the predominant 17-ketosteroid of blood and serves as a marker of adrenarche. &nbsp;",
"   </p>",
"   <p>",
"    These adrenarchal changes are ACTH-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], but they are caused by changes in response to ACTH rather than a change in ACTH secretion. This pattern of steroid secretion is very different from that caused by excessive ACTH stimulation in the preadrenarchal child [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/10\">",
"     10",
"    </a>",
"    ]. After adrenarche, glucocorticoid administration suppresses adrenal androgens more easily than cortisol, providing further evidence that these hormones are differentially regulated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Anatomic site and mechanism of biochemical changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The zona reticularis of the adrenal cortex seems to be a major source of the adrenarchal steroids (",
"    <a class=\"graphic graphic_figure graphicRef58179 \" href=\"UTD.htm?8/10/8355\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/3,5,13,14\">",
"     3,5,13,14",
"    </a>",
"    ]. The increased synthesis of 17-hydroxypregnenolone, DHEA, and DHEA-S during adrenarche is a byproduct of ACTH stimulation of cortisol synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cells of the zona reticularis probably originate from stem cells located in the outer definitive zone of the fetal adrenal gland [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], rather than from persistent cells of the fetal zone that have failed to undergo involution, as was originally postulated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/17\">",
"     17",
"    </a>",
"    ]. In rhesus monkeys, the fetal zone develops from a cell type that is distinctly different from the reticularis zone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The zona reticularis begins to form in the central adrenal cortex at three years of age. At about five years of age, it begins to develop into a continuous zone. Within about a year, the adrenarchal increase in DHEA-S production becomes perceptible.",
"   </p>",
"   <p>",
"    The adrenarchal pattern of adrenal secretion results from a unique enzyme expression profile in the zona reticularis. These cells express low levels of the gene encoding 3&szlig;-hydroxysteroid dehydrogenase type 2 (HSD3B2) but high levels of the genes encoding cytochrome b5 (CYB5), steroid sulfotransferase 2A1 (SULT2A1), and 17&szlig;-hydroxysteroid dehydrogenase type 5 (HSD17B5) (",
"    <a class=\"graphic graphic_figure graphicRef58179 \" href=\"UTD.htm?8/10/8355\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/5,14,18\">",
"     5,14,18",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Low activity of the HSD3B2 enzyme (3&szlig;-HSD2) underlies these cells&rsquo; poor production of cortisol and other",
"    <span class=\"nowrap\">",
"     &Delta;",
"     <sup>",
"      4",
"     </sup>",
"    </span>",
"    steroids in favor of formation of",
"    <span class=\"nowrap\">",
"     &Delta;",
"     <sup>",
"      5",
"     </sup>",
"     -steroids",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/13,19\">",
"     13,19",
"    </a>",
"    ]. This enzyme activity is low not only because of low gene expression, but because enzyme activity is inhibited by substrate end-products in a dose-related manner, particularly cortisol [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/20\">",
"     20",
"    </a>",
"    ] and estradiol [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/21\">",
"     21",
"    </a>",
"    ]. High fatty acid levels also seem to inhibit activity of this enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activity of CYP17 is also increased in the zona reticularis. This cytochrome P450 enzyme has two actions: 17&alpha;-hydroxylase activity and 17,20-lyase activity, which respectively and preferentially catalyze the conversion of pregnenolone to 17-hydroxypregnenolone (which is an essential precursor of both cortisol and DHEA) and then 17-hydroxypregnenolone to DHEA (",
"    <a class=\"graphic graphic_figure graphicRef58179 \" href=\"UTD.htm?8/10/8355\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/14,23\">",
"     14,23",
"    </a>",
"    ]. Preferential expression of CYB5 in the zona reticularis appears to underlie the enhanced lyase activity of CYP17 (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=see_link\">",
"     \"Adrenal steroid biosynthesis\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    All of the above factors favor the formation of DHEA from 17-hydroxypregnenolone by the zona reticularis. The coincident preferential expression of SULT2A1 in this zone then converts DHEA to the relatively inert DHEA-S, which acts as a \"sump\" to direct steroidogenesis to this terminal product and prevents DHEA from being converted into biologically active androgens [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/24\">",
"     24",
"    </a>",
"    ]. Enhanced expression of HSD17B5 by this zone seems to account for adrenal testosterone secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Triggers of adrenarche",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major factor stimulating the biochemical changes of adrenarche is not known.",
"   </p>",
"   <p>",
"    The stimulus has long been thought to be of pituitary origin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/3,26\">",
"     3,26",
"    </a>",
"    ]. Several possible stimuli have been proposed: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A product of the corticotroph cell, such as a proopiomelanocortin (POMC) product.",
"     </li>",
"     <li>",
"      A hormone that is distinct from POMC, called pituitary adrenal cortex androgen-stimulating hormone, termed CASH by its proponents [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/27\">",
"       27",
"      </a>",
"      ] and AASH by its detractors [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A",
"      <span class=\"nowrap\">",
"       Pit-1/POU1F1-dependent",
"      </span>",
"      factor, possibly prolactin. Adrenarche is severely attenuated in",
"      <span class=\"nowrap\">",
"       Pit-1/POU1F1",
"      </span>",
"      deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/28\">",
"       28",
"      </a>",
"      ]. This is informative because this pituitary transcription factor is necessary for the secretion of growth hormone, thyrotropin, and prolactin, but not ACTH or other pituitary hormones. These data suggest that prolactin interaction with ACTH, and possibly unknown pituitary factors, is required for adrenarche.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We favor the hypothesis that whatever the factor(s) responsible for adrenarche, it needs to only affect the growth or differentiation of zona reticularis precursor cells so that they acquire the enzymatic properties that permit them to respond to ACTH by secreting androgens.",
"   </p>",
"   <p>",
"    Such a factor might either promote the growth of precursor cells that have a unique biosynthetic capacity, or change the function of cells in the zona reticularis by modifying their pattern of enzyme activity, such as by decreasing the activity of 3&beta;-HSD or enhancing the 17,20-lyase activity of P450c17 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/14,18,20\">",
"     14,18,20",
"    </a>",
"    ]. Interleukin-6 is a candidate mediator since it is strongly expressed in the zona reticularis of the adrenal cortex and is capable of stimulating DHEA secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nutritional status, both pre- and postnatal, seems to play a role in the development of adrenarche, particularly in girls. The highest adrenal androgen levels in mid-childhood are associated with rapid weight gain during early childhood, especially in children with low birthweight [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/30\">",
"     30",
"    </a>",
"    ]. Adrenarche begins at about the same time as the preadolescent increase in adiposity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/31\">",
"     31",
"    </a>",
"    ] and leptin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/32\">",
"     32",
"    </a>",
"    ]. Leptin, an adipocyte hormone, stimulates the 17,20-lyase activity of adrenocortical cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/33\">",
"     33",
"    </a>",
"    ], which shunts adrenal steroidogenesis away from cortisol and toward DHEA-S production. It has been postulated that the relationship of adrenarche to body fat in girls is mediated by the compensatory hyperinsulinemia of insulin resistance or the growth",
"    <span class=\"nowrap\">",
"     hormone/insulin-like",
"    </span>",
"    growth factor-I axis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/34\">",
"     34",
"    </a>",
"    ]. However, insulin-like growth factor-I seems likely to be related to adrenal growth in early childhood rather than to zona reticularis regulation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/35\">",
"     35",
"    </a>",
"    ]. It has alternatively been postulated that the increasing body size-to-adrenal size ratio that occurs with somatic growth brings about a rise in the intra-adrenal concentration of cortisol that accentuates adrenarche by inhibiting 3&szlig;-HSD2 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gonadal function affects DHEA-S levels. The ovary appears to modulate adrenal DHEA-S levels. Ovarian failure and ovariectomy precipitate an earlier rise [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/36\">",
"     36",
"    </a>",
"    ] and early decline in DHEA-S levels, yet estrogen replacement has no beneficial effect on the DHEA-S decline [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/37\">",
"     37",
"    </a>",
"    ]. The testes seem to contribute directly to DHEA-S production. Serum DHEA-S levels are 50 percent higher in men than women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/2\">",
"     2",
"    </a>",
"    ], which is probably explicable by peripheral sulfation of gonadal DHEA since testicular secretion of DHEA-S is modest [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS OF ADRENARCHE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenarchal androgens contribute to the appearance of pubic hair (pubarche) and sebaceous gland and apocrine gland development. Androgens are a prerequisite for the growth and development of the pilosebaceous unit (PSU) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Before puberty, the androgen-dependent PSU consists of a prepubertal vellus follicle in which the hair and sebaceous gland components are virtually invisible to the naked eye.",
"     </li>",
"     <li>",
"      Under the influence of adrenarchal levels of androgens, the PSUs of sexual hair areas gradually switch to producing a type of terminal hair follicle. In acne-prone areas, androgen causes the prepubertal vellus follicle to develop into a sebaceous gland.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adrenarchal levels of androgens suffice to successively initiate sebaceous gland development, apocrine gland development, and the growth of pubic hair. Progressively greater amounts of androgen ordinarily stimulate terminal hair development along a pubic to cranial gradient. All these effects of androgen are reversible by antiandrogens. Estrogens also seem to directly promote the growth of sexual hair to a small extent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adrenarchal androgen action on sebaceous glands is first manifest clinically as microcomedonal acne, which is the basis of the change in facial complexion that occurs in mid-childhood. Adrenarchal androgen action on apocrine glands is manifest as an increase in adult-type body odor. On the basis of correlations between adrenal androgen levels and bone mineral parameters, it has been suggested that adrenal androgens make stronger cortical bone in healthy children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether adrenarche plays a more fundamental role in puberty is unknown. It is possible that a threshold level of adrenarchal steroids plays a role in the subtle transient increase in growth rate that is apparent in some growth models at around the age of seven years (\"the midgrowth spurt\") or in advancement of the onset of puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/42\">",
"     42",
"    </a>",
"    ]. Circulating DHEA-S is a precursor for ovarian testosterone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/43\">",
"     43",
"    </a>",
"    ], while DHEA-S formation within the adrenal cortex protects against adrenal hyperandrogenism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/24\">",
"     24",
"    </a>",
"    ]. Notably, DHEA-S and its precursor, pregnenolone sulfate, are unique among steroids in having direct neurostimulatory effects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. The association of adrenarchal changes with the emergence of sexually dimorphic sexual attraction, stress-adaptive, and social maturational behavior during middle childhood, prior to true puberty, has led to the suggestion that adrenarchal steroids play a role in activating these behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DHEA has been suspected of having a number of other unique functions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. However, these seem inconsistent, and whether they differ from those of low-dose testosterone remains to be established [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23302/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24070796\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adrenarche describes the maturational increase in adrenal androgen production, which begins at about six years of age in both girls and boys. Adrenarche seems to be unrelated to the pubertal maturation of the hypothalamic-pituitary-gonadal axis, although the clinical manifestations of adrenarche ordinarily closely follow gonadarche. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adrenarche represents a change in the pattern of adrenal secretory response to adrenocorticotropic hormone (ACTH), resulting in increases in dehydroepiandrosterone sulfate (DHEA-S), which serves as a marker of adrenarche. After adrenarche, administration of glucocorticoids suppresses DHEA-S more readily than cortisol. (See",
"      <a class=\"local\" href=\"#H24070873\">",
"       'Physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major stimulus of the biochemical changes of adrenarche is not known. It may be of pituitary origin. Whatever the factor may be, it seems to either promote the growth of zona reticularis precursor cells that have a unique biosynthetic capacity or promote the differentiation of the enzymatic properties that permit them to respond to ACTH by secreting androgens. Nutritional status seems to play a role in the development of adrenarche, which begins at about the same time as the preadolescent increase in adiposity and leptin levels. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Triggers of adrenarche'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Adrenarchal androgens contribute to development of sebaceous glands and pubic hair (pubarche), and possibly to bone mineralization. It is less clear whether adrenarche contributes to the subtle transient increase in growth rate that is sometimes observed around the age of seven years (the &ldquo;midgrowth spurt&rdquo;) and prepubertal behavior patterns. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations of adrenarche'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20349885\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Kenan Qin, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/1\">",
"      Korth-Schutz S, Levine LS, New MI. Dehydroepiandrosterone sulfate (DS) levels, a rapid test for abnormal adrenal androgen secretion. J Clin Endocrinol Metab 1976; 42:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/2\">",
"      de Peretti E, Forest MG. Pattern of plasma dehydroepiandrosterone sulfate levels in humans from birth to adulthood: evidence for testicular production. J Clin Endocrinol Metab 1978; 47:572.",
"     </a>",
"    </li>",
"    <li>",
"     Grumbach M, Richards C, Conte F, Kaplan S. Clinical disorders of adrenal function and puberty: An assessment of the role of the adrenal cortex in normal and abnormal puberty in man and evidence for an ACTH-like pituitary adrenal androgen stimulating hormone. In: The endocrine function of the human adrenal cortex, James V, Serio M, Giusti C, Martini L (Eds), Academic Press, London 1978. p.583.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/4\">",
"      Ib&aacute;&ntilde;ez L, Dimartino-Nardi J, Potau N, Saenger P. Premature adrenarche--normal variant or forerunner of adult disease? Endocr Rev 2000; 21:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/5\">",
"      Nakamura Y, Gang HX, Suzuki T, et al. Adrenal changes associated with adrenarche. Rev Endocr Metab Disord 2009; 10:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/6\">",
"      Nguyen AD, Mapes SM, Corbin CJ, Conley AJ. Morphological adrenarche in rhesus macaques: development of the zona reticularis is concurrent with fetal zone regression in the early neonatal period. J Endocrinol 2008; 199:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/7\">",
"      Conley AJ, Plant TM, Abbott DH, et al. Adrenal androgen concentrations increase during infancy in male rhesus macaques (Macaca mulatta). Am J Physiol Endocrinol Metab 2011; 301:E1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/8\">",
"      Rich BH, Rosenfield RL, Lucky AW, et al. Adrenarche: changing adrenal response to adrenocorticotropin. J Clin Endocrinol Metab 1981; 52:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/9\">",
"      Weber A, Clark AJ, Perry LA, et al. Diminished adrenal androgen secretion in familial glucocorticoid deficiency implicates a significant role for ACTH in the induction of adrenarche. Clin Endocrinol (Oxf) 1997; 46:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/10\">",
"      Rosenfield RL. Plasma 17-ketosteroids and 17-beta hydroxysteroids in girls with premature development of sexual hair. J Pediatr 1971; 79:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/11\">",
"      Rittmaster RS, Givner ML. Effect of daily and alternate day low dose prednisone on serum cortisol and adrenal androgens in hirsute women. J Clin Endocrinol Metab 1988; 67:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/12\">",
"      Brigell DF, Fang VS, Rosenfield RL. Recovery of responses to ovine corticotropin-releasing hormone after withdrawal of a short course of glucocorticoid. J Clin Endocrinol Metab 1992; 74:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/13\">",
"      Endoh A, Kristiansen SB, Casson PR, et al. The zona reticularis is the site of biosynthesis of dehydroepiandrosterone and dehydroepiandrosterone sulfate in the adult human adrenal cortex resulting from its low expression of 3 beta-hydroxysteroid dehydrogenase. J Clin Endocrinol Metab 1996; 81:3558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/14\">",
"      Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 2011; 32:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/15\">",
"      Hui XG, Akahira J, Suzuki T, et al. Development of the human adrenal zona reticularis: morphometric and immunohistochemical studies from birth to adolescence. J Endocrinol 2009; 203:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/16\">",
"      Lalli E. Adrenal cortex ontogenesis. Best Pract Res Clin Endocrinol Metab 2010; 24:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/17\">",
"      Blackman, SJ. Concerning the function and origin of the reticular zone of the adrenal cortex. Bull Hopkins Hosp 1946; 78:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/18\">",
"      Rainey WE, Carr BR, Sasano H, et al. Dissecting human adrenal androgen production. Trends Endocrinol Metab 2002; 13:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/19\">",
"      Dickerman Z, Grant DR, Faiman C, Winter JS. Intraadrenal steroid concentrations in man: zonal differences and developmental changes. J Clin Endocrinol Metab 1984; 59:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/20\">",
"      Topor LS, Asai M, Dunn J, Majzoub JA. Cortisol stimulates secretion of dehydroepiandrosterone in human adrenocortical cells through inhibition of 3betaHSD2. J Clin Endocrinol Metab 2011; 96:E31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/21\">",
"      Winter JS, Smail PJ. Effects of ACTH and estradiol on steroid production by cultured adrenal cells from an anencephalic fetus and from normal adults. Steroids 1983; 42:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/22\">",
"      Bellanger S, Battista MC, Fink GD, Baillargeon JP. Saturated fatty acid exposure induces androgen overproduction in bovine adrenal cells. Steroids 2012; 77:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/23\">",
"      Schiebinger RJ, Albertson BD, Cassorla FG, et al. The developmental changes in plasma adrenal androgens during infancy and adrenarche are associated with changing activities of adrenal microsomal 17-hydroxylase and 17,20-desmolase. J Clin Invest 1981; 67:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/24\">",
"      Noordam C, Dhir V, McNelis JC, et al. Inactivating PAPSS2 mutations in a patient with premature pubarche. N Engl J Med 2009; 360:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/25\">",
"      Nakamura Y, Hornsby PJ, Casson P, et al. Type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in the adrenal reticularis. J Clin Endocrinol Metab 2009; 94:2192.",
"     </a>",
"    </li>",
"    <li>",
"     Mills I, Brooks R, Prunty F. The relationship between the production of cortisol and androgen by the human adrenal. In: The human adrenal cortex, Currie A, Symington T, Grant J (Eds), Williams &amp; Wilkins, Baltimore 1962.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/27\">",
"      Parker LN. Adrenarche. Endocrinol Metab Clin North Am 1991; 20:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/28\">",
"      Taha D, Mullis PE, Ib&aacute;&ntilde;ez L, de Zegher F. Absent or delayed adrenarche in Pit-1/POU1F1 deficiency. Horm Res 2005; 64:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/29\">",
"      Ehrhart-Bornstein M, Hinson JP, Bornstein SR, et al. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev 1998; 19:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/30\">",
"      Ong KK, Potau N, Petry CJ, et al. Opposing influences of prenatal and postnatal weight gain on adrenarche in normal boys and girls. J Clin Endocrinol Metab 2004; 89:2647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/31\">",
"      Smith CP, Dunger DB, Williams AJ, et al. Relationship between insulin, insulin-like growth factor I, and dehydroepiandrosterone sulfate concentrations during childhood, puberty, and adult life. J Clin Endocrinol Metab 1989; 68:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/32\">",
"      B��ogowska A, Rzepka-G&oacute;rska I, Krzyzanowska-Swiniarska B. Body composition, dehydroepiandrosterone sulfate and leptin concentrations in girls approaching menarche. J Pediatr Endocrinol Metab 2005; 18:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/33\">",
"      Biason-Lauber A, Zachmann M, Schoenle EJ. Effect of leptin on CYP17 enzymatic activities in human adrenal cells: new insight in the onset of adrenarche. Endocrinology 2000; 141:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/34\">",
"      Guercio G, Rivarola MA, Chaler E, et al. Relationship between the growth hormone/insulin-like growth factor-I axis, insulin sensitivity, and adrenal androgens in normal prepubertal and pubertal girls. J Clin Endocrinol Metab 2003; 88:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/35\">",
"      Baquedano MS, Berensztein E, Saraco N, et al. Expression of the IGF system in human adrenal tissues from early infancy to late puberty: implications for the development of adrenarche. Pediatr Res 2005; 58:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/36\">",
"      Martin DD, Schweizer R, Schwarze CP, et al. The early dehydroepiandrosterone sulfate rise of adrenarche and the delay of pubarche indicate primary ovarian failure in Turner syndrome. J Clin Endocrinol Metab 2004; 89:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/37\">",
"      Cumming DC, Rebar RW, Hopper BR, Yen SS. Evidence for an influence of the ovary on circulating dehydroepiandrosterone sulfate levels. J Clin Endocrinol Metab 1982; 54:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/38\">",
"      Laatikainen T, Laitinen EA, Vihko R. Secretion of free and sulfate-conjugated neutral steroids by the human testis. Effect of administration of human chorionic gonadotropin. J Clin Endocrinol Metab 1971; 32:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/39\">",
"      Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med 2005; 353:2578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/40\">",
"      Rosenfield RL, Fang VS. The effects of prolonged physiologic estradiol therapy on the maturation of hypogonadal teen-agers. J Pediatr 1974; 85:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/41\">",
"      Remer T, Boye KR, Hartmann M, et al. Adrenarche and bone modeling and remodeling at the proximal radius: weak androgens make stronger cortical bone in healthy children. J Bone Miner Res 2003; 18:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/42\">",
"      Remer T, Shi L, Buyken AE, et al. Prepubertal adrenarchal androgens and animal protein intake independently and differentially influence pubertal timing. J Clin Endocrinol Metab 2010; 95:3002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/43\">",
"      Haning RV Jr, Hackett RJ, Flood CA, et al. Plasma dehydroepiandrosterone sulfate serves as a prehormone for 48% of follicular fluid testosterone during treatment with menotropins. J Clin Endocrinol Metab 1993; 76:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/44\">",
"      Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992; 6:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/45\">",
"      Asaba H, Hosoya K, Takanaga H, et al. Blood-brain barrier is involved in the efflux transport of a neuroactive steroid, dehydroepiandrosterone sulfate, via organic anion transporting polypeptide 2. J Neurochem 2000; 75:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/46\">",
"      Campbell BC. Adrenarche and middle childhood. Hum Nat 2011; 22:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/47\">",
"      Del Giudice M. Sex, attachment, and the development of reproductive strategies. Behav Brain Sci 2009; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/48\">",
"      Herdt G, McClintock M. The magical age of 10. Arch Sex Behav 2000; 29:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/49\">",
"      Brooke AM, Kalingag LA, Miraki-Moud F, et al. Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement. J Clin Endocrinol Metab 2006; 91:3773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/50\">",
"      Mortola JF, Yen SS. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 1990; 71:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/51\">",
"      Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006; 355:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23302/abstract/52\">",
"      Davis SR, Panjari M, Stanczyk FZ. Clinical review: DHEA replacement for postmenopausal women. J Clin Endocrinol Metab 2011; 96:1642.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5798 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-2030A22EB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_48_23302=[""].join("\n");
var outline_f22_48_23302=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24070796\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24070873\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Anatomic site and mechanism of biochemical changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Triggers of adrenarche",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS OF ADRENARCHE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24070796\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20349885\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5798\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5798|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/5/18527\" title=\"figure 1\">",
"      DHEAS pubic hair develop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/34/38447\" title=\"figure 2\">",
"      Hormonal changes during adrenarche",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/10/8355\" title=\"figure 3\">",
"      Steroidogenesis by zone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5798|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/59/43965\" title=\"table 1\">",
"      Androgen range child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=related_link\">",
"      Adrenal steroid biosynthesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_48_23303="The mental status examination in adults";
var content_f22_48_23303=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The mental status examination in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/48/23303/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/48/23303/contributors\">",
"     Po-Haong Lu, Psy. D",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/48/23303/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/48/23303/contributors\">",
"     Mario F Mendez, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/48/23303/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/48/23303/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/48/23303/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H28388579\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the technological advances in neuroimaging, there is still no way of directly observing cognitive function. Neuroscientists and clinicians continue to rely on the mental status or neuropsychological examination for much of their knowledge of the state and functioning of the brain. The study of the behavioral expression of brain dysfunction is the essence of mental status examination and neuropsychological assessment, which is critical to diagnostic accuracy, patient care and treatment planning, rehabilitation and treatment evaluation, and research.",
"   </p>",
"   <p>",
"    Methods of examining cognition include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bedside or clinic mental status testing. This is generally the initial assessment of cognition and mental status and can be brief or more extensive depending on the setting and level of concern.",
"     </li>",
"     <li>",
"      Mental status scales. These are usually used as a screening tool but also as a baseline measure to follow patients over time.",
"     </li>",
"     <li>",
"      Neuropsychological testing for extensive evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The goals of the mental status examination are to distinguish normal from abnormal cognition and dementia from delirium or primary psychiatric disease. Bedside or clinic mental status testing is not standardized. Determination of deficits versus strengths often depends on extrapolated norms from standardized neuropsychological tests. Patterns of deficits in the mental status examination can sometimes allow a preliminary hypothesis as to the underlying pathogenesis of a dementing process. The mental status examination also allows a measure of the severity of a patient&rsquo;s problems that can be followed over time.",
"   </p>",
"   <p>",
"    This topic will review the mental status examination as performed at the patient's bedside or in an outpatient office. The use of mental status scales and detailed neuropsychological testing are presented separately. Other features of the neurologic examination are discussed separately. Other facets of the evaluation of patients with cognitive disorders are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28388586\">",
"    <span class=\"h1\">",
"     CLINICAL INTERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of mental status, whether in the office or at the bedside, begins with direct questioning and careful observation of the patient during the course of the initial medical history-taking. Many aspects of mental status and cognition can be assessed in this interview: attention, speed of responses, and ability to answer questions and provide relevant information, as well as their overall appearance and degree of cooperation. These observations, along with any specific complaints brought forward by the patient or family member, can guide the examiner into performing a more or less detailed mental status examination.",
"   </p>",
"   <p>",
"    The clinical history provides important information that is supplemental to the mental status examination. The patient's age, educational level, and premorbid functioning are obviously relevant, as are medical history and current medications. How the patient functions in his or her daily life as well as any changes in personality, behavior, and interpersonal relationships with family and friends are important features to ask about. In this regard, having an independent person to interview, preferably one who lives with the patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    has a long-standing history with them, is invaluable.",
"   </p>",
"   <p>",
"    The clinical interview also provides an opportunity to establish rapport with the patient and make",
"    <span class=\"nowrap\">",
"     him/her",
"    </span>",
"    comfortable. The collection of information that is relatively mundane and functional is less stressful than overt testing of cognition. Performance in this setting may provide a less biased assessment than explicit testing, which often contributes to test and performance anxiety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28388593\">",
"    <span class=\"h1\">",
"     MENTAL STATUS EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An assessment of mental status should specifically note deficits in the following spheres:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Level of consciousness (arousal)",
"     </li>",
"     <li>",
"      Attention and concentration",
"     </li>",
"     <li>",
"      Memory",
"     </li>",
"     <li>",
"      Language",
"     </li>",
"     <li>",
"      Visual spatial perception",
"     </li>",
"     <li>",
"      Executive functioning",
"     </li>",
"     <li>",
"      Mood and thought content",
"     </li>",
"     <li>",
"      Praxis",
"     </li>",
"     <li>",
"      Calculations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These spheres as categorized are somewhat arbitrary and overlapping, as are the tests used to evaluate them. The following sections will outline some simple, and some relatively more detailed, tests of assessing these.",
"   </p>",
"   <p>",
"    Whenever possible, it is optimal to conduct mental status examination and neuropsychological testing in a quiet room, without distractions. This may be difficult in busy hospital or clinic settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28388600\">",
"    <span class=\"h2\">",
"     Arousal",
"    </span>",
"    &nbsp;&mdash;&nbsp;While taking the history and examining the patient, it is first important to observe whether the patient is alert, attentive, sleepy, or unresponsive. An adequate state of arousal is a prerequisite for further mental status testing. The evaluation of a patient in stupor or coma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=see_link\">",
"     \"Stupor and coma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28388607\">",
"    <span class=\"h2\">",
"     Attention and concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention is the ability to focus and direct cognitive processes and to resist distraction; concentration is the ability to focus and sustain attention over a period of time. Assessment of attention is critical to the interpretation of other elements of the neurocognitive examination because patients who are inattentive will exhibit disturbances in cognitive performance, particularly in memory and executive function, thus confounding the interpretation of the contribution of specific cognitive failures.",
"   </p>",
"   <p>",
"    Abnormal attention is often evident in the clinical interview; the patient may have difficulty concentrating, be easily distracted by stimuli, lose",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    train of thought, and tend to ramble.",
"   </p>",
"   <p>",
"    The most elementary assessment of attention is accomplished through the digit span test [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/1\">",
"     1",
"    </a>",
"    ]. The examiner recites number digits at the rate of one number per second and asks the patient to repeat back the number sequence in exactly the same order. The string of digits increases in length. A normal span is seven digits plus or minus two digits for adults, regardless of age or educational level [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/2\">",
"     2",
"    </a>",
"    ]. Spelling simple words backward or stating the months of the year in reverse are other simple tests of attention and concentration.",
"   </p>",
"   <p>",
"    More complex tests of sustained attention also involve cognitive processing speed; time of performance is an important component in these tasks. Examples include part A of the Trailmaking Test (Trails A) (",
"    <a class=\"graphic graphic_figure graphicRef66230 \" href=\"UTD.htm?33/16/34062\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/3-7\">",
"     3-7",
"    </a>",
"    ], symbol-copying tasks (eg, Digit Symbol) (",
"    <a class=\"graphic graphic_figure graphicRef74553 \" href=\"UTD.htm?13/12/13504\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/8,9\">",
"     8,9",
"    </a>",
"    ] and letter-cancellation tasks (",
"    <a class=\"graphic graphic_figure graphicRef63183 \" href=\"UTD.htm?2/35/2614\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. While these tests can be part of the office assessment, they are more typically administered in the setting of formal neuropsychologic testing.",
"   </p>",
"   <p>",
"    Prominent deficits in attention and concentration are typical in patients with toxic metabolic encephalopathy and with acute psychiatric disorders, but are less conspicuous in early neurodegenerative disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36889?source=see_link\">",
"     \"Acute toxic-metabolic encephalopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28388614\">",
"    <span class=\"h2\">",
"     Memory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired memory is a common complaint which may be presented by patients",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    family members. Memory has multiple dimensions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate and working memory is assessed by tests of attention including the digit span [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H28388607\">",
"       'Attention and concentration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recent memory involves the learning of new material. Testing orientation to time and place and asking the patient about events of the day are useful tools in the office or at the bedside to assess recent memory [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. A more explicit test of recent memory, is asking patient to remember three to four words, having them repeat them to ensure normal",
"      <span class=\"nowrap\">",
"       attention/immediate",
"      </span>",
"      memory, and then ask them to recall the words after 5 to 10 minutes of distraction. For patients who are unable to recall the original words, category hints (eg, \"animal\") or multiple-choice cues (\"cow, horse, or dog\") can be given to further assess the severity of the deficit. Longer lists of 8 to 10 words can also be used to increase the sensitivity of the test. Normal older adults should be able to remember three out of three words without cues and up to eight words with cues [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/2\">",
"       2",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The \"three-words three-shapes\" memory test is another test of recent memory that can be useful in the office setting [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/12\">",
"       12",
"      </a>",
"      ]. In this test, patients are asked to copy three words (eg, justice, courage, thirst) along with three abstract shapes. Delayed recall is tested in 5, 15, and 30 minutes with re-exposure to the stimuli as needed. If recall is faulty, multiple-choice recognition is tested.",
"     </li>",
"     <li>",
"      Retrieval of remote memories can be tested by asking for the names of United States Presidents in reverse order as far back as the patient can remember, or by asking about important historical events and dates as well as sporting events and popular television shows [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. The patient can also be asked about details of personal life such as his or her birth date, the names and ages of children and grandchildren, and work history, assuming independent verification is available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Memory functions can also be separated into episodic memory (for specific events and contexts) versus semantic memory (for vocabulary and concepts). These can be differentially affected by neurologic disease. Semantic memory is assessed by asking the patient the meanings of words, phrases, and symbols. Bidirectional naming tasks, in which the patient not only names an object but describes its use or function, is another assessment tool.",
"   </p>",
"   <p>",
"    Assessment of memory functions should include learning of visual as well as verbal information. Most bedside assessments of memory employ verbal tasks. In the setting of neuropsychological testing, visual memory is tested using simple and complex line figures (eg, Rey-Osterrieth complex figure) (",
"    <a class=\"graphic graphic_figure graphicRef53426 \" href=\"UTD.htm?28/46/29422\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/9\">",
"     9",
"    </a>",
"    ]. The patient is required to construct the figure immediately after exposure and then to reproduce the design after a specified time interval. Other visual memory tasks not involving a constructional component can include the use of photographs; recalling events of a photograph shown to the patient can test recent memory, while remote memory testing might employ photographs of famous individuals. However, failure to recognize familiar faces can also be a visual perception problem, as discussed below.",
"   </p>",
"   <p>",
"    Supraspan learning tasks involving a word list are used in the setting of neuropsychologic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/13\">",
"     13",
"    </a>",
"    ]. Learning trials usually involve repetition of a list of 15 to 20 words over several trials to assess whether the patient exhibits a learning curve. A second list is usually administered to serve as a distractor, followed by a short-delay recall trial. Long-delay recall of the original words is typically administered after 20 to 30 minutes. The majority of list-learning and memory tasks also involve a recognition memory format, in which target words are interspersed with foils; patients are asked whether they remember hearing the word through \"yes-no\" multiple choice format or circling the target words from either lists or stories.",
"   </p>",
"   <p>",
"    Many patterns of memory loss may occur. Amnestic disorders are characterized by normal working and impaired recent memory and imply mesial limbic and hippocampal dysfunction. This is a typical early deficit in individuals with Alzheimer disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Alzheimer disease\"",
"    </a>",
"    .) Patients with Korsakoff psychosis can have even more profound loss of recent memory, which is often, but not always accompanied by confabulation (fabricated material). Retrieval deficit syndromes are more typical of those with frontal-subcortical circuit dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28388621\">",
"    <span class=\"h2\">",
"     Language",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of language functions begins with listening to the patient's spontaneous speech during the clinical interview. Written and oral language function is further assessed by formal testing and noting deficits in the following domains:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluency. This is usually assessed by listening to the patient's spontaneous speech.",
"     </li>",
"     <li>",
"      Content. Language errors during spontaneous or tested speech can include paraphasic errors and neologisms.",
"     </li>",
"     <li>",
"      Repetition. Patients are asked to repeat phrases of increasing complexity. A common screening phrase used is \"no ifs, ands, or buts\".",
"     </li>",
"     <li>",
"      Naming. Patients are typically asked to name real or pictorial objects presented to them, again usually beginning with words more frequently used and progressing to those that are less common.",
"     </li>",
"     <li>",
"      Comprehension. Understanding of both written and oral language is evaluated by giving a sequence of commands, beginning with one-step, midline commands (\"Close your eyes\") and progressing to multi-step commands.",
"     </li>",
"     <li>",
"      Reading. Patients are asked to read aloud from a newspaper or from a list of single words.",
"     </li>",
"     <li>",
"      Writing. The patient is asked to write a sentence spontaneously.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Verbal fluency tasks ask patients to generate words within a specified length of time. While not specific for language function, this test provides a means for rapid assessment of word knowledge and verbal executive function. Patients may perform differently on category fluency tests (eg, lists of animals) and letter fluency test (eg, lists of words beginning with F). Normal performance is age related, with at least 15 items expected after one minute at age 65 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of Alzheimer disease\", section on 'Language'",
"    </a>",
"    .) Cut-off scores of 12 for animals and 10 for F words are also commonly employed in clinic settings.",
"   </p>",
"   <p>",
"    Validated scales such as the Boston diagnostic aphasia examination and Western aphasia battery are often used in clinical studies and as part of neuropsychologic test batteries; these are too time-consuming to administer in the typical office setting [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A loss of ability to produce",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    understand written or spoken language is called aphasia. This may be an isolated finding or may be one feature of a patient's cognitive impairment. In the former situation, the assessment of language as described above is used to classify the aphasia according to one of the classic language syndromes listed in the table (",
"    <a class=\"graphic graphic_table graphicRef72780 \" href=\"UTD.htm?23/44/24269\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The assessment of language function and the categorization of aphasias are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20041?source=see_link\">",
"     \"Approach to the patient with aphasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28388628\">",
"    <span class=\"h2\">",
"     Visual spatial perception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Problems with visual spatial perception are suggested by a history of losing objects, getting lost, or difficulty navigating familiar or unfamiliar terrain. Patients may also exhibit frank visuospatial neglect when they are observed by family and friends to ignore visual stimuli in one visual field (usually the left) as when searching for objects in the refrigerator or ignoring half their plate at meal time.",
"   </p>",
"   <p>",
"    Visuospatial functions encompass perceptual and constructional abilities, which are typically assessed through",
"    <span class=\"nowrap\">",
"     copying/drawing",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     building/assembly",
"    </span>",
"    tasks [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/2\">",
"     2",
"    </a>",
"    ]. In the former, patients are asked to copy visual stimuli such as a diamond, overlapping pentagons, a three-dimensional cube, or more complex designs (eg, Rey-Osterrieth diagram) (",
"    <a class=\"graphic graphic_figure graphicRef53426 \" href=\"UTD.htm?28/46/29422\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Line bisection and Letter Cancellation tests (",
"    <a class=\"graphic graphic_figure graphicRef63183 \" href=\"UTD.htm?2/35/2614\">",
"     figure 3",
"    </a>",
"    ) can be useful to elicit visuospatial neglect [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clock drawing is another sensitive tool for visual spatial problems but encompasses abilities from other cognitive domains. Some recommend this single task as a screening tool for dementia.",
"   </p>",
"   <p>",
"    Careful observation of abnormal spatial relationships, absence of detail, stimulus-boundedness, loss of three-dimensional perspective, or neglect of one part of the drawing can help distinguish between perceptual failures, spatial confusion, or apraxia.",
"   </p>",
"   <p>",
"    The Block Design subtest of the Wechsler Adult Intelligence Scale, third edition (WAIS-III) is typically used as a part of the neuropsychologic test battery and involves constructing blocks to match abstract designs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/1\">",
"     1",
"    </a>",
"    ]. While deficits in drawing or assembly can co-occur, the two types of activities are more likely to be dissociative and can help discriminate between spatial and visual aspects of a constructional disability, and estimate the relative contribution of each.",
"   </p>",
"   <p>",
"    Prominent problems with visual spatial tasks out of proportion to other cognitive deficits, particularly when visuospatial neglect is elicited, suggest specific injury within the nondominant parietal lobe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28388635\">",
"    <span class=\"h2\">",
"     Praxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Praxis, or more specifically, ideomotor praxis, refers to the performance of learned motor movements in the absence of primary deficits in motor and spatial abilities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/2,18\">",
"     2,18",
"    </a>",
"    ]. Frank problems with ideomotor praxis may be obvious when patient or family member reports difficulty dressing, feeding, and bathing that is not explained by gross motor deficits.",
"   </p>",
"   <p>",
"    On testing, ideomotor praxis is evaluated by asking the patient to perform increasingly complex motor tasks. As an example, the patient may be asked to demonstrate the use of an object (eg, comb, hammer, fork) with and without the actual object in hand. Difficulty with this type of task is often labeled ideomotor apraxia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/1,18,19\">",
"     1,18,19",
"    </a>",
"    ]. A step-wise series of coordinated tasks \"take this piece of paper, fold it in half, and place it in the envelope\" is another way to demonstrate praxis, in this case, ideational praxis, which refers to the capacity to carry out a sequential set of actions toward a final goal.",
"   </p>",
"   <p>",
"    A significant language disorder or motor deficit can affect the ability to assess praxis. Common errors include using the wrong object or body part to perform a task. Many patients who cannot perform motor tasks to command can do so spontaneously or by imitation.",
"   </p>",
"   <p>",
"    Patients with neurodegenerative disease may also have difficultly performing a series of coordinated tasks. More specific or isolated problems with praxis suggest involvement of the dominant parietal lobe [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/19\">",
"     19",
"    </a>",
"    ]. Ideomotor apraxia is a relatively prominent feature of corticobasal degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link&amp;anchor=H9#H9\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\", section on 'Corticobasal degeneration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28388642\">",
"    <span class=\"h2\">",
"     Calculations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple mathematical problems are given to the patient to assess their ability to perform calculations. These include adding a series of coins, and perform \"serial sevens\" (sequentially subtract 7, beginning with 100). Calculation testing is sensitive to impaired attention and performance (test) anxiety as well as to the patient's educational level.",
"   </p>",
"   <p>",
"    Acalculia is the inability to perform mathematical calculations. There are many forms of acalculias, the most specific of which is associated with left angular gyrus lesions. Acalculia is also a feature of neurodegenerative dementia occurring along with other cognitive deficits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28388649\">",
"    <span class=\"h2\">",
"     Executive functioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Executive functioning is a complex set of capacities including volition, planning, purposive action, and effective performance that enable a person to engage successfully in appropriate, goal-directed, socially responsible, and self-serving behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/4\">",
"     4",
"    </a>",
"    ]. The prefrontal cortex and their connections through the caudate nuclei are the main source of executive functions.",
"   </p>",
"   <p>",
"    An overview of executive function is obtained in the history, in which patients and family members may be asked about function in everyday life and with which tasks they may require help or direction. Impairments in insight and judgment are early indicators of executive dysfunction; these are also better assessed in the clinical history (eg, \"what problems do you think you are having?\"; how would you handle [eg, minor household emergencies]?) rather than by a specific test.",
"   </p>",
"   <p>",
"    Evaluation of executive functions is difficult; formal neuropsychological assessment of this domain is usually broadly divided into five types of mental tasks [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Working memory is the ability to temporarily hold information in mind and manipulate the information in order to carry out complex cognitive tasks. It is often tested with serial reversal tasks (eg, digits backwards) or sequencing of mixed numbers",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      letters of alphabet in ascending order.",
"     </li>",
"     <li>",
"      The ability to divide attention and ability to change sets (ie, mental flexibility). Examples include the Trailmaking Test, part B (",
"      <a class=\"graphic graphic_figure graphicRef66230 \" href=\"UTD.htm?33/16/34062\">",
"       figure 1",
"      </a>",
"      ) and the Wisconsin Card Sorting Test (",
"      <a class=\"graphic graphic_figure graphicRef50407 \" href=\"UTD.htm?39/13/40159\">",
"       figure 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/3,20,21\">",
"       3,20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Generative ideation through measures of verbal and design fluency [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/20\">",
"       20",
"      </a>",
"      ]. Verbal fluency tasks are described above. (See",
"      <a class=\"local\" href=\"#H28388621\">",
"       'Language'",
"      </a>",
"      above.) Analogously, design fluency tests assess the ability of the patient to generate novel designs within a defined time period.",
"     </li>",
"     <li>",
"      Motor programming. Tests of motor programming include asking the patient to imitate simple rhythms (eg, clap, clap, tap, knock) or to copy a sequence of m's and n's [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/1,2,20\">",
"       1,2,20",
"      </a>",
"      ]. Another example is the Luria \"fist-edge-palm\" test, in which the patient is asked to tap that aspect of their hand to the desk in repeated sequences [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/20\">",
"       20",
"      </a>",
"      ]. Impaired patients typically demonstrate perseveration, which refers to the phenomenon of being &ldquo;stuck-in-set&rdquo; and continuing elements of previous actions into the present activity.",
"     </li>",
"     <li>",
"      The ability to inhibit responses. This can be tested by",
"      <span class=\"nowrap\">",
"       \"go/no",
"      </span>",
"      go\" tests [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/2,20\">",
"       2,20",
"      </a>",
"      ]. As an example, the patient is asked to \"tap when I tap once\" and to \"not tap when I tap twice\". Another test of this function is the Stroop Color-Word Interference (",
"      <a class=\"graphic graphic_figure graphicRef72016 \" href=\"UTD.htm?43/12/44228\">",
"       figure 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/20,22\">",
"       20,22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abstract reasoning is a related executive function and usually assessed by asking the patient to interpret similarities and differences (eg, between word pairs such as watch-ruler, child-midget), idioms (eg, warm-hearted), and proverbs (eg, \"a rolling stone gathers no moss\") [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/1,20\">",
"     1,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28388656\">",
"    <span class=\"h2\">",
"     Mood and thought content",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mood and emotional state have a strong impact on mental status and cognitive functioning. Patients and family should be questioned about mood and outlook. The patient's affect (ie, the outward expression of their mood) should be noted. Depression can present with cognitive impairment and is suggested by a withdrawn affect that can include poor eye contact, tearfulness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blunting. Apathy can be difficult to distinguish from depression. Mood and affect can be incongruent in the case of pseudobulbar palsy where",
"    <span class=\"nowrap\">",
"     tearfulness/laughing",
"    </span>",
"    is disproportionate to the underlying feeling, and in brain injury or multiple sclerosis where euphoria in some cases covers up clinical depression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23303/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient's thought content as expressed through the patient's spontaneous speech in the clinical interview and examination should also be assessed. Any abnormal intrusions, preoccupations, perseverations, delusions, or hallucinations should be noted as these are vital to understanding the underlying process. If the patient is poorly communicative it is often worthwhile to specifically elicit such a history of abnormal thoughts, by asking the patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    family members about these symptoms.",
"   </p>",
"   <p>",
"    In the setting of neuropsychological testing, the examiner may employ symptom checklists and other survey instruments to elicit difficulties with mood, abnormal thought processes, and other relevant symptoms that may impact test performance and interpretation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Minnesota Multiphasic Personality Inventory",
"     </li>",
"     <li>",
"      Beck Depression Inventory",
"     </li>",
"     <li>",
"      Geriatric Depression Scale",
"     </li>",
"     <li>",
"      Neuropsychiatric Inventory",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28388663\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;While not routinely assessed, the examiner may wish to test for right-left orientation and finger agnosia, both features of the Gerstmann syndrome which includes dysgraphia and acalculia and localizes to lesions in the posterior left hemisphere. Right-left orientation may be tested by asking the patient to point to or move body parts on the right or left side. Finger agnosia is tested by asking patient to point to or manipulate named fingers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28388670\">",
"    <span class=\"h1\">",
"     BRIEF COGNITIVE ASSESSMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously discussed, a clinical interview in the office can provide an adequate screening of mental status in many, if not most, individuals.",
"   </p>",
"   <p>",
"    Over the course of long-term follow-up, when prolonged interviews are not routinely part of a brief scheduled office visit, clinicians caring for the elderly often use brief cognitive assessments to screen for cognitive decline and dementia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mini-mental state examination (MMSE) is popular and well known. This tool is assessed on a scale of 0 to 30. The included items cover most cognitive domains, particularly those abilities most relevant to dementia of the Alzheimer&rsquo;s type (AD). The MMSE can be performed in a relatively short time interval (5 to 10 minutes).",
"     </li>",
"     <li>",
"      Clock drawing has also become popular as a screening tool for cognitive problems as a single task that covers multiple cognitive domains.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These and other brief cognitive assessments are discussed in detail separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28388677\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough mental status assessment is arguably more important in the diagnosis and management of central nervous system syndromes, particularly dementing disorders, than any other procedure or laboratory tests, including neuroimaging.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mental status examination, performed at the bedside or outpatient office, provides an initial assessment of cognition and mental status and can be brief or more extensive depending on the setting and level of concern.",
"     </li>",
"     <li>",
"      The mental status examination can generally distinguish those with normal versus abnormal cognition, and also dementia from delirium or primary psychiatric disease. Determination of severity of deficits and documentation of relative strengths with respect to age and education requires extrapolated norms from standardized neuropsychological testing. Patterns of deficits in the mental status examination can sometimes allow a preliminary hypothesis as to the underlying pathogenesis of a dementing process. The mental status examination also allows a measure of the severity of a patient's problems that can be followed over time.",
"     </li>",
"     <li>",
"      A thorough evaluation of mental status notes competency",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      deficits in the following cognitive spheres:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Attention and concentration",
"     </li>",
"     <li>",
"      Memory",
"     </li>",
"     <li>",
"      Language",
"     </li>",
"     <li>",
"      Visual spatial perception",
"     </li>",
"     <li>",
"      Praxis",
"     </li>",
"     <li>",
"      Calculations",
"     </li>",
"     <li>",
"      Executive functioning",
"     </li>",
"     <li>",
"      Mood and thought content",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific tests that provide an assessment of these functions are suggested in individual sections above.",
"    <br/>",
"    <br/>",
"    Mental status testing is hierarchical; problems with arousal impede attention, which in turn impedes language and memory and so forth. Furthermore, each test can be affected by multiple cognitive domains. As an example, digit symbol assesses not only attention and information processing speed, but also visual scanning, memory, graphomotor tracking, etc. It is not to interpret individual tests in isolation but to sample at least two tests in each of the mental status areas. (See",
"    <a class=\"local\" href=\"#H28388593\">",
"     'Mental status examination'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial screening assessment of mental status is usually provided during the clinical interview. (See",
"      <a class=\"local\" href=\"#H28388586\">",
"       'Clinical interview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patient settings in which an extended interview is not performed, brief cognitive assessments are suggested as a useful tool to screen for cognitive decline and dementia. (See",
"      <a class=\"local\" href=\"#H28388670\">",
"       'Brief cognitive assessments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuropsychological testing can be of added value by providing a more precise measure of a patient's cognitive strengths and weaknesses and assisting in differential diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Strub RL, Black FW. The Mental Status Examination in Neurology, 2nd ed, FA Davis, Philadelphia 1989.",
"    </li>",
"    <li>",
"     Mendez MF, Cummings JL. Mental status assessment. In: Dementia: A Clinical Approach, Butterworth Heinemann, Philadelphia 2003.",
"    </li>",
"    <li>",
"     Reitan RM, Wolfson D. he Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation, Neuropsychology Press, Tucson, AZ 1989.",
"    </li>",
"    <li>",
"     Lezak MD. Neuropsychological Assessment, 4th ed, Oxford University Press, New York 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23303/abstract/5\">",
"      Corrigan JD, Hinkeldey NS. Relationships between parts A and B of the Trail Making Test. J Clin Psychol 1987; 43:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23303/abstract/6\">",
"      Gaudino EA, Geisler MW, Squires NK. Construct validity in the Trail Making Test: what makes Part B harder? J Clin Exp Neuropsychol 1995; 17:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23303/abstract/7\">",
"      O'Donnell WE, Reynolds DM, De Soto CB. Neuropsychological impairment scale (NIS): initial validation study using trailmaking test (A &amp; B) and WAIS digit symbol (scaled score) in a mixed grouping of psychiatric, neurological, and normal patients. J Clin Psychol 1983; 39:746.",
"     </a>",
"    </li>",
"    <li>",
"     Wechlser, D. Wechsler Adult Intelligence Scale, 3rd edition: Administration and Scoring Manual, Psychological Corporation, San Antonio 1997.",
"    </li>",
"    <li>",
"     Meyers J, Meyers K. Rey Complex Figure and Recognition Trial: Professional Manual, Psychological Assessment Resources, Odessa, Fl 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23303/abstract/10\">",
"      Uttl B, Pilkenton-Taylor C. Letter cancellation performance across the adult life span. Clin Neuropsychol 2001; 15:521.",
"     </a>",
"    </li>",
"    <li>",
"     Weintraub S. Neuropsychological assessment of mental state. In: Principles of Behavioral and Cognitive Neurology, Mesulam MM (Ed), Oxford University Press, New York 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23303/abstract/12\">",
"      Weintraub S, Peavy GM, O'Connor M, et al. Three words three shapes: A clinical test of memory. J Clin Exp Neuropsychol 2000; 22:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23303/abstract/13\">",
"      Turcotte J, Gagnon S, Poirier M. The effect of old age on the learning of supraspan sequences. Psychol Aging 2005; 20:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23303/abstract/14\">",
"      Cerhan JH, Ivnik RJ, Smith GE, et al. Diagnostic utility of letter fluency, category fluency, and fluency difference scores in Alzheimer's disease. Clin Neuropsychol 2002; 16:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23303/abstract/15\">",
"      Berthier ML. Poststroke aphasia : epidemiology, pathophysiology and treatment. Drugs Aging 2005; 22:163.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplan E, Goodglass H, Weintraub S. Boston Naming Test, Lea &amp; Febiger, Philadelphia 1983.",
"    </li>",
"    <li>",
"     Benton AL, Hamsher KdeS. Multilingual Aphasia Examination. AJA Associates, Iowa City 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23303/abstract/18\">",
"      Gross RG, Grossman M. Update on apraxia. Curr Neurol Neurosci Rep 2008; 8:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23303/abstract/19\">",
"      Wheaton LA, Hallett M. Ideomotor apraxia: a review. J Neurol Sci 2007; 260:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23303/abstract/20\">",
"      Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000; 55:1621.",
"     </a>",
"    </li>",
"    <li>",
"     Heaton RK, Chelune GJ, Talley JL, et al. Wisconsin Card Sorting Test Manual: Revised and Expanded, Psychological Assessment Resources, Odessa, FL 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23303/abstract/22\">",
"      COMALLI PE Jr, WAPNER S, WERNER H. Interference effects of Stroop color-word test in childhood, adulthood, and aging. J Genet Psychol 1962; 100:47.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14067 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A1F0AAE071-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_48_23303=[""].join("\n");
var outline_f22_48_23303=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28388677\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28388579\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28388586\">",
"      CLINICAL INTERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28388593\">",
"      MENTAL STATUS EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28388600\">",
"      Arousal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28388607\">",
"      Attention and concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28388614\">",
"      Memory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28388621\">",
"      Language",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28388628\">",
"      Visual spatial perception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28388635\">",
"      Praxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28388642\">",
"      Calculations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28388649\">",
"      Executive functioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28388656\">",
"      Mood and thought content",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28388663\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28388670\">",
"      BRIEF COGNITIVE ASSESSMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28388677\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/14067\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14067|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/16/34062\" title=\"figure 1\">",
"      Trails test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/12/13504\" title=\"figure 2\">",
"      Digit symbol test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/35/2614\" title=\"figure 3\">",
"      Letter cancellation test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/46/29422\" title=\"figure 4\">",
"      Rey-Osterrieth complex figure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/13/40159\" title=\"figure 5\">",
"      Wisconsin card sort test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/12/44228\" title=\"figure 6\">",
"      Stroop test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14067|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/44/24269\" title=\"table 1\">",
"      Aphasia syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36889?source=related_link\">",
"      Acute toxic-metabolic encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20041?source=related_link\">",
"      Approach to the patient with aphasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=related_link\">",
"      Clinical manifestations and diagnosis of Alzheimer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=related_link\">",
"      Frontotemporal dementia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_48_23304="Venous drainage of the pancreas and variations";
var content_f22_48_23304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 626px\">",
"   <div class=\"ttl\">",
"    Venous drainage of the pancreas and variations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 606px; height: 572px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Venous drainage of the pancreas. Variations in the relation of the portal, splenic, superior mesenteric, and inferior mesenteric veins are shown at the bottom.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Vickers SM, Arnoletti JP, Brunicardi FC, Andersen DK. Pancreas Anatomy and Physiology. In: Greenfield's Surgery: Scientific Principles and Practice, 4th Edition, Mulholland MW, Lillemoe KD, Doherty GM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_48_23304=[""].join("\n");
var outline_f22_48_23304=null;
var title_f22_48_23305="Treatment and prevention of leprosy";
var content_f22_48_23305=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of leprosy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/48/23305/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/48/23305/contributors\">",
"     David Scollard, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/48/23305/contributors\">",
"     Barbara Stryjewska, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/48/23305/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/48/23305/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/48/23305/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/48/23305/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/48/23305/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H310299817\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leprosy (also known as Hansen&rsquo;s Disease) is an infectious disease caused by Mycobacterium leprae and involving the skin and peripheral nerves. Leprosy is an important global health concern; early diagnosis and a full course of treatment are critical for preventing lifelong neuropathy and disability [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leprosy remains poorly understood and often feared by the general public and even by some in the health care professions, although (contrary to popular folklore) it is not highly contagious, and very effective treatment is available [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Multidrug therapy has cured approximately 11 million patients over the last 15 to 20 years, but not all patients have access to the drugs and not all countries have the infrastructure to support leprosy control efforts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Worldwide the number of dedicated leprosy programs is declining, and international migration is bringing patients to nearly every region [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/5\">",
"     5",
"    </a>",
"    ]. As a result, increasingly the treatment of leprosy is being delivered by clinicians with less and less experience.",
"   </p>",
"   <p>",
"    Although the infection is highly responsive to treatment, disabilities of the eyes, hands, and feet due to neuropathy are often not reversible and may require lifelong care and rehabilitation. Therefore, early diagnosis and complete treatment are necessary to minimize the likelihood of these disabilities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment and prevention of leprosy are reviewed here. The epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18105?source=see_link\">",
"     \"Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7448168\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leprosy has been classified into the following categories based on the Ridley Jopling classification (",
"    <a class=\"graphic graphic_figure graphicRef67611 \" href=\"UTD.htm?3/47/3831\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tuberculoid (TT)",
"     </li>",
"     <li>",
"      Borderline tuberculoid (BT)",
"     </li>",
"     <li>",
"      Mid-borderline (BB)",
"     </li>",
"     <li>",
"      Borderline lepromatous (BL)",
"     </li>",
"     <li>",
"      Lepromatous (LL)",
"     </li>",
"     <li>",
"      Indeterminate (I)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The classification of leprosy is discussed in further detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18105?source=see_link&amp;anchor=H21480360#H21480360\">",
"     \"Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy\", section on 'Classification and terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H310298018\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of leprosy consists of multiple drug therapy (MDT), to prevent development of resistance. Promine, a sulfone, was the first antimicrobial agent successfully used to treat leprosy; subsequently efficacy was also demonstrated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , its parent compound [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. After many years of monotherapy with these agents, drug resistance was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1981, a World Health Organization (WHO) Study group met to consider multi-drug therapy for leprosy, mindful of the experience with the development of drug resistance after monotherapy for tuberculosis. In light of the &ldquo;imperative need for therapeutic regimens&rdquo; the group made an empiric recommendation to use the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    for tuberculoid leprosy, and to add clofazimine for lepromatous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of the individual agents had been demonstrated clinically and in mouse studies, and was subsequently confirmed in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. No controlled trials comparing drug combination regimens have been done; designing trials for treatment of a noncultivable pathogen is complicated by the lack of an accurate quantitative end-point. In addition, a very long observation period is required for identification of relapse (approximately 15 to 20 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2779397\">",
"     'Relapse'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21479664\">",
"    <span class=\"h2\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;MDT has important individual as well as public health benefits since it is active against M. leprae and rapidly renders the patient noninfectious [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. First line medications include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , and, for lepromatous disease, clofazimine. Used in combination, these have proven to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration of treatment previously recommended by the WHO in 1982 was 6 to 12 months for tuberculoid disease (TT and BT) and 24 months for lepromatous disease (BB, BL, and LL). Subsequently in 1998, the WHO reduced the recommended duration to 6 months and 12 months, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/20\">",
"     20",
"    </a>",
"    ], in part to reflect cost considerations for resource limited settings [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/17,18,21\">",
"     17,18,21",
"    </a>",
"    ]. However, shorter treatment regimens have been associated with a greater incidence of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/22\">",
"     22",
"    </a>",
"    ]. Therefore, the National Hansen&rsquo;s Disease Programs (NHDP) in the United States continues to recommend the longer duration of therapy; NHDP also advocates daily rather than monthly administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (as recommended by the WHO) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/23\">",
"     23",
"    </a>",
"    ]. Dosing regimens are outlined in the Tables (",
"    <a class=\"graphic graphic_table graphicRef51183 \" href=\"UTD.htm?39/0/39948\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64965 \" href=\"UTD.htm?4/21/4445\">",
"     table 2",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    Alternative agents for treatment of leprosy include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    . Evidence for the efficacy of newer drug combinations or shorter regimens is weak [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/24\">",
"     24",
"    </a>",
"    ]. Earlier attempts to treat patients with &ldquo;single lesion paucibacillary disease&rdquo; with a single dose combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (600 mg), ofloxacin (400 mg), and minocycline (100 mg) were based on a multicenter trial in which this regimen demonstrated slightly less clinical improvement compared with the standard WHO PB regimen during 18 months of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/17,25\">",
"     17,25",
"    </a>",
"    ]. Another report indicated that one month of rifampin plus ofloxacin was insufficient for the treatment of lepromatous (MB) disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuritis (pain, burning or tingling, sudden numbness, or loss of function) must be treated aggressively to prevent or minimize nerve injury and subsequent deformity and disability. Neuritis is treated primarily with corticosteroids. Nerve function appears to improve after corticosteroid treatment in 60 to 70 percent of patients, but it may remain impaired in patients with pre-existing or recurrent neuritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/27\">",
"     27",
"    </a>",
"    ]. About one-third of impaired nerves do not improve with corticosteroid treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/28\">",
"     28",
"    </a>",
"    ]. In a controlled trial of treatment for Type 1 Reactions with three different treatment regimens, the greatest improvement in nerve function occurred in the group receiving higher dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (60 mg) and longer duration (20 weeks or longer) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/29\">",
"     29",
"    </a>",
"    ]. Treatment is best individualized; in some cases even higher doses and longer duration of prednisone may be required. No long-term benefit has been associated with prophylactic corticosteroid treatment for prevention of neuritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H310298161\">",
"     'Treatment of immunologic reactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the United States, medication for the treatment of leprosy are provided free of charge by the NHDP: 1-800-642-2477 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/5\">",
"     5",
"    </a>",
"    ]. Outside the United States, the WHO distributes medications through the Ministry of Health in each country [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H310298033\">",
"    <span class=\"h3\">",
"     Therapeutic agents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       Dapsone",
"      </a>",
"      &mdash; Dapsone is inexpensive and generally well tolerated in the doses used for the treatment of leprosy. Adverse effects include dapsone hypersensitivity syndrome, methemoglobinemia, and agranulocytosis. Shortened red cell survival is common with dapsone though severe hemolytic anemia is uncommon except in those with a severe glucose-6-phosphate dehydrogenase (G6PD) deficiency; all patients should be screened for G6PD deficiency before receiving dapsone. Because the antibacterial activity of dapsone is inhibited by p-aminobenzoic acid (PABA), it is thought that dapsone has a mechanism of action similar to that of the sulfonamides, which involves inhibition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      synthesis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of methemoglobinemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=see_link\">",
"       \"Drug-induced neutropenia and agranulocytosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=see_link\">",
"       \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A dose of 100 mg daily is weakly bactericidal against M. leprae, but such a dose exceeds the minimum inhibitory concentration (MIC) of the organism by a factor of about 500. Such doses even inhibit the multiplication of M. leprae mutants with low to moderate degrees of dapsone resistance. The maximum dose should be used from the start and should not be reduced during immunologic reactions. Dapsone resistance is generally reported in areas where monotherapy has been used; it is extremely rare in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      &mdash; Rifampin is the most bactericidal drug available for the treatment of leprosy. An estimated 99.999 percent of bacilli are killed with three monthly doses. The standard dose in the United States dose is 600 mg daily but even a single dose of 600 mg monthly, as used in the WHO regimens, is highly bactericidal. Rifampin binds the DNA-dependent RNA polymerase complex, uncoupling transcription. The target for rifampin is the beta subunit of the RNA polymerase encoded by rpoB61.",
"      <br/>",
"      <br/>",
"      Toxicity of the drug is relatively low, but is related to the size of the dose and the interval between doses. The standard doses for leprosy have proven relatively non-toxic, although occasional cases of renal failure, bone marrow suppression, \"flu-like\" syndrome, and hepatitis have been reported. Daily administration of rifampin has major effects on drug metabolism by the liver cytochrome 3A4 (CYP 3A4), which greatly affects other medications such as oral contraceptives, corticosteroids, and HIV protease inhibitors, among many others. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=see_link\">",
"       \"Rifampin and other rifamycins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Clofazamine",
"      </strong>",
"      &mdash; Clofazamine is well tolerated in the standard dose of 50 mg daily used for leprosy. The major effect seen is pigmentation of the skin (especially within skin lesions), since the drug is lipophilic and accumulates in the lipid-rich cell wall of M. leprae. At higher doses (200 mg daily), hyperpigmentation may be noticeable within four weeks; at lower doses it may take four to six months. Clofazimine causes phototoxicity which can accelerate darkening of the skin with sun exposure. This pigmentation usually clears within one to two years after treatment is discontinued. Some patients are reluctant to take clofazamine because of the pigmentation but will usually accept it if the temporary nature of the pigmentation and the benefit of reducing the likelihood of a debilitating treatment reaction are carefully explained. The higher doses of clofazimine (up to 300 mg daily) sometimes used for the control of reactions may occasionally produce severe gastrointestinal side effects.",
"      <br/>",
"      <br/>",
"      The mechanisms of action of clofazimine are not known. The drug is weakly bactericidal against M. leprae, but the combination of clofazimine and dapsone is much more active than either drug alone, killing 99.999 percent of bacilli in mouse studies within three months [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/33\">",
"       33",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Clofazimine is not available in pharmacies in the United States. It is classified by the United States Food and Drug Administration (FDA) as an investigational drug. Requests for clofazimine to treat leprosy should be directed to the NHDP (an agency within the Department of Health and Human Services), which holds the IND for this indication. The Administrative Officer may be contacted at 225-756-3773 (phone) or 225-768-3806 (FAX).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       Minocycline",
"      </a>",
"      &mdash; Minocycline is the only",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      with significant activity against M. leprae. This may be due to its lipophilic properties, which allow the drug to penetrate cell walls. It is bactericidal for M. leprae to a somewhat greater degree than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      but much less so than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      . Minocycline was very effective when given as monotherapy for two months in a small series of eight LL or BL patients, although monotherapy is not recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/34\">",
"       34",
"      </a>",
"      ]. Minocycline inhibits protein synthesis via reversible binding at the 30S ribosomal subunit, thereby blocking the binding of aminoacyl-transfer RNA to the mRNA ribosomal complex. Side effects include discoloration of teeth in children, occasional pigmentation of the skin and mucous membranes, gastrointestinal complaints, and CNS toxicity, including dizziness and unsteadiness.",
"     </li>",
"     <li>",
"      <strong>",
"       Macrolides",
"      </strong>",
"      &mdash; Several macrolides have been evaluated for activity against M. leprae;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      is the only effective agent. The drug has potent bactericidal activity, but is less bactericidal than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      . At a dose of 500 mg daily in leprosy patients, 99 percent of M. leprae are killed in 28 days and 99.9 percent by 56 days [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/35\">",
"       35",
"      </a>",
"      ]. The drug acts by inhibition of bacterial protein synthesis by linking to the 50S ribosomal subunit, thereby preventing elongation of the protein chain. Gastrointestinal irritation, nausea, vomiting, and diarrhea are the most common adverse effects, but they do not usually necessitate discontinuation of the drug.",
"     </li>",
"     <li>",
"      <strong>",
"       Fluoroquinolones",
"      </strong>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"       Ofloxacin",
"      </a>",
"      has good antibacterial activity and is the most widely accepted fluoroquinolone for treatment of leprosy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/33\">",
"       33",
"      </a>",
"      ]. It acts by interfering with bacterial DNA replication by inhibiting the A subunit of the DNA gyrase. A single 400 mg dose has bactericidal activity against M. leprae, although less than that demonstrated by a single dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      , and two doses are capable of killing 99.99 percent of the viable M. leprae.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      , the active L-racemer of ofloxacin has replaced ofloxacin in many United States formularies.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       Moxifloxacin",
"      </a>",
"      is also highly bactericidal against M. leprae; further study of rifampin and moxifloxacin as combination short-term therapy is needed [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      is not active against M. leprae. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link\">",
"       \"Fluoroquinolones\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5171460\">",
"    <span class=\"h3\">",
"     Drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug resistance in leprosy is rare. The WHO has convened a working group of collaborating laboratories to use molecular methods for monitoring of drug resistance globally [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/32\">",
"     32",
"    </a>",
"    ]. In a 2010 report of drug resistance mutations for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    , resistance was observed in 6, 4, and 1 percent of samples tested, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/1\">",
"     1",
"    </a>",
"    ]. These resistant cases were observed among patients with relapsed infection.",
"   </p>",
"   <p>",
"    Molecular techniques are available for the identification of several mutations associated with resistance to individual agents [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/38\">",
"     38",
"    </a>",
"    ]. The rpoB gene of M. leprae and other mycobacteria is associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Mutations in the dihydropteroate synthase gene (folP1) predicted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    resistance in a survey of 38 M. leprae strains isolated from skin biopsies of patients with multibacillary leprosy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Molecular Biology laboratory of the NHDP is a participant in the global surveillance program and provides testing for drug resistance, when indicated, usually in the setting of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/5\">",
"     5",
"    </a>",
"    ]. There is no role for routine baseline resistance testing. (See",
"    <a class=\"local\" href=\"#H2779397\">",
"     'Relapse'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H310298098\">",
"    <span class=\"h2\">",
"     Response and follow up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The erythema and induration of skin lesions may diminish within a few months of initiating therapy. It may take a few years for cutaneous lesions to resolve fully, depending on the initial number of lesions and severity of infection. Most lesions heal without scarring.",
"   </p>",
"   <p>",
"    Once killed, dead M. leprae bacilli are removed from the tissues very slowly; some may persist in the tissues for several years (",
"    <a class=\"graphic graphic_picture graphicRef74309 \" href=\"UTD.htm?25/18/25897\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/41\">",
"     41",
"    </a>",
"    ]. Since M. leprae cannot be grown in culture and its viability cannot be assessed in biopsies, a definitive bacteriological endpoint for treatment is not available. The presence of bacilli in smears or biopsies during and after treatment does not, in itself, indicate treatment failure or drug resistance. There is no evidence that prolonged antimicrobial treatment enhances the removal of dead M. leprae from tissues.",
"   </p>",
"   <p>",
"    Given the lack of a definitive therapeutic endpoint, assessing compliance is especially important in assessing completeness of treatment. Laboratory evidence indicates that M. leprae are killed rapidly after exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and the other drugs used [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/42\">",
"     42",
"    </a>",
"    ]. Experience with multi-drug therapy has provided good evidence of cure with very few relapses using NHDP or WHO protocols with one to two years of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/1\">",
"     1",
"    </a>",
"    ]. Therefore, if adherence to the well-established MDT protocols is good, killing of the bacilli and resolution of the lesions can be expected.",
"   </p>",
"   <p>",
"    While on treatment, the first follow up visit should be done in two to four weeks to evaluate for side effects of medications. After that, routine follow-up visits should be scheduled every three months. Visits should consist of a clinical examination, including assessment of the skin, nerves, limbs and eyes, as well as laboratory studies to assess drug toxicity. Patients should report any new skin lesions, sensory or motor loss, eye symptoms, reactions, or other complaints.",
"   </p>",
"   <p>",
"    Disease progression that occurs during therapy is almost always due to poor adherence to treatment. Therefore, patient education is an important part of each visit; compliance with a prolonged drug regimen is unlikely unless the patient fully understands the necessity for it. Cooperation of the family is also important.",
"   </p>",
"   <p>",
"    For areas of the hands and feet where sensation has been lost, patients need to be taught to evaluate these areas regularly for evidence of injury and to obtain treatment promptly. Special protective shoes may be needed to avoid injury or ulceration. Motor loss resulting in deformities may require corrective surgery.",
"   </p>",
"   <p>",
"    Examination of the eyes should include assessment of lid closure, cornea, and conjunctiva [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/43\">",
"     43",
"    </a>",
"    ]. Complex problems such as iridocyclitis should be managed by a specialist. Corneal anesthesia and lagophthalmos require protective measures and corrective surgery.",
"   </p>",
"   <p>",
"    In lepromatous (MB) cases, skin biopsies from the same lesion can be performed at one to two year intervals to assess the response to treatment by evaluating the reduction of inflammation and the decline of bacilli in the tissues. Processing and interpretation of biopsies for this purpose are available from the NHDP at no cost (",
"    <a class=\"external\" href=\"file://www.hrsa.gov/hansensdisease/diagnosis/biopsy.html\">",
"     file://www.hrsa.gov/hansensdisease/diagnosis/biopsy.html",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Routine laboratory studies to assess drug toxicity while on treatment include a complete blood count, urinalyses, creatinine, and liver function tests (",
"    <a class=\"graphic graphic_table graphicRef76797 \" href=\"UTD.htm?42/47/43772\">",
"     table 3",
"    </a>",
"    ). Drug toxicity is relatively uncommon after the first year of treatment, and serious toxicity may manifest clinically before it is detected in the laboratory. Asymptomatic liver enzyme elevation of up to three times normal is acceptable.",
"   </p>",
"   <p>",
"    After completion of treatment, annual follow up for five more years is warranted for tuberculoid (PB) cases, and for least 10 more years is warranted for lepromatous (MB) patients. Patients should be advised to return for evaluation if new lesions or other problems develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H310298161\">",
"    <span class=\"h1\">",
"     TREATMENT OF IMMUNOLOGIC REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunologic reactions are systemic inflammatory complications that occur either before treatment (some patients initially present for medical attention in the setting of a reaction), during treatment, or months to years after treatment has been completed. A general feeling of fatigue, malaise, and fever may be present. Other manifestations include neuritis, arthritis, iritis, and nasopharyngeal symptoms. The inflammation associated with reactions can lead to severe nerve injury with subsequent paralysis and deformity. Immunologic reactions are discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18105?source=see_link&amp;anchor=H2780036#H2780036\">",
"     \"Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy\", section on 'Immunologic reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, antimicrobial therapy should be continued in the setting of immunologic reactions, and patients should be reassured that the symptoms are not a reaction to the medications. Options for treatment of immunologic reactions include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , with or without other anti-inflammatory agents. Use of prednisone should prompt reduction in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    administration from 600 mg daily to 600 mg once monthly. Patients should be monitored carefully for neuropathy or neuritis and treated aggressively if these develop or worsen. Tapering of prednisone and other anti-inflammatory agents is empiric, based on clinical response.",
"   </p>",
"   <p>",
"    Progression of the infection may occur in cases of noncompliance or drug resistance. Clinically, skin lesions may remain unchanged or may appear to worsen (with erythema and swelling) during the first year of treatment. In the setting of true disease progression, skin biopsies may demonstrate an increase in bacterial load, but this is difficult to document unless the biopsies are taken from adjacent sites of the same lesion. Drug resistance in leprosy is rare; in general, inadequate response to treatment is almost always due to inadequate adherence. Moreover, new lesions are almost always due to immunologic reactions, for which there are no well&ndash;established laboratory markers. (See",
"    <a class=\"local\" href=\"#H5171460\">",
"     'Drug resistance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2781552\">",
"    <span class=\"h2\">",
"     Type 1 reaction (T1R, reversal reaction)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of Type 1 reactions are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18105?source=see_link&amp;anchor=H2780051#H2780051\">",
"     \"Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy\", section on 'Type 1 reaction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mild reactions without neuritis, ulceration, or other severe symptoms can be managed with supportive care. Severe type 1 reactions with neuritis require prompt treatment with corticosteroids to avoid permanent nerve damage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/44\">",
"     44",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    (40 to 60",
"    <span class=\"nowrap\">",
"     mg/d)",
"    </span>",
"    should be started and slowly tapered when the reaction has been controlled (in general, from three months in BT to nine months in BL) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/45\">",
"     45",
"    </a>",
"    ]. Occasional patients with severe, protracted reactions require extended corticosteroid treatment for several additional months due to severe nerve pain, and some data suggests that higher doses and longer duration are more beneficial in ameliorating pain and other inflammatory symptoms than lower doses and shorter duration of corticosteroid treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/29\">",
"     29",
"    </a>",
"    ]. However, a review of clinical trials has demonstrated that prolonged corticosteroid regimens of many months do not provide long-term functional neurological benefits for most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/46\">",
"     46",
"    </a>",
"    ]. No long-term benefit has been associated with prophylactic corticosteroid treatment for prevention of type 1 reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    may be a useful second line treatment for severe Type 1 reactions in patients not responding to or unable to take corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/3\">",
"     3",
"    </a>",
"    ]. It has been demonstrated to improve sensory nerve impairment and skin lesions in small numbers of patients in Brazil, Ethiopia, and Nepal; some significant toxicity was also noted [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Further study is needed to determine optimal dosing and to compare the efficacy and toxicity with corticosteroids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H310298210\">",
"    <span class=\"h2\">",
"     Type 2 reaction (T2R, erythema nodosum leprosum, ENL)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of type 2 reactions are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18105?source=see_link&amp;anchor=H2780058#H2780058\">",
"     \"Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy\", section on 'Type 2 reaction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mild reactions without neuritis, ulceration, or other severe symptoms can be managed with supportive care. Severe type 2 reactions with neuritis and systemic symptoms require prompt treatment with corticosteroids to avoid permanent nerve damage.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    (40 to 60",
"    <span class=\"nowrap\">",
"     mg/d)",
"    </span>",
"    should be started and quickly tapered (over a two-week period) when the reaction has been controlled; in the absence of clinical response, higher doses of prednisone may be administered. A relatively short course may be sufficient, but the reaction can recur and intermittent symptoms may continue for a year or more. If prolonged therapy will be needed in such cases, transitioning prednisone dosing to an every-other-day schedule may diminish steroid side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clofazamine is not useful for the management of acute T2R but may be of value in chronic cases. It is generally increased to a dose of 300 mg daily for four weeks and tapered slowly after response to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    within 12 months. Gastrointestinal complaints may limit the use of higher doses. The clofazimine component of the MB regimen may have some protective effect in preventing reactions since T2R appears to have become less common after the introduction of MDT. Clofazimine is not available in pharmacies and in the US can only be obtained through the NHDP at 225-756-3773 (phone) or 225-768-3806 (FAX).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    is very effective in treating Type 2 leprosy reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/50\">",
"     50",
"    </a>",
"    ], but teratogenicity limits its use in women of childbearing age. Of note, the efficacy of thalidomide in treating Type 2 reactions is the only reason it has not been completely banned by all pharmacies. Thalidomide is approved for marketing only under a special restricted distribution program approved by the FDA called &ldquo;The System for Thalidomide Education and Prescribing Safety&rdquo; (STEPS). Under this restricted distribution program, only prescribers and pharmacists registered with the program are allowed to prescribe and dispense the product. In addition, patients must be advised of, agree to, and comply with the requirements of the STEPS Program in order to receive the drug.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    is administered initially in a dose of 300 to 400 mg daily; frequently this regimen controls the reaction within 48 hours. Subsequently the dose should be tapered to a maintenance level, generally around 100 mg daily; every few months attempts are made to taper off the drug. To control ENL, thalidomide may be continued for several years. Development of neuropathy should prompt immediate discontinuation. In the authors&rsquo; experience, a few patients with severe, prolonged Type 2 reactions have continued to use thalidomide for up to 10 years.",
"   </p>",
"   <p>",
"    Management of the Lucio phenomenon (necrotizing vasculopathy in patients with longstanding untreated lepromatous leprosy) requires antimicrobial therapy and corticosteroids as well as skin and wound care comparable to that given for extensive burns [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H310298238\">",
"    <span class=\"h2\">",
"     Alternative agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytokines and their inhibitors are not routinely used for the treatment of leprosy or its immunological reactions, although some information is available concerning the effects of these agents. Inhibitors of tumor necrosis factor-alpha (TNF-alpha) have been observed to be beneficial in two cases of chronic, recurrent Type 2 reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. The benefit was not long-lasting in either case. Conversely, use these agents for treatment of severe arthritis can be a risk factor for development of leprosy in certain individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experimental treatment of lepromatous leprosy by intra-lesional injection of recombinant interferon gamma (IFN&gamma;) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/55,56\">",
"     55,56",
"    </a>",
"    ] or IL-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/57\">",
"     57",
"    </a>",
"    ] has demonstrated some evidence of improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/58\">",
"     58",
"    </a>",
"    ], but has also associated with the development of T2R in an unusually high percentage of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other immunosuppressive drugs have been tested in the treatment of Type 2 reactions, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, but no consistently beneficial results have been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2779390\">",
"    <span class=\"h1\">",
"     OTHER TREATMENT ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2779397\">",
"    <span class=\"h2\">",
"     Relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapse of leprosy is relatively rare, and must be distinguished from immunological reaction (which is more common). The WHO has reported a slowly increasing trend in the number of relapses, with 3120 cases worldwide in 2009 (1.3 percent of the number of new cases reported) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most relapses occur 5 to 10 years after completion of treatment. Relapse is more likely to occur in the setting of incomplete treatment or a very high bacterial load at the onset of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/60\">",
"     60",
"    </a>",
"    ]. During true relapse, the tissue bacterial load generally rises steadily. The bacterial load may be expressed as bacteriologic index (BI), which is the number of bacilli per 100x field, expressed as a logarithmic scale (over 1000 bacilli per average field = 6+; 100-1000 bacilli = 5+, etc) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/61\">",
"     61",
"    </a>",
"    ]. An increase in the biopsy or skin smear BI of 2 or more indicates probable relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relapse can be distinguished from immunologic reaction in that the latter should improve after a short course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H310298161\">",
"     'Treatment of immunologic reactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is little evidence to guide the approach to re-treatment after relapse. In general, treatment consists of reinitiating the same regimen used for initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/62\">",
"     62",
"    </a>",
"    ]. Patients who presented initially with tuberculoid (PB) disease but relapse with lepromatous (MB) leprosy should be retreated with an MB regimen. Drug resistance is extremely unlikely to have developed as long as the original M. leprae strain was fully sensitive to the drugs used, although there is no role for baseline testing of drug resistance. When indicated, testing for mutations can be done from paraffin embedded tissues taken at the time of diagnosis (ie, before treatment), and at the time of suspected relapse or resistance. (See",
"    <a class=\"local\" href=\"#H5171460\">",
"     'Drug resistance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2779411\">",
"    <span class=\"h2\">",
"     Leprosy and HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been no increase in leprosy in regions where HIV is prevalent. In patients co-infected with M. leprae and HIV, initiation of antiretroviral therapy may trigger a Type 1 reaction; this is a manifestation of the immune reconstitution inflammatory syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The response to leprosy treatment in HIV-infected individuals appears to be comparable to the response in HIV-negative individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2779418\">",
"    <span class=\"h2\">",
"     Leprosy in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunologic reactions appear to occur more frequently in pregnant and postpartum women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. In two small series, such reactions were observed in up to 38 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Type 2 reactions were observed more frequently during pregnancy; Type 1 reactions were observed more frequently in the postpartum period.",
"   </p>",
"   <p>",
"    Management of leprosy and immunologic reactions in pregnancy is the same as described above for other patients.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , clofazimine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    are listed by the FDA as category C for use in pregnancy;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    is category D. Regimens of all medications must be modified appropriately if the mother is breastfeeding. (See",
"    <a class=\"local\" href=\"#H310298018\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H310298245\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control measures for leprosy include clinical management of active cases as well as contact management. Household contacts should be evaluated annually for evidence of disease for at least five years, and should be educated to seek immediate attention if suspicious skin or neurologic changes develop. In the United States, free diagnostic clinics are available [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prophylaxis for contacts is not warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/72\">",
"     72",
"    </a>",
"    ]. In randomized trial in Bangladesh, a single dose of rifampicin for contacts of patients with newly diagnosed leprosy was effective for preventing development of clinical disease within two years; beyond two years no difference between the placebo and rifampicin groups was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaccination with Bacillus Calmette-Guerin (BCG) is partially protective for leprosy; a single dose appears to be 50 percent protective, and two doses further increase protection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. BCG is administered at birth in most countries with high rates of leprosy; vaccination for prevention of leprosy in other regions is not economically feasible except in areas with an extremely high incidence of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/76\">",
"     76",
"    </a>",
"    ]. Development of an improved BCG vaccine, BCG booster, or alternate vaccine strain is an important research goal that could benefit control of both TB and leprosy. Skin test antigen studies and the identification of the appropriate protective M. leprae genomic DNA sequence could also lead to an improved vaccine for leprosy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23305/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89888451\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leprosy (also known Hansen&rsquo;s Disease) is an infectious disease caused by Mycobacterium leprae which involves the skin and peripheral nerves. Leprosy is an important global health concern; early diagnosis and a full course of treatment are critical for preventing lifelong neuropathy and disability. (See",
"      <a class=\"local\" href=\"#H310299817\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of leprosy consists of multiple drug treatment (MDT). We suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      (100 mg daily), rifampicin (600 mg daily), and, for lepromatous disease, clofazimine (50 mg daily) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Treatment of tuberculoid disease (TT and BT) consists of 12 months of therapy with dapsone and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ; treatment of lepromatous disease (LL, BL, and BB) consists of 24 months of therapy with all three drugs. The WHO favors an alternative duration of therapy as outlined above. It is not necessary or desirable to continue treatment until all bacilli disappear from the tissues, since the dead bacilli are removed slowly.(See",
"      <a class=\"local\" href=\"#H21479664\">",
"       'Clinical approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuritis must be treated aggressively to try to prevent or minimize nerve injury and thus prevent deformity and disability. We suggest treatment of neuritis with corticosteroids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21479664\">",
"       'Clinical approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While on treatment, routine follow-up visits should be scheduled every three months. Visits should consist of a clinical examination, including assessment of the skin, nerves, limbs, and eyes, as well as laboratory studies to assess drug toxicity. Patient education is important; disease progression during therapy is almost always due to poor adherence to treatment. (See",
"      <a class=\"local\" href=\"#H310298098\">",
"       'Response and follow up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunologic reactions are systemic inflammatory complications that occur before, during, or after treatment. In general, antimicrobial therapy should be continued in the setting of immunologic reactions, and patients should be reassured that the symptoms are not a reaction to the medications. Mild reactions without neuritis or ulceration can be managed with supportive care. For severe reactions with neuritis, we suggest prompt treatment with corticosteroids to avoid permanent nerve damage (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In such cases",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      administration should be reduced to once monthly. Second line agents for treatment of immunologic reactions are discussed above. (See",
"      <a class=\"local\" href=\"#H310298161\">",
"       'Treatment of immunologic reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Control measures for leprosy include clinical management of active cases as well as contact management. Vaccination with Bacillus Calmette-Guerin (BCG) is partially protective for leprosy. Development of an improved vaccine is an important research goal for prevention. (See",
"      <a class=\"local\" href=\"#H310298245\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     WHO. Global leprosy situation, 2010. Weekly Epidemiol Rec 2010; 85:337.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/2\">",
"      Moschella SL. An update on the diagnosis and treatment of leprosy. J Am Acad Dermatol 2004; 51:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/3\">",
"      Scollard DM, Adams LB, Gillis TP, et al. The continuing challenges of leprosy. Clin Microbiol Rev 2006; 19:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/4\">",
"      Leprosy. Global target attained. Wkly Epidemiol Rec 2001; 76:155.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.hrsa.gov/hansensdisease/ (Accessed on June 20, 2011).",
"    </li>",
"    <li>",
"     WHO Global Leprosy Strategy agreed for 2011-2015. www.searo.who.int/EN/Section980/Section2572/Section2578_14961.htm (Accessed on October 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/7\">",
"      FAGET GH, POGGE RC, JOHANSEN FA. Promizole treatment of leprosy. Public Health Rep 1946; 61:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/8\">",
"      LOWE J. Treatment of leprosy with diamino-diphenyl sulphone by mouth. Lancet 1950; 1:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/9\">",
"      Cochrane RG, Ramanujam K, Paul H, Russel D. Two-and-a-half years' experimental work on the sulphone group of drugs. Lepr Rev 1949; 20:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/10\">",
"      PETTIT JH, REES RJ. SULPHONE RESISTANCE IN LEPROSY. AN EXPERIMENTAL AND CLINICAL STUDY. Lancet 1964; 2:673.",
"     </a>",
"    </li>",
"    <li>",
"     jacobson RR. Treatment. In: Leprosy, Hastings RC.  (Ed), Churchill Livingstone, New York 1985. p.193.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/12\">",
"      Chemotherapy of leprosy for control programmes. World Health Organ Tech Rep Ser 1982; 675:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/13\">",
"      Levy L, Ng H, Evans MJ, Krahenbuhl JL. Susceptibility of thymectomized and irradiated mice to challenge with several organisms and the effect of dapsone on infection with Mycobacterium leprae. Infect Immun 1975; 11:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/14\">",
"      Holmes IB, Banerjee DK, Hilson GR. Effect of rifampin, clofazimine, and B1912 on the viability of Mycobacterium leprae in established mouse footpad infection. Proc Soc Exp Biol Med 1976; 151:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/15\">",
"      Franzblau SG. Drug susceptibility testing of Mycobacterium leprae in the BACTEC 460 system. Antimicrob Agents Chemother 1989; 33:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/16\">",
"      Cochrane RG, Ramanujam K, Paul H and Russell D. Two and a half years' experimental work on the sulphone group of drugs. Lepr Rev 1949; 20:3440370.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. Expert Committee on Leprosy. Seventh Report. Geneva; 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/18\">",
"      Ji B. Why multidrug therapy for multibacillary leprosy can be shortened to 12 months. Lepr Rev 1998; 69:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/19\">",
"      Freerksen E, Rosenfeld M, Depasquale G, et al. The Malta Project--a country freed itself of leprosy. A 27-year progress study (1972-1999) of the first successful eradication of leprosy. Chemotherapy 2001; 47:309.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Expert Committee on Leprosy. WHO Expert Committee on Leprosy: Seventh Report. WHO Tech Rep Ser 874; Geneva, 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/21\">",
"      Waters MF. Is it safe to shorten multidrug therapy for lepromatous (LL and BL) leprosy to 12 months? Lepr Rev 1998; 69:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/22\">",
"      Fajardo TT, Villahermosa L, Pardillo FE, et al. A comparative clinical trial in multibacillary leprosy with long-term relapse rates of four different multidrug regimens. Am J Trop Med Hyg 2009; 81:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/23\">",
"      Dacso MM, Jacobson RR, Scollard DM, et al. Evaluation of multi-drug therapy for leprosy in the United States using daily rifampin. South Med J 2011; 104:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/24\">",
"      Lockwood DN, Kumar B. Treatment of leprosy. BMJ 2004; 328:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/25\">",
"      Efficacy of single dose multidrug therapy for the treatment of single-lesion paucibacillary leprosy. Single-lesion Multicentre Trial Group. Indian J Lepr 1997; 69:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/26\">",
"      Ji B, Jamet P, Sow S, et al. High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks. Antimicrob Agents Chemother 1997; 41:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/27\">",
"      Britton WJ, Lockwood DN. Leprosy. Lancet 2004; 363:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/28\">",
"      Wilder-Smith EP, Van Brakel WH. Nerve damage in leprosy and its management. Nat Clin Pract Neurol 2008; 4:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/29\">",
"      Rao PS, Sugamaran DS, Richard J, Smith WC. Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy. Lepr Rev 2006; 77:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/30\">",
"      Smith WC, Anderson AM, Withington SG, et al. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). BMJ 2004; 328:1459.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization - Leprosy Today file://www.who.int/lep/en/.",
"    </li>",
"    <li>",
"     WHO. Meeting on Sentinel Surveillance for Drug Resistance in Leprosy. Geneva; 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/33\">",
"      Ji B, Perani EG, Petinom C, Grosset JH. Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Antimicrob Agents Chemother 1996; 40:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/34\">",
"      Gelber RH, Fukuda K, Byrd S, et al. A clinical trial of minocycline in lepromatous leprosy. BMJ 1992; 304:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/35\">",
"      Ji B, Jamet P, Perani EG, et al. Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. J Infect Dis 1993; 168:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/36\">",
"      Pardillo FE, Burgos J, Fajardo TT, et al. Powerful bactericidal activity of moxifloxacin in human leprosy. Antimicrob Agents Chemother 2008; 52:3113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/37\">",
"      Pardillo FE, Burgos J, Fajardo TT, et al. Rapid killing of M. leprae by moxifloxacin in two patients with lepromatous leprosy. Lepr Rev 2009; 80:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/38\">",
"      Williams DL, Gillis TP. Molecular detection of drug resistance in Mycobacterium leprae. Lepr Rev 2004; 75:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/39\">",
"      Cambau E, Bonnafous P, Perani E, et al. Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. Clin Infect Dis 2002; 34:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/40\">",
"      Cambau E, Carthagena L, Chauffour A, et al. Dihydropteroate synthase mutations in the folP1 gene predict dapsone resistance in relapsed cases of leprosy. Clin Infect Dis 2006; 42:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/41\">",
"      Katoch K, Natarajan M, Bagga A, Katoch VM. Clinical and bacteriological progress of highly bacillated BL-LL patients discontinuing treatment after different periods of MDT. Int J Lepr Other Mycobact Dis 1991; 59:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/42\">",
"      Franzblau SG. In vitro activities of aminoglycosides, lincosamides, and rifamycins against Mycobacterium leprae. Antimicrob Agents Chemother 1991; 35:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/43\">",
"      Daniel E, Ffytche TJ, Kempen JH, et al. Incidence of ocular complications in patients with multibacillary leprosy after completion of a 2 year course of multidrug therapy. Br J Ophthalmol 2006; 90:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/44\">",
"      Walker SL, Lockwood DN. Leprosy type 1 (reversal) reactions and their management. Lepr Rev 2008; 79:372.",
"     </a>",
"    </li>",
"    <li>",
"     Bryceson A, Pfaltzgraff RE. Leprosy (Medicine in the Tropics), 3rd Ed, Churchill Livingston, New York 1990. p.129.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/46\">",
"      van Veen NH, Nicholls PG, Smith WC, Richardus JH. Corticosteroids for treating nerve damage in leprosy. A Cochrane review. Lepr Rev 2008; 79:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/47\">",
"      Marlowe SN, Leekassa R, Bizuneh E, et al. Response to ciclosporin treatment in Ethiopian and Nepali patients with severe leprosy Type 1 reactions. Trans R Soc Trop Med Hyg 2007; 101:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/48\">",
"      Sena CB, Salgado CG, Tavares CM, et al. Cyclosporine A treatment of leprosy patients with chronic neuritis is associated with pain control and reduction in antibodies against nerve growth factor. Lepr Rev 2006; 77:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/49\">",
"      Van Veen NH, Lockwood DN, van Brakel WH, et al. Interventions for erythema nodosum leprosum. Cochrane Database Syst Rev 2009; :CD006949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/50\">",
"      SHESKIN J. THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS. Clin Pharmacol Ther 1965; 6:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/51\">",
"      Rea TH, Jerskey RS. Clinical and histologic variations among thirty patients with Lucio's phenomenon and pure and primitive diffuse lepromatosis (Latapi's lepromatosis). Int J Lepr Other Mycobact Dis 2005; 73:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/52\">",
"      Ramien ML, Wong A, Keystone JS. Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept. Clin Infect Dis 2011; 52:e133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/53\">",
"      Faber WR, Jensema AJ, Goldschmidt WF. Treatment of recurrent erythema nodosum leprosum with infliximab. N Engl J Med 2006; 355:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/54\">",
"      Scollard DM, Joyce MP, Gillis TP. Development of leprosy and type 1 leprosy reactions after treatment with infliximab: a report of 2 cases. Clin Infect Dis 2006; 43:e19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/55\">",
"      Nathan C, Squires K, Griffo W, et al. Widespread intradermal accumulation of mononuclear leukocytes in lepromatous leprosy patients treated systemically with recombinant interferon gamma. J Exp Med 1990; 172:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/56\">",
"      Kaplan G. Recent advances in cytokine therapy in leprosy. J Infect Dis 1993; 167 Suppl 1:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/57\">",
"      Kaplan G, Britton WJ, Hancock GE, et al. The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy. J Exp Med 1991; 173:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/58\">",
"      Kaplan G, Mathur NK, Job CK, et al. Effect of multiple interferon gamma injections on the disposal of Mycobacterium leprae. Proc Natl Acad Sci U S A 1989; 86:8073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/59\">",
"      Sampaio EP, Moreira AL, Sarno EN, et al. Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992; 175:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/60\">",
"      Gelber RH, Balagon VF, Cellona RV. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low. Int J Lepr Other Mycobact Dis 2004; 72:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/61\">",
"      RIDLEY DS. Therapeutic trials in leprosy using serial biopsies. Lepr Rev 1958; 29:45.",
"     </a>",
"    </li>",
"    <li>",
"     Enhanced global strategy for further reducing the disease burden due to leprosy, 2011-2015. SEA-GLP-2209.4, World Health Organization; WHO Regional Office for SE Asia, New Delhi, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/63\">",
"      Martiniuk F, Rao SD, Rea TH, et al. Leprosy as immune reconstitution inflammatory syndrome in HIV-positive persons. Emerg Infect Dis 2007; 13:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/64\">",
"      Lawn SD, Lockwood DN. Leprosy after starting antiretroviral treatment. BMJ 2007; 334:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/65\">",
"      Lockwood DN, Lambert SM. Human immunodeficiency virus and leprosy: an update. Dermatol Clin 2011; 29:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/66\">",
"      Duncan ME. An historical and clinical review of the interaction of leprosy and pregnancy: a cycle to be broken. Soc Sci Med 1993; 37:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/67\">",
"      Lockwood DN, Sinha HH. Pregnancy and leprosy: a comprehensive literature review. Int J Lepr Other Mycobact Dis 1999; 67:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/68\">",
"      Saunderson P, Gebre S, Desta K, Byass P. The ALERT MDT Field Evaluation Study (AMFES): a descriptive study of leprosy in Ethiopia. Patients, methods and baseline characteristics. Lepr Rev 2000; 71:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/69\">",
"      Maurus JN. Hansen's disease in pregnancy. Obstet Gynecol 1978; 52:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/70\">",
"      Duncan ME, Pearson JM. The association of pregnancy and leprosy--III. Erythema nodosum leprosum in pregnancy and lactation. Lepr Rev 1984; 55:129.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.hrsa.gov/hansens/clinics.htm (Accessed on June 22, 2011).",
"    </li>",
"    <li>",
"     Group WS. Chemotherapy of Leprosy. Geneva; 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/73\">",
"      Moet FJ, Pahan D, Oskam L, et al. Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ 2008; 336:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/74\">",
"      Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet 1996; 348:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/75\">",
"      Bertolli J, Pangi C, Frerichs R, Halloran ME. A case-control study of the effectiveness of BCG vaccine for preventing leprosy in Yangon, Myanmar. Int J Epidemiol 1997; 26:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/76\">",
"      D&uuml;ppre NC, Camacho LA, da Cunha SS, et al. Effectiveness of BCG vaccination among leprosy contacts: a cohort study. Trans R Soc Trop Med Hyg 2008; 102:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23305/abstract/77\">",
"      Gillis T. Is there a role for a vaccine in leprosy control? Lepr Rev 2007; 78:338.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16520 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_48_23305=[""].join("\n");
var outline_f22_48_23305=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H89888451\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H310299817\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7448168\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H310298018\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21479664\">",
"      Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H310298033\">",
"      - Therapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5171460\">",
"      - Drug resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H310298098\">",
"      Response and follow up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H310298161\">",
"      TREATMENT OF IMMUNOLOGIC REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2781552\">",
"      Type 1 reaction (T1R, reversal reaction)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H310298210\">",
"      Type 2 reaction (T2R, erythema nodosum leprosum, ENL)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H310298238\">",
"      Alternative agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2779390\">",
"      OTHER TREATMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2779397\">",
"      Relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2779411\">",
"      Leprosy and HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2779418\">",
"      Leprosy in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H310298245\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89888451\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/16520\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16520|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/47/3831\" title=\"figure 1\">",
"      Classification of leprosy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16520|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/18/25897\" title=\"picture 1\">",
"      M leprae in skin during and after treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16520|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/0/39948\" title=\"table 1\">",
"      Treatment of leprosy in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/21/4445\" title=\"table 2\">",
"      Treatment of leprosy in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/47/43772\" title=\"table 3\">",
"      Laboratory monitoring during leprosy treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=related_link\">",
"      Drug-induced neutropenia and agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18105?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=related_link\">",
"      Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=related_link\">",
"      Rifampin and other rifamycins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_48_23306="Immunizations in solid organ transplant candidates and recipients";
var content_f22_48_23306=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immunizations in solid organ transplant candidates and recipients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/48/23306/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/48/23306/contributors\">",
"     Patricia L Hibberd, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/48/23306/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/48/23306/contributors\">",
"     Michael Boeckh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/48/23306/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/48/23306/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/48/23306/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of infection is of paramount importance to the increasing population of solid organ transplant recipients. Infection in these patients results in excessive morbidity and mortality and antimicrobial therapy is often less effective than in the immunocompetent host [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/1\">",
"     1",
"    </a>",
"    ]. Although immunization appears to be an obvious way to prevent infection, many immunocompromised patients are unable to mount protective immune responses. Furthermore, immunization with live virus vaccines may result in unchecked proliferation of attenuated vaccine strains and is therefore generally avoided in solid organ transplant recipients.",
"   </p>",
"   <p>",
"    The rationale for immunizing patients who are awaiting or have undergone solid organ transplantation will be reviewed here. Issues related to immunizations in patients who have had hematopoietic cell transplants, who have undergone chemotherapy for treatment of hematologic malignancies or solid tumors, who have HIV infection, and in healthy adults, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=see_link\">",
"     \"Immunizations after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link\">",
"     \"Immunizations in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=see_link\">",
"     \"Approach to immunizations in healthy adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMMUNOGENICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of acquiring infection and the inability to prevent infection by immunization are directly related to the patient's \"net state of immunosuppression.\" The greater the degree of immunosuppression, the less likely the patient is to respond to immunization. The factors contributing to immunosuppression in this setting include the underlying disease (eg, renal or hepatic insufficiency), the presence of allograft rejection, and the immunosuppressive therapy administered after transplantation.",
"   </p>",
"   <p>",
"    Although certain vaccines provide some benefit to the immunocompromised patient, an adequate vaccine response cannot be assumed. Protection of the immunocompromised patient may require the use of vaccines",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    passive immunization (ie, intravenous immunoglobulin) as well as adjunctive measures, such as antiviral drug prophylaxis during influenza A outbreaks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TIMING OF IMMUNIZATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solid organ transplant candidates often have to wait unpredictable periods before a suitable donor is available. This waiting period should be used to maintain or boost antibody concentrations for all recommended vaccines. Although vaccination responses in some patients awaiting transplantation are suboptimal, antibody responses are usually even more attenuated when vaccines are administered after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other reasons to immunize patients before transplantation include the fact that live virus vaccines (eg, measles, mumps, rubella, varicella, and the intranasal influenza vaccine) are usually avoided posttransplant. The American Society of Transplantation (AST) recommends waiting a minimum of four weeks between live virus vaccine administration and transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/4\">",
"     4",
"    </a>",
"    ]. Some centers avoid all immunizations following solid organ transplantation, based on case reports of allograft rejection following immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/5\">",
"     5",
"    </a>",
"    ]. However, multiple studies have shown the safety of inactivated vaccinations following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/6-11\">",
"     6-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important issue is the optimal timing to resume immunization following solid organ transplantation. As stated in the AST guidelines, most transplant centers restart vaccination at approximately three to six months after transplantation, once maintenance immunosuppression levels have been attained [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2009, the American Society of Transplantation (AST) updated the guidelines for vaccination of pediatric and adult solid organ transplant candidates and recipients, as well as health care workers, household contacts, and other close contacts of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/4\">",
"     4",
"    </a>",
"    ]. The AST guidelines can be found at the following URL:",
"    <a class=\"external\" href=\"file://onlinelibrary.wiley.com/doi/10.1111/j.1600-6143.2009.02917.x/pdf\">",
"     file://onlinelibrary.wiley.com/doi/10.1111/j.1600-6143.2009.02917.x/pdf",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Our recommendations are generally in keeping with the AST guidelines. In addition, since the Infectious Diseases Society of America has convened a panel to write guidelines for the immunization of the immunocompromised host, additional changes are expected in the near future. Clinicians in other countries should refer to their national guidelines for recommendations regarding immunization of solid organ transplant candidates and recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INACTIVATED VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inactivated vaccines are generally considered to be safe following solid organ transplantation, although there has been concern about their potential for triggering organ rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/5,12\">",
"     5,12",
"    </a>",
"    ]. However, this has not been substantiated by clinical studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tetanus, diphtheria, and pertussis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetanus, diphtheria, and pertussis immunizations should be kept up to date throughout adult life, regardless of transplantation status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Td",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of published information on the response of both transplant candidates and recipients to tetanus and diphtheria immunizations (Td) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Hemodialysis patients appear to have an impaired response to primary immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In one series, all 164 renal transplant recipients immunized with tetanus toxoid 1 to 24 months (median 7 months) after transplantation developed protective tetanus titers that remained protective for at least one year after immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/16\">",
"     16",
"    </a>",
"    ]. Although 89 percent of these patients also developed protective",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/15/21745?source=see_link\">",
"     diphtheria antitoxin",
"    </a>",
"    levels, 38 percent had titers that were no longer protective at one year. None of these patients had an episode of rejection and the estimated glomerular filtration rate remained stable after immunization.",
"   </p>",
"   <p>",
"    Another study evaluated responses to a Td booster in 42 pediatric renal transplant recipients who were immunized against tetanus and diphtheria prior to transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/15\">",
"     15",
"    </a>",
"    ]. Protective antibodies against diphtheria were observed in 38 percent and against tetanus in 90 percent prior to receiving the booster. Following booster immunization, 95 percent had protective antibodies against diphtheria at one month, and 76 percent at 12 months. Protection against tetanus occurred and persisted for the duration of the study in all patients following the booster. No change in allograft function was seen following vaccine administration.",
"   </p>",
"   <p>",
"    Based upon these studies, immunization against tetanus and diphtheria after transplantation is considered safe. Diphtheria immunization does not produce a durable response in many solid organ transplant recipients, and ideally",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/15/21745?source=see_link\">",
"     diphtheria antitoxin",
"    </a>",
"    titers would be checked one year after immunization with administration of a booster dose if the levels are not protective (&lt;0.1",
"    <span class=\"nowrap\">",
"     IU/mL).",
"    </span>",
"    However, in practice this is rarely done, and the 2009 ATS recommendations do not recommend checking diphtheria titers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/4\">",
"     4",
"    </a>",
"    ]. Routine booster doses should also be administered at least every 10 years, according to standard recommendations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=see_link\">",
"     \"Approach to immunizations in healthy adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Tdap",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Advisory Committee on Immunization Practices (ACIP) recommends a single dose of a vaccine containing tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap; Adacel or Boostrix) in place of Td for",
"    <strong>",
"     all",
"    </strong>",
"    adults aged 19 years and older to address waning immunity against pertussis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Boostrix has been approved by the US Food and Drug Administration for individuals 10 years of age and older, whereas Adacel has only been approved for individuals between the ages of 11 and 64 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/18\">",
"     18",
"    </a>",
"    ]. In adults aged 65 years and older, Boostrix should be used when possible. If only Adacel is available, it may be used in this age group, since it has been shown to be immunogenic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link&amp;anchor=H5#H5\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\", section on 'Indications for Td or Tdap vaccination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=see_link&amp;anchor=H12882667#H12882667\">",
"     \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The acellular pertussis component was added to the Td vaccine because immunity to Bordetella pertussis wanes 5 to 10 years after immunization, which has led to a significant number of cases of pertussis infection in the United States.",
"   </p>",
"   <p>",
"    Tdap should be safe in solid organ transplant recipients since it is not a live vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the efficacy of the acellular pertussis component in solid organ transplant recipients is not known. Prior to transplantation, individuals should receive Tdap according to the recommendations for healthy populations. Following transplantation, TdaP should be administered to adults who have not previously received it [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=see_link&amp;anchor=H12882667#H12882667\">",
"     \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pediatric solid organ transplant candidates and recipients should be vaccinated against tetanus, diphtheria, and pertussis according to the routine immunization schedule for healthy children. The tetanus, diphtheria, pertussis vaccine (TDaP) for children aged six years and younger is a different formulation from the one approved for those 11 years and older (Tdap). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment and prevention of Bordetella pertussis infection in infants and children\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Poliovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since global polio eradication is well underway, adults in the developed world do not need routine polio immunization. The small number of transplant candidates and recipients at risk of exposure to polio (by travel or work) should receive a primary series of the inactivated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/58/35749?source=see_link\">",
"     poliovirus vaccine",
"    </a>",
"    (IPV) if there is no documentation of vaccination status. Only one lifetime booster with IPV is recommended for vaccinated adults at continued risk of exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/19\">",
"     19",
"    </a>",
"    ], although the duration of protection is unclear in solid organ transplant recipients. In a series of 164 renal transplant recipients, only 3 percent of previously vaccinated patients had protective antibodies against all three poliovirus serotypes compared with 13 percent of healthy controls. A single posttransplant IPV booster led to protective immunity in 92 percent of transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pediatric solid organ transplant candidates and recipients should be vaccinated with IPV according to the routine immunization schedule for healthy children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17223?source=see_link&amp;anchor=H10#H10\">",
"     \"Poliovirus vaccination\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral polio vaccine, no longer available in the United States, should not be administered to transplant candidates or recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pneumococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Streptococcus pneumoniae is a common cause of pneumonia in solid organ transplant recipients. All adult solid organ transplant candidates and recipients in the United States should be vaccinated against pneumococcus with",
"    <strong>",
"     both",
"    </strong>",
"    the 23-valent polysaccharide pneumococcal vaccine (PPSV23) and the 13-valent pneumococcal conjugate vaccine (PCV13). PCV13 has replaced the 7-valent pneumococcal conjugate vaccine (PCV7) in the United States. Pneumococcal conjugate vaccines that contain a different number of serotypes (eg, PCV10) are used in some countries in Europe and elsewhere. Patients should be vaccinated against pneumococcus according to their national guidelines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H3#H3\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Conjugate vaccines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PPSV23 has been recommended for immunocompromised adults in the United States for many years, but in 2012, the ACIP also began recommending PCV13 for individuals aged 19 or older with certain high-risk conditions, including solid organ transplantation (",
"    <a class=\"graphic graphic_table graphicRef86782 \" href=\"UTD.htm?11/48/12046\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/20\">",
"     20",
"    </a>",
"    ]. The evidence supporting the use of pneumococcal conjugate vaccination in high-risk adults comes from a randomized trial of the 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In accordance with the ACIP, we recommend that solid organ transplant candidates and recipients receive PCV13 in addition to PPSV23 as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have not previously received either PCV13 or PPSV23, a single dose of PCV13 should be given, followed by a dose of PPSV23 at least eight weeks later.",
"     </li>",
"     <li>",
"      For patients who have previously received one or more doses of PPSV23, a single dose of PCV13 should be given one or more years after the last PPSV23 dose was received.",
"     </li>",
"     <li>",
"      For patients who require additional doses of PPSV23, the first such dose should be given no sooner than eight weeks after PCV13 and at least five years after the most recent dose of PPSV23.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pneumococcal vaccination in adults is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pediatric solid organ transplant candidates and recipients should also be vaccinated against pneumococcus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/23\">",
"     23",
"    </a>",
"    ]. The following Table summarizes the recommendations for vaccination against pneumococcus in high-risk children up to 6 years of age (",
"    <a class=\"graphic graphic_table graphicRef62519 \" href=\"UTD.htm?20/63/21501\">",
"     table 2",
"    </a>",
"    ). For children &ge;6 years of age who have not received at least one dose of PCV13, we suggest one dose of PCV13 followed by PPSV23 at least 8 weeks later [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H13#H13\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The success of pneumococcal immunization after transplantation is difficult to assess because of varying definitions of protective titers. In one study, for example, immunization with PPSV23 one year after heart transplantation was successful (defined as protective titers of &gt;300",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    to eight of nine selected serotypes) in 75 to 100 percent of recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/25\">",
"     25",
"    </a>",
"    ]. However, only 50 percent of the transplant recipients developed protective levels to pneumococcal serotype 3, compared with a 91 percent response rate in healthy individuals.",
"   </p>",
"   <p>",
"    Because of the suboptimal immunogenicity of PPSV23 in solid organ transplant recipients, there has been interest in the use of a pneumococcal conjugate vaccine in this population. PCV7 has been studied most extensively, but PCV13 replaced it in the United States in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/26\">",
"     26",
"    </a>",
"    ]. In trials comparing PCV7 with PPSV23 in renal transplant recipients, there was no difference in immunogenicity between the vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Antibody response rates to each individual serotype were poor eight weeks following administration of each vaccine (13 to 40 percent with PPSV23, 17 to 50 percent with PCV7) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/27\">",
"     27",
"    </a>",
"    ]. Among patients who had adequate responses eight weeks following vaccination, responses to each serotype persisted in only 42 to 85 percent of individuals at three years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A trial that randomly assigned liver transplant recipients to either PCV7 followed by a PPSV23 booster eight weeks later or to PPSV23 alone showed no improvement in immunogenicity in patients who received both vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Haemophilus influenzae",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. influenzae is a cause of pneumonia in solid organ transplant recipients, though less common than pneumococcus. Little is known about the immunogenicity of the H. influenzae type B (HIB) conjugate vaccine in these patients. In one study, a single dose of the conjugate vaccine was administered at various times after transplantation to 43 adult renal transplant recipients who did not have protective titers against HIB [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/30\">",
"     30",
"    </a>",
"    ]. Only 35 percent developed protective antibodies (compared with 71 percent of healthy control subjects).",
"   </p>",
"   <p>",
"    Based upon this single study, it is not possible to make a recommendation about routine use of the HIB vaccine in adult solid organ transplant candidates or recipients. However, it is reasonable to consider using the vaccine in lung transplant recipients who may be at higher risk of pneumonia, although there are no data to support this approach. The optimal timing and duration of protection for this vaccine is unknown.",
"   </p>",
"   <p>",
"    In contrast, pediatric solid organ transplant recipients should receive the HIB conjugate vaccine according to the routine schedule for children (",
"    <a class=\"graphic graphic_table graphicRef77170 \" href=\"UTD.htm?5/59/6077\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42489?source=see_link&amp;anchor=H5#H5\">",
"     \"Prevention of Haemophilus influenzae infection\", section on 'Hib conjugate vaccine schedules'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza is a common infection in solid organ transplant recipients and is associated with higher morbidity and mortality than in immunocompetent hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition to the usual complications of influenza (eg pneumonitis), influenza infection can cause rejection in solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine seasonal administration of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    is recommended for all transplant candidates and recipients every year, including during the first year after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/4\">",
"     4",
"    </a>",
"    ]. The intranasal live-attenuated influenza vaccine is contraindicated in transplant recipients. Influenza resistance patterns may limit efficacy of chemoprophylaxis, further emphasizing the importance of vaccination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/60/39880?source=see_link\">",
"     \"Antiviral drug resistance among seasonal influenza viruses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the success of immunization cannot be guaranteed, chemoprophylaxis should be considered for high-risk situations (such as diagnosis of influenza in a household member). Immunization of family members and hospital staff is also strongly recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both the underlying disease necessitating transplantation and the immunosuppressive regimen following transplantation may limit the immunogenicity of the influenza vaccine. Response rates in dialysis patients vary from 25 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/1,33,34\">",
"     1,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The response in solid organ transplant recipients varies among studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study evaluated immunogenicity of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      in 165 renal transplant recipients, a median of 6.3 years following transplantation (range 3.1-10.4 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/11\">",
"       11",
"      </a>",
"      ]. Seroprotection (defined as a hemagglutination-inhibiting [HI] titer &ge;40) one month following immunization was observed at the following rates: 93 percent against influenza",
"      <span class=\"nowrap\">",
"       A/H1N1,",
"      </span>",
"      79 percent against influenza",
"      <span class=\"nowrap\">",
"       A/H3N2,",
"      </span>",
"      and 83 percent against influenza B. Seroprotection rates were actually higher in transplant recipients compared with 41 healthy controls, possibly reflecting more frequent prior influenza vaccination in recipients compared with healthy individuals.",
"     </li>",
"     <li>",
"      Among 49 renal transplant recipients who were immunized at least one year after transplantation, 46 percent developed protective titers to influenza A but only 21 percent developed protective titers to influenza B [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among heart transplant recipients who were vaccinated at least one year posttransplantation, at least a four-fold increase in influenza titers occurred in 38 to 63 percent of recipients in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/25\">",
"       25",
"      </a>",
"      ], and in 32 to 100 percent in another report [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Better responses were noted in a series of liver transplant recipients who were immunized, with 92 to 95 percent developing protective titers [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study of the immune response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      in pediatric liver transplant recipients, transplant recipients achieved similar rates of antibody seroprotection and seroconversion compared to their healthy siblings [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/37\">",
"       37",
"      </a>",
"      ]. However, interferon-gamma responses were significantly lower in the transplant recipients compared to their siblings, which suggests a diminished T cell response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One possible reason for the variable immune responses observed in the above studies is a difference in the degree and type of immunosuppression. As an example, in one study, patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil as part of their immunosuppressive regimen had significantly lower seroprotection rates against influenza A viruses than patients not receiving this agent (89 versus 100 percent against influenza",
"    <span class=\"nowrap\">",
"     A/H1N1,",
"    </span>",
"    74 versus 87 percent against influenza",
"    <span class=\"nowrap\">",
"     A/H3N2)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/11\">",
"     11",
"    </a>",
"    ]. Another reason that immune responses vary widely among studies may be that different influenza vaccines do not have equivalent immunogenicity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The antibody response in transplant recipients is durable over at least a one year period and administration of a second dose of the vaccine during the same season does not improve the antibody response [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/11,38\">",
"     11,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There were no episodes of acute rejection as a result of immunization in any of the above studies or in studies specifically evaluating cellular or humoral activation in heart and renal transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/7,39\">",
"     7,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solid organ transplant recipients, unlike hematopoietic cell transplant (HCT) recipients, remain at increased risk of developing hepatitis B infection since they remain on immunosuppressive drugs indefinitely. Disturbingly, two reports noted that hepatitis B was acquired",
"    <strong>",
"     after",
"    </strong>",
"    transplantation in 20 percent of heart transplant recipients and 9 percent of liver transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of preventing hepatitis B infection among solid organ transplant candidates and recipients is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among renal transplant recipients with chronic hepatitis B infection, hepatitis B-associated liver failure is the cause of death in up to 73 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among heart transplant recipients with chronic hepatitis B infection, hepatitis B causes cirrhosis in 55 percent within the first 10 years after transplantation, and death in 17 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, since a transplant candidate may be offered an organ from a hepatitis B surface antigen-negative, core antibody-positive (\"core-positive\") donor, there is additional benefit to completing hepatitis B immunization before transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, transplant candidates, especially those with cirrhosis, often have a suboptimal response to hepatitis B immunization, particularly when accelerated schedules for vaccine administration are used [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study evaluating the immunogenicity of a high-dose, short-interval hepatitis B vaccination schedule (40 mcg of recombinant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      administered monthly for three doses) in patients with chronic hepatitis C, 109 of 152 patients (72 percent) developed antibodies against hepatitis B surface antigen (anti-HBsAg) compared with 24 of 26 controls (92 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/44\">",
"       44",
"      </a>",
"      ]. The response rate was significantly lower in cirrhotic patients compared with non-cirrhotic patients (54 versus 80 percent).",
"     </li>",
"     <li>",
"      In another study in which 49 patients with cirrhosis received 20 mcg of recombinant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      monthly for three doses, only 14 of 49 patients (28 percent) developed anti-HBsAg antibodies compared with 97 percent of healthy controls [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Using another accelerated schedule (20 mcg dose of recombinant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      administered on days 0, 7 and 21), only 7 of 20 liver transplant candidates (36 percent) developed a protective titer [",
"      <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    administration after transplantation varies greatly, with ranges reported from 17 to 89 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. Unfortunately, titers decline more rapidly than usual, even in those who develop protective levels of antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/48,51\">",
"     48,51",
"    </a>",
"    ], and booster doses produce suboptimal responses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/48\">",
"     48",
"    </a>",
"    ]. These results underscore the value of pretransplant immunization, ideally done prior to the onset of advanced renal or liver failure. It is reasonable to check antibody levels every one to two years and to administer a booster dose if the level falls below 10",
"    <span class=\"nowrap\">",
"     IU/L,",
"    </span>",
"    although the value of repeated boosters in this patient population has not been proven. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link&amp;anchor=H15#H15\">",
"     \"Hepatitis B virus vaccination\", section on 'Postvaccination testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many transplant centers administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=see_link\">",
"     hepatitis B immune globulin",
"    </a>",
"    (HBIG) to liver transplant recipients with hepatitis B-induced liver disease for at least 12 months after transplantation to prevent hepatitis B infection in the transplanted liver [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. Anti-HBsAg antibody levels are maintained above 100",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/55\">",
"     55",
"    </a>",
"    ]. The presence of hepatitis B DNA in peripheral mononuclear blood cells after this 12-month period may predict an indefinite risk of graft infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/56,57\">",
"     56,57",
"    </a>",
"    ], requiring lifelong administration of HBIG. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=see_link\">",
"     \"Liver transplantation for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    , following a course of HBIG, has been evaluated to prevent posttransplantation hepatitis B infection in liver transplant recipients with hepatitis B and in those who received grafts from anti-hepatitis B core antigen positive donors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. One study included 17 liver transplant recipients who had nonreplicative hepatitis B infection (HBsAg positive, hepatitis B e antigen negative, hepatitis B DNA negative) prior to transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/58\">",
"     58",
"    </a>",
"    ]. After at least 18 months of HBIG administration, none had evidence of HBV recurrence and all had normal allograft function on low-grade immunosuppression. HBIG was discontinued, and all patients received hepatitis B vaccine (40 mcg of recombinant hepatitis B vaccine at 0, 1, and 6 months, starting a median of two weeks after the last dose of HBIG). Fourteen of the 17 patients responded to the vaccine, but in two cases antibody levels fell to less than 10",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    over a median of 14 months. None of the 14 had a recurrence of HBV. These promising results may lead to a more cost-effective approach to prevention of hepatitis B recurrence in liver transplantation, but further study is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hepatitis A",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     Hepatitis A vaccine",
"    </a>",
"    is indicated for all transplant candidates with chronic liver disease because of the increased risk of fulminant hepatic failure in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. While the hepatitis A seroconversion rate in patients with chronic hepatitis C and B ranges from 94 to 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/64\">",
"     64",
"    </a>",
"    ], only 7 of 14 of patients with liver failure evaluated at one transplant center responded to the hepatitis A vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/65\">",
"     65",
"    </a>",
"    ]. None of eight adult liver transplant recipients responded to two doses of the hepatitis A vaccine administered two months apart.",
"   </p>",
"   <p>",
"    Little is known about the durability of responses to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     hepatitis A vaccine",
"    </a>",
"    administered before transplantation. In one study of liver transplant recipients who acquired natural hepatitis A infection prior to transplantation, 4 of 22 patients (18 percent) and 7 of 24 patients (29 percent) became seronegative one and two years after transplantation, respectively, raising the possibility that durability of vaccine antibody may also be limited [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/66\">",
"     66",
"    </a>",
"    ]. Patients should be immunized as early as possible after the diagnosis of chronic liver disease, even before transplantation is being considered, since liver failure appears to blunt the immune response to the vaccine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Meningococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of meningococcal disease after solid organ transplantation is unknown, and there is no information on the efficacy of meningococcal vaccines in patients with renal or liver failure or in solid organ transplant recipients. A meningococcal vaccine should be administered to solid organ transplant recipients and candidates who have a specific risk factor for invasive meningococcal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/4,67-70\">",
"     4,67-70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H18#H18\">",
"     \"Meningococcal vaccines\", section on 'Country-specific vaccination guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest a meningococcal conjugate vaccine for all solid organ transplant candidates and recipients who have an indication (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"     table 4",
"    </a>",
"    ). Available formulations in the US include Menactra and Menveo; Menactra has been approved for individuals from 9 months to 55 years of age, and Menveo has been approved for individuals from 2 to 55 years of age. We believe that it is reasonable to use a meningococcal conjugate vaccine even in solid organ transplant candidates and recipients over 55 years of age, although this has not been studied adequately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H19#H19\">",
"     \"Meningococcal vaccines\", section on 'United States'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommendations for revaccination are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H22#H22\">",
"     \"Meningococcal vaccines\", section on 'Revaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Human papillomavirus virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female solid organ transplant recipients with human papillomavirus (HPV) infection are at 20- to 100-fold increased risk of cervical intraepithelial neoplasia and both male and female recipients are at risk for other anogenital cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/5,71\">",
"     5,71",
"    </a>",
"    ]. In 2006, a vaccine against HPV made from virus-like particles (VLP) was licensed in the United States for use in girls and women from 9 to 26 years of age. Girls and women who fit within the recommendations for HPV vaccination should be vaccinated prior to transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link\">",
"     \"Recommendations for the use of human papillomavirus vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data on the immunogenicity of the HPV VLP vaccine in solid organ transplant recipients, but it should be safe to administer following transplantation since it is not a live vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/72\">",
"     72",
"    </a>",
"    ]. We suggest giving the HPV vaccine at least to unvaccinated solid organ transplant candidates and recipients who fit within the vaccination recommendations described above [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may be a role for HPV vaccine in male transplant recipients and female transplant recipients outside the age range of 9 to 26 years to prevent anogenital warts, anal cancer, and HPV-associated skin cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/72\">",
"     72",
"    </a>",
"    ]. We anticipate that there will be a future recommendation to broaden the indications for use of the HPV vaccine in transplant recipients, pending reporting of results of an ongoing study of the safety and efficacy of HPV in solid organ transplant recipients up to age 35 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     LIVE VIRUS VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Society of Transplantation recommends waiting a minimum of four weeks between live virus vaccine administration and solid organ transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/4\">",
"     4",
"    </a>",
"    ]. Live organism vaccines are generally avoided following solid organ transplantation given the potential for active infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Measles, mumps, and rubella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measles, mumps, and rubella infections are rare after solid organ transplantation, but the potential severity of these diseases is well recognized for nonimmunized individuals. In one study of children who were on dialysis when they received the measles, mumps, and rubella (MMR) vaccine, 70, 50, and 80 percent developed protective titers against measles, mumps and rubella, respectively, but only 30 percent were protected against all three infections [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In order to immunize pediatric solid organ transplant candidates prior to transplantation, the American Society of Transplantation (AST) states that the MMR vaccine can be given as early as six months of age even though the vaccine is most effective after one year of age when maternal antibodies have waned [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/4\">",
"     4",
"    </a>",
"    ]. If transplantation has not occurred by one year of age, another dose should be given, provided that &ge;4 weeks has elapsed since the first dose. It is suggested that at least four weeks elapse between live virus vaccine administration and transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the severe complications related to measles infection in transplant recipients and the experience of administering MMR in HIV-infected children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/74\">",
"     74",
"    </a>",
"    ], some transplant centers have started to use MMR after solid organ transplantation for children or others who have not completed the recommended series of MMR [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/75\">",
"     75",
"    </a>",
"    ]. However, this practice is not widespread. In one study, 7 of 17 seronegative children developed protective titers against measles after immunization, and none developed clinical measles [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These limited data are inadequate to support a recommendation for posttransplant immunization with MMR in nonimmunized individuals. Every effort should be made to immunize such transplant candidates at least one month prior to transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/24\">",
"     24",
"    </a>",
"    ]. We suggest checking antibody titers after immunization, prior to transplantation, because of the variability in the vaccine response.",
"   </p>",
"   <p>",
"    Immunization of household and other contacts is discussed below. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Live virus vaccines in household contacts'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Varicella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to widespread vaccination, varicella occurred in up to 2 percent of pediatric renal transplant recipients in the first year after transplantation, and was associated with significant morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/77\">",
"     77",
"    </a>",
"    ]. Although adults are rarely susceptible to varicella, morbidity and mortality is high in those who acquire primary infection after transplantation.",
"   </p>",
"   <p>",
"    With the availability of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    , there has been a focus on pretransplant immunization for susceptible candidates who are not taking immunosuppressive mediations and do not have impaired cellular immunity. Durable protective varicella titers have been described in 49 to 100 percent of children on dialysis; following transplantation, those with protective titers developed neither varicella nor herpes zoster [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential concern for patients high on the waiting list is the possibility that transplantation could occur shortly after vaccination, subjecting a recently vaccinated patient to high-dose immunosuppression and the risk of unchecked proliferation of the attenuated strain. A conservative approach would be to delay transplantation for three months after immunization, but it is consistent with the 2009 American Society of Transplantation recommendations for the use of MMR to delay transplantation for a minimum of four weeks after immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/4\">",
"     4",
"    </a>",
"    ]. For adults, this would require a delay after the second of the two recommended vaccine doses. If transplantation is urgently indicated in a patient who has received the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    within the previous month, peri- and post-transplant prophylaxis with IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    should be given.",
"   </p>",
"   <p>",
"    Preliminary data are encouraging regarding the efficacy of varicella immunization after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. As an example, in one study, 16 varicella zoster virus (VZV)-naive pediatric renal and liver transplant recipients were immunized with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    during the late posttransplant period (range eight months to six years) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/81\">",
"     81",
"    </a>",
"    ]. Evidence of humoral immunity developed in 13 of 15 patients (87 percent) and cell-mediated immunity developed in 12 of 14 patients (86 percent). Following vaccination, four patients had fever and four developed vesicular rashes, three of whom received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    . Subsequent VZV exposures in four patients, one of whom received varicella immune globulin, did not result in VZV infection. Case reports of disseminated VZV have been described following varicella vaccination in solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]; one case was proven to be caused by the vaccine strain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the risk of severe varicella infection in non-immune solid organ transplant recipients, we suggest immunization with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    prior to transplantation. In patients who do not receive the varicella vaccine pretransplant, we do NOT give it posttransplant due to concern for disseminated VZV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Post-exposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8326?source=see_link\">",
"     Varicella zoster immune globulin",
"    </a>",
"    (VZIG) is no longer available in most transplant centers and it is challenging to obtain the unlicensed VariZIGTM (Cangene Corporation, Winnipeg, Canada) in a timely way because an investigational new drug application is needed. Since questions have also been raised about the efficacy of VZIG in solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/85\">",
"     85",
"    </a>",
"    ], many clinicians prefer to administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    for three weeks after varicella exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Close contact for adults is defined as: continuous household contact, hospital contact in the same two to four-bed room; or prolonged face-to-face contact with an infectious staff member. All transplant recipients should be monitored carefully after exposure, even if antiviral prophylaxis or VZIG is administered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41016?source=see_link\">",
"     \"Post-exposure prophylaxis against varicella-zoster virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prompt admission for intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is indicated at the first sign of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunization of household contacts is discussed below. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Live virus vaccines in household contacts'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Varicella zoster (shingles)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The varicella-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    , Zostavax, is contraindicated in solid organ transplant recipients because it is a live virus vaccine. It can be given to patients prior to transplantation, although its efficacy in preventing varicella zoster following transplantation is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/5\">",
"     5",
"    </a>",
"    ]. Age-specific recommendations for the use of Zostavax are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\", section on 'Recommendations for use of zoster vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Rotavirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotavirus infection can lead to significant morbidity among solid organ transplant recipients, and is particularly prevalent among pediatric solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/88\">",
"     88",
"    </a>",
"    ]. Age-appropriate rotavirus vaccination is recommended for pediatric solid organ transplant candidates prior to transplantation, but is not recommended following transplantation since it is a live vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40937?source=see_link&amp;anchor=H6#H6\">",
"     \"Rotavirus vaccines\", section on 'Schedule'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Live virus vaccines in household contacts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-immune household contacts of solid organ transplant recipients should be immunized with MMR, since vaccinated persons do not transmit these viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    in household contacts of transplant recipients has been the subject of much discussion. The American Academy of Pediatrics (AAP) recommends use of the varicella vaccine in household contacts but cautions that vaccinees who develop a rash should avoid contact with transplant recipients for the duration of the rash [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/89\">",
"     89",
"    </a>",
"    ]. The 2009 AST guidelines also support this view and recommend that close contacts and family members aged 12 months or older should be vaccinated against VZV if they have never received the vaccination, have no history of varicella or herpes zoster, and have no contraindications to vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/90\">",
"     90",
"    </a>",
"    ]. Transplant recipients should be isolation from vaccine recipients who develop a rash. If isolation is not possible, then the non-varicella immune transplant recipient should be monitored for the development of a rash, and antiviral therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    ) should be started in the unlikely event that a rash suggestive of varicella develops.",
"   </p>",
"   <p>",
"    Similarly, it is reasonable to administer the varicella zoster (shingles) vaccine to household contacts who have an indication to receive it. Whenever possible, the varicella",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    should be given to household contacts before the solid organ transplant candidate undergoes transplantation in order to reduce the risk of transmission of the vaccine strain of the virus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\", section on 'Clinical trial data on zoster vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PASSIVE IMMUNIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are specific indications for the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=see_link\">",
"     hepatitis B immune globulin",
"    </a>",
"    (HBIG) and varicella-zoster immune globulin (VZIG) in solid organ transplant recipients, the utility of using passive antibody immunotherapy (intravenous immunoglobulin) for other indications is less clear. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Hepatitis B'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H19\">",
"     'Varicella'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The use of cytomegalovirus (CMV)-specific immune globulin is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     FUTURE ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with hematopoietic cell transplant recipients, one of the major challenges for solid organ transplantation is to develop safe and effective vaccines against major pathogens, such as CMV. One such vaccine that has shown promise in a phase 2 trial is a CMV glycoprotein B vaccine adjuvanted with MF59 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/48/23306/abstract/91\">",
"     91",
"    </a>",
"    ]. Renal and liver transplant candidates were randomly assigned to receive either the CMV vaccine or placebo at baseline and one and six months later; half of the individuals enrolled in the trial were CMV seropositive and half were CMV seronegative. Glycoprotein B antibody titers were significantly increased in both CMV seronegative and seropositive recipients of the vaccine. In those who developed viremia following transplantation, glycoprotein B antibody titers correlated inversely with the duration of viremia. In the seronegative patients with seropositive donors, both the duration of viremia and the number of days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    treatment were reduced in vaccine recipients.",
"   </p>",
"   <p>",
"    There is also an urgent need to develop standardized approaches to the administration and evaluation of immunizations in solid organ transplantation that will allow more meaningful comparisons between studies. Ideally, these standard immunization protocols will be used concurrently as new immunosuppressive agents are tested in phase III clinical trials, so that vaccine response and safety can be evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     IMMUNIZATIONS IN TRAVELERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunizations in travelers are discussed separately. The use of the different vaccines must be considered in relation to the issues described above. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=see_link&amp;anchor=H17#H17\">",
"     \"Immunizations for travel\", section on 'Immunocompromised patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although immunizations are important for the prevention of infection in solid organ transplant recipients, many immunocompromised patients are unable to mount protective immune responses and live vaccines are usually avoided. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunizations should be administered to solid organ transplant candidates as early as possible in the transplant evaluation in order to optimize immune responses and provide immunity to pathogens against which there is only a live vaccine (measles, mumps, rubella, varicella). We recommend waiting a minimum of four weeks between live virus vaccine administration and transplantation (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Timing of immunizations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most transplant centers restart vaccination at approximately three to six months after transplantation, once maintenance immunosuppression levels have been attained. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Timing of immunizations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In 2009, the American Society of Transplantation updated the guidelines for vaccination of pediatric and adult solid organ transplant candidates and recipients, as well as health care workers, household contacts, and other close contacts of these patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inactivated vaccines are generally considered to be safe following solid organ transplantation. Although efficacy may be suboptimal, we recommend that inactivated vaccines be administered to solid organ transplant candidates and recipients according to the usual schedules (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Inactivated vaccines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition, we recommend that solid organ transplant candidates and recipients be vaccinated against the pneumococcus (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pneumococcus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <strong>",
"       not",
"      </strong>",
"      using live vaccines (measles, mumps, rubella, varicella, varicella zoster (shingles), intranasal influenza vaccine) in solid organ transplant recipients (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Live virus vaccines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The measles, mumps, and rubella vaccine is considered safe in household contacts of solid organ transplant recipients. The use of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      in household contacts is a matter of debate. We suggest administering the varicella vaccine to non-immune household contacts (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We also suggest that the varicella zoster (shingles) vaccine be administered to household contacts when indicated (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Vaccinees who develop a rash should avoid contact with transplant recipients for the duration of the rash. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Live virus vaccines in household contacts'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/1\">",
"      Hibberd PL, Rubin RH. Approach to immunization in the immunosuppressed host. Infect Dis Clin North Am 1990; 4:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/2\">",
"      Molrine DC, Hibberd PL. Vaccines for transplant recipients. Infect Dis Clin North Am 2001; 15:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/3\">",
"      Gangappa S, Kokko KE, Carlson LM, et al. Immune responsiveness and protective immunity after transplantation. Transpl Int 2008; 21:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/4\">",
"      Danzinger-Isakov L, Kumar D, AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009; 9 Suppl 4:S258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/5\">",
"      Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant 2008; 8:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/6\">",
"      Burbach G, Bienzle U, Stark K, et al. Influenza vaccination in liver transplant recipients. Transplantation 1999; 67:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/7\">",
"      Kimball P, Verbeke S, Flattery M, et al. Influenza vaccination does not promote cellular or humoral activation among heart transplant recipients. Transplantation 2000; 69:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/8\">",
"      Lawal A, Basler C, Branch A, et al. Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant 2004; 4:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/9\">",
"      Magnani G, Falchetti E, Pollini G, et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. J Heart Lung Transplant 2005; 24:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/10\">",
"      White-Williams C, Brown R, Kirklin J, et al. Improving clinical practice: should we give influenza vaccinations to heart transplant patients? J Heart Lung Transplant 2006; 25:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/11\">",
"      Scharp&eacute; J, Evenepoel P, Maes B, et al. Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant 2008; 8:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/12\">",
"      Blumberg EA, Fitzpatrick J, Stutman PC, et al. Safety of influenza vaccine in heart transplant recipients. J Heart Lung Transplant 1998; 17:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/13\">",
"      Girndt M, Pietsch M, K&ouml;hler H. Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure. Am J Kidney Dis 1995; 26:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/14\">",
"      Kr&uuml;ger S, M&uuml;ller-Steinhardt M, Kirchner H, Kreft B. A 5-year follow-up on antibody response after diphtheria and tetanus vaccination in hemodialysis patients. Am J Kidney Dis 2001; 38:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/15\">",
"      Enke BU, B&ouml;kenkamp A, Offner G, et al. Response to diphtheria and tetanus booster vaccination in pediatric renal transplant recipients. Transplantation 1997; 64:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/16\">",
"      Huzly D, Neifer S, Reinke P, et al. Routine immunizations in adult renal transplant recipients. Transplantation 1997; 63:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/17\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/18\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2012; 61:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/19\">",
"      Prevots DR, Burr RK, Sutter RW, et al. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/20\">",
"      Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/21\">",
"      French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812.",
"     </a>",
"    </li>",
"    <li>",
"     Advisory Committee on Immunization Practices. Summary Report, February 22-23, 2012. file://www.cdc.gov/vaccines/recs/acip/downloads/min-feb12.pdf (Accessed on June 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/23\">",
"      Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Immunocompromised children. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.74.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/25\">",
"      Dengler TJ, Strnad N, B&uuml;hring I, et al. Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation. Transplantation 1998; 66:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/26\">",
"      Centers for Disease Control and Prevention (CDC). Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010; 59:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/27\">",
"      Kumar D, Rotstein C, Miyata G, et al. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 2003; 187:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/28\">",
"      Kumar D, Welsh B, Siegal D, et al. Immunogenicity of pneumococcal vaccine in renal transplant recipients--three year follow-up of a randomized trial. Am J Transplant 2007; 7:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/29\">",
"      Kumar D, Chen MH, Wong G, et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin Infect Dis 2008; 47:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/30\">",
"      Sever MS, Yildiz A, Eraksoy H, et al. Immune response to Haemophilus influenzae type B vaccination in renal transplant recipients with well-functioning allografts. Nephron 1999; 81:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/31\">",
"      Ison MG, Hayden FG. Viral infections in immunocompromised patients: what's new with respiratory viruses? Curr Opin Infect Dis 2002; 15:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/32\">",
"      Vilchez RA, McCurry K, Dauber J, et al. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2002; 2:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/33\">",
"      Beyer WE, Versluis DJ, Kramer P, et al. Trivalent influenza vaccine in patients on haemodialysis: impaired seroresponse with differences for A-H3N2 and A-H1N1 vaccine components. Vaccine 1987; 5:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/34\">",
"      Versluis DJ, Beyer WE, Masurel N, et al. Value of booster immunisation with influenza vaccine in patients undergoing haemodialysis. Br Med J (Clin Res Ed) 1987; 294:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/35\">",
"      Sanchez-Fructuoso AI, Prats D, Naranjo P, et al. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine. Transplantation 2000; 69:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/36\">",
"      Fraund S, Wagner D, Pethig K, et al. Influenza vaccination in heart transplant recipients. J Heart Lung Transplant 1999; 18:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/37\">",
"      Madan RP, Tan M, Fernandez-Sesma A, et al. A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings. Clin Infect Dis 2008; 46:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/38\">",
"      Blumberg EA, Albano C, Pruett T, et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 1996; 22:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/39\">",
"      Candon S, Thervet E, Lebon P, et al. Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am J Transplant 2009; 9:2346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/40\">",
"      Wedemeyer H, Pethig K, Wagner D, et al. Long-term outcome of chronic hepatitis B in heart transplant recipients. Transplantation 1998; 66:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/41\">",
"      Pessoa MG, Terrault NA, Ferrell LD, et al. Hepatitis after liver transplantation: the role of the known and unknown viruses. Liver Transpl Surg 1998; 4:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/42\">",
"      Kliem V, Ringe B, Holhorst K, Frei U. Kidney transplantation in hepatitis B surface antigen carriers. Clin Investig 1994; 72:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/43\">",
"      Chung RT, Feng S, Delmonico FL. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant 2001; 1:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/44\">",
"      Idilman R, De MN, Colantoni A, et al. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. Am J Gastroenterol 2002; 97:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/45\">",
"      Villeneuve E, Vincelette J, Villeneuve JP. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol 2000; 14 Suppl B:59B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/46\">",
"      Dom&iacute;nguez M, B&aacute;rcena R, Garc&iacute;a M, et al. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl 2000; 6:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/47\">",
"      Kallinowski B, Benz C, Buchholz L, Stremmel W. Accelerated schedule of hepatitis B vaccination in liver transplant candidates. Transplant Proc 1998; 30:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/48\">",
"      Loinaz C, de Juanes JR, Gonzalez EM, et al. Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterology 1997; 44:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/49\">",
"      Chang SH, Suh KS, Yi NJ, et al. Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology 2003; 37:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/50\">",
"      Serrano B, Bayas JM, Bruni L, D&iacute;ez C. Solid organ transplantation and response to vaccination. Vaccine 2007; 25:7331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/51\">",
"      Grob PJ, Binswanger U, Zaruba K, et al. Immunogenicity of a hepatitis B subunit vaccine in hemodialysis and in renal transplant recipients. Antiviral Res 1983; 3:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/52\">",
"      Lauchart W, M&uuml;ller R, Pichlmayr R. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc 1987; 19:4051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/53\">",
"      Muller R, Samuel D, Fassati LR, et al. 'EUROHEP' consensus report on the management of liver transplantation for hepatitis B virus infection. European Concerted Action on Viral Hepatitis. J Hepatol 1994; 21:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/54\">",
"      Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/55\">",
"      Perrillo RP, Mason AL. Hepatitis B and liver transplantation. Problems and promises. N Engl J Med 1993; 329:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/56\">",
"      F&eacute;ray C, Zignego AL, Samuel D, et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. Transplantation 1990; 49:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/57\">",
"      Lanford RE, Michaels MG, Chavez D, et al. Persistence of extrahepatic hepatitis B virus DNA in the absence of detectable hepatic replication in patients with baboon liver transplants. J Med Virol 1995; 46:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/58\">",
"      S&aacute;nchez-Fueyo A, Rimola A, Grande L, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/59\">",
"      Kwon CH, Suh KS, Yi NJ, et al. Long-term protection against hepatitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation. Pediatr Transplant 2006; 10:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/60\">",
"      Soejima Y, Ikegami T, Taketomi A, et al. Hepatitis B vaccination after living donor liver transplantation. Liver Int 2007; 27:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/61\">",
"      Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/62\">",
"      Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/63\">",
"      Willner IR, Uhl MD, Howard SC, et al. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med 1998; 128:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/64\">",
"      Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998; 27:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/65\">",
"      Dumot JA, Barnes DS, Younossi Z, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 1999; 94:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/66\">",
"      Arslan M, Wiesner RH, Poterucha JJ, et al. Hepatitis A antibodies in liver transplant recipients: evidence for loss of immunity posttransplantation. Liver Transpl 2000; 6:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/67\">",
"      Bilukha OO, Rosenstein N, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/68\">",
"      Centers for Disease Control and Prevention (CDC). Notice to readers: Recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children aged 2--10 years at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2007; 56(48):1265-1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/69\">",
"      Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices. Revised recommendations of the Advisory Committee on Immunization Practices to Vaccinate all Persons Aged 11-18 Years with Meningococcal Conjugate Vaccine. MMWR Morb Mortal Wkly Rep 2007; 56:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/70\">",
"      Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010; 59:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/71\">",
"      Human papillomavirus infection. Am J Transplant 2004; 4 Suppl 10:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/72\">",
"      Kwak EJ, Julian K, AST Infectious Diseases Community of Practice. Human papillomavirus infection in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4:S151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/73\">",
"      Schulman SL, Deforest A, Kaiser BA, et al. Response to measles-mumps-rubella vaccine in children on dialysis. Pediatr Nephrol 1992; 6:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/74\">",
"      Palumbo P, Hoyt L, Demasio K, et al. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1992; 11:1008.",
"     </a>",
"    </li>",
"    <li>",
"     Ellis D, Gilboa N, Bellinger M, Shapiro R. Renal transplantation in infants and children. In: Renal Transplantation, Shaprio R, Simmons RL, Starzl TE (Eds), Appleton and Lange, Stamford, CT 1997. p.461.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/76\">",
"      Rand EB, McCarthy CA, Whitington PF. Measles vaccination after orthotopic liver transplantation. J Pediatr 1993; 123:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/77\">",
"      Furth SL, Sullivan EK, Neu AM, et al. Varicella in the first year after renal transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1997; 1:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/78\">",
"      Broyer M, Tete MJ, Guest G, et al. Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics 1997; 99:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/79\">",
"      Webb NJ, Fitzpatrick MM, Hughes DA, et al. Immunisation against varicella in end stage and pre-end stage renal failure. Trans-Pennine Paediatric Nephrology Study Group. Arch Dis Child 2000; 82:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/80\">",
"      Zamora I, Simon JM, Da Silva ME, Piqueras AI. Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol 1994; 8:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/81\">",
"      Weinberg A, Horslen SP, Kaufman SS, et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant 2006; 6:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/82\">",
"      Khan S, Erlichman J, Rand EB. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant 2006; 10:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/83\">",
"      Kraft JN, Shaw JC. Varicella infection caused by Oka strain vaccine in a heart transplant recipient. Arch Dermatol 2006; 142:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/84\">",
"      Levitsky J, Te HS, Faust TW, Cohen SM. Varicella infection following varicella vaccination in a liver transplant recipient. Am J Transplant 2002; 2:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/85\">",
"      Lynfield R, Herrin JT, Rubin RH. Varicella in pediatric renal transplant recipients. Pediatrics 1992; 90:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/86\">",
"      Boeckh M. Prevention of VZV infection in immunosuppressed patients using antiviral agents. Herpes 2006; 13:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/87\">",
"      Weinstock DM, Boeckh M, Boulad F, et al. Postexposure prophylaxis against varicella-zoster virus infection among recipients of hematopoietic stem cell transplant: unresolved issues. Infect Control Hosp Epidemiol 2004; 25:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/88\">",
"      Stelzmueller I, Wiesmayr S, Swenson BR, et al. Rotavirus enteritis in solid organ transplant recipients: an underestimated problem? Transpl Infect Dis 2007; 9:281.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Varicella-zoster infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.774.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/90\">",
"      Pergam SA, Limaye AP, AST Infectious Diseases Community of Practice. Varicella zoster virus (VZV) in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4:S108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/48/23306/abstract/91\">",
"      Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011; 377:1256.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3892 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-199.231.185.123-114CC7A202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_48_23306=[""].join("\n");
var outline_f22_48_23306=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMMUNOGENICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TIMING OF IMMUNIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INACTIVATED VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tetanus, diphtheria, and pertussis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Td",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Tdap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Poliovirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pneumococcus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Haemophilus influenzae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Influenza",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hepatitis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Meningococcus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Human papillomavirus virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      LIVE VIRUS VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Measles, mumps, and rubella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Varicella",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Post-exposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Varicella zoster (shingles)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Rotavirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Live virus vaccines in household contacts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PASSIVE IMMUNIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      FUTURE ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      IMMUNIZATIONS IN TRAVELERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3892\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3892|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/48/12046\" title=\"table 1\">",
"      Pneumococcal vaccination indications for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/63/21501\" title=\"table 2\">",
"      PCV and PPSV23 in high risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/59/6077\" title=\"table 3\">",
"      Hib schedule US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/48/9999\" title=\"table 4\">",
"      Meningococcal vaccination indications in the US",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/60/39880?source=related_link\">",
"      Antiviral drug resistance among seasonal influenza viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=related_link\">",
"      Approach to immunizations in healthy adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=related_link\">",
"      Immunizations after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=related_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=related_link\">",
"      Liver transplantation for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17223?source=related_link\">",
"      Poliovirus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41016?source=related_link\">",
"      Post-exposure prophylaxis against varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42489?source=related_link\">",
"      Prevention of Haemophilus influenzae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=related_link\">",
"      Prevention of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40937?source=related_link\">",
"      Rotavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_48_23307="UVB initial dose by phototype";
var content_f22_48_23307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F88228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F88228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    UVB phototherapy: Recommended initial doses according to skin phototype",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Skin phototype",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial BB-UVB dose",
"        <br/>",
"        (mJ/cm",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial NB-UVB dose",
"        <br/>",
"        (mJ/cm",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        I",
"       </td>",
"       <td class=\"centered\">",
"        20",
"       </td>",
"       <td class=\"centered\">",
"        130",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        II",
"       </td>",
"       <td class=\"centered\">",
"        25",
"       </td>",
"       <td class=\"centered\">",
"        220",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        III",
"       </td>",
"       <td class=\"centered\">",
"        30",
"       </td>",
"       <td class=\"centered\">",
"        260",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        IV",
"       </td>",
"       <td class=\"centered\">",
"        40",
"       </td>",
"       <td class=\"centered\">",
"        330",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        V",
"       </td>",
"       <td class=\"centered\">",
"        50",
"       </td>",
"       <td class=\"centered\">",
"        350",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        VI",
"       </td>",
"       <td class=\"centered\">",
"        60",
"       </td>",
"       <td class=\"centered\">",
"        400",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_48_23307=[""].join("\n");
var outline_f22_48_23307=null;
var title_f22_48_23308="Allografts";
var content_f22_48_23308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Allografts",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tissue source",
"       </td>",
"       <td class=\"subtitle1\">",
"        Manufacturer",
"       </td>",
"       <td class=\"subtitle1\">",
"        Product",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preservation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Crosslinking",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sterilization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Fascia Lata",
"       </td>",
"       <td>",
"        Bard",
"       </td>",
"       <td>",
"        FasLata&reg;",
"       </td>",
"       <td>",
"        Lyophilized*",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Irradiation&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mentor",
"       </td>",
"       <td>",
"        Suspend&reg;&Delta;",
"       </td>",
"       <td>",
"        Solvent dehydrated",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Irradiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tutogen",
"       </td>",
"       <td>",
"        Tutoplast&reg;&Delta;",
"       </td>",
"       <td>",
"        Solvent dehydrated",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Irradiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Dermis",
"       </td>",
"       <td>",
"        Bard",
"       </td>",
"       <td>",
"        RTI Dermis&reg;",
"       </td>",
"       <td>",
"        Lyophilized",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Irradiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LifeCell",
"       </td>",
"       <td>",
"        AlloDerm&reg;&loz;",
"       </td>",
"       <td>",
"        Freeze dried",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Irradiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Boston Scientific",
"       </td>",
"       <td>",
"        Repliform&reg;&loz;",
"       </td>",
"       <td>",
"        Lyophilized",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Ethylene Oxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AMS",
"       </td>",
"       <td>",
"        UroGen&reg;",
"       </td>",
"       <td>",
"        Lyophilized",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Irradiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mentor",
"       </td>",
"       <td>",
"        Axis&reg;",
"       </td>",
"       <td>",
"        Solvent dehydrated",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Irradiation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Freeze-dried under vacuum.",
"     <br>",
"      &bull; Gamma radiation.",
"      <br>",
"       &Delta; Tutoplast&reg; and Suspend&reg; are the same material, sold and trademarked by Tutogen Medical and Mentor, respectively.",
"       <br>",
"        &loz; AlloDerm&reg; and Repliform&reg; are the same material, sold by LifeCell and Boston Scientific, respectively.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_48_23308=[""].join("\n");
var outline_f22_48_23308=null;
var title_f22_48_23309="Depression rating scales";
var content_f22_48_23309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Measures used to monitor clinical improvement of depressive symptoms and global functioning in depressed children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Depressive symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Children's Depressive Rating Scale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Revised (CDRS-R) Clinician rating scale based on a semi-structured interview with child/adolescent patient and parent informant. The CDRS is the most widely used and highly regarded clinician scale for monitoring response to treatment in children and adolescents. Modeled after the adult Hamilton Rating Scale for Depression, the CDRS was developed to assess current severity of depression in children ages 6 to 12 years and is often used for adolescents as well. The revision of the CDRS examines 17 symptom areas (eg, depressed feelings, sleep disturbance, social withdrawal, etc.) and can be administered in 15 to 20 minutes. The CDRS-R can be purchased at www.proedinc.com.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Revised Hamilton Rating Scale for Depression (RHRSD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clinician rating for adult depression that is used often with older adolescents. The revision retains the original Hamilton items, adds items, and includes a self-report version. The RHRSD takes 5 to 10 minutes to administer and is available for purchase at www.wpspublish.com.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Children's Depression Inventory-2 (CDI-2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Self report measure designed for assessment of depressive symptoms in children/adolescents ages 7 to 17.&nbsp;CDI-2 is revision of the CDI, the most widely used depression rating scale for children and adolescents.&nbsp;Revision includes new items, revised scales, and updated norms. Assesses current severity of depressive symptoms.&nbsp;Parent and teacher versions of CDI are available.&nbsp;A self rating short form takes about 5 to 10 minutes to complete.&nbsp;All versions are available through",
"        <a href=\"file://www.mhs.com\">",
"         www.mhs.com",
"        </a>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Beck Depression Inventory II (BDI-II)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Widely used self-report rating scale designed for use with adults and adolescents older than 13 years of age. It takes 5 to 10 minutes to complete. It is available for purchase at www.harcourtassessment.com.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Reynolds Adolescent Depression Scale, Second Edition (RADS-2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Self-report measure designed for assessment of depressive symptoms in adolescents 11 to 20 years of age. It may be administered in 5 to 10 minutes and is available at www.parinc.com or www.wpspublish.com.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Center for Epidemiological Studies Depression Scale Modified for Children (CES-DC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adapted version of the adult Center for Epidemiological Studies Depression Scale. It is a 20-item scale designed for use with children/adolescents ages 6 to 17. The CES-DC takes approximately five minutes to complete and is available in the public domain. Scores greater than 15 suggest significant levels of depressive symptoms. It can be found at www.brightfutures.org/mentalhealth/pdf/tools.html (scroll to \"Bridges\" section and then will find under a Mood Disorders link).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Clinical Global Impression (CGI) Scale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        The CGI is a three-item clinician rating scale used to assess treatment response (typically in research settings, often as an adjunct outcome measure). It is an unanchored measure (ie, there is no specific assessment). The ratings refer to the global impression of the patient and require substantial clinical experience with the syndrome under assessment. The three items are Severity of Illness, Global Improvement, and an Efficacy Index. Most use only the severity and improvement indices.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        The Severity of Illness item (CGI-S) requires a seasoned clinician to rate the severity of the patient's illness on a 7-point scale from 1 (\"normal,\" not ill) to 7 (extremely ill).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        The Global Improvement item (CGI-I) requires a seasoned clinician (who has knowledge of the patient's history) to rate how much the patient's illness has improved or worsened relative to baseline status. The patient's illness is compared to baseline rated on a 7-point scale from 1 (very much improved) to 7 (very much worse).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Global functioning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Global Assessment of Functioning (GAF) Scale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The GAF is a modified version of the adult GAS. The GAF is a single 100-point scale designed for clinicians to rate the severity of functional impairment. The GAF scale can be found in the DSM-IV.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Children's Global Assessment Scale (C-GAS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The C-GAS is adapted from the GAF and includes content relevant to child and adolescent functioning. It is designed for use with children from 4 to 16 years of age.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Liza Bonin, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_48_23309=[""].join("\n");
var outline_f22_48_23309=null;
var title_f22_48_23310="Discharge CRP levels outcome";
var content_f22_48_23310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Elevated discharge serum CRP in unstable angina predicts worse outcome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 439px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The incidence of readmission for unstable angina or myocardial infarction during follow-up correlates with the serum concentration of C-reactive protein (CRP) measured at discharge in patients with unstable angina. Upper panel: Patients in upper tertile of serum CRP (&ge;0.87 mg/dL) had significantly more events during follow-up than patients in the middle (0.26 to 0.86 mg/dL) or lower (&le;0.25 mg/dL) tertiles. Bottom panel: The one-year survival free of readmission for myocardial infarction or unstable angina was lower in patients with increased serum CRP at discharge compared to those with normal levels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Biasucci LM, Liuzzo G, Grillo RL, et al. Circulation 1999; 99:855.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_48_23310=[""].join("\n");
var outline_f22_48_23310=null;
var title_f22_48_23311="Osteochondroma knee Xray";
var content_f22_48_23311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osteochondroma of the distal femur",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 248px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Frontal radiograph of the knee demonstrates a metaphyseal femoral pedunculated bone lesion, oriented away from the joint, consistent with an osteochondroma (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_48_23311=[""].join("\n");
var outline_f22_48_23311=null;
